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Pyrroline-5-carboxylate

reductases

(EC

1.5.1.2)

are

important

housekeeping enzymes of L-proline biosynthesis, which generate L-proline and
influence redox cycling of NAD(P)H/NAD(P)+ to support cellular growth in all
domains of life. Structural evidence from X-ray crystal structures of HsPYCR1
(PDB codes 5UAT, 5UAU, and 5UAV) shows both NADPH bound in the Nterminal Rao-Rossmann fold motif and an important hydrogen bond or proton
donor role for Thr238 with L-P5C. A Thr238Ala mutation results in a 10-fold loss
in catalytic efficiency with varied L-P5C relative to the wild-type enzyme, thus
indicating an important role for Thr238 during catalysis. For HsPYCR2, HenriMichaelis-Menten kinetic analysis reveals a 164-fold loss in catalytic efficiency for
the Arg119Cys mutant, with varied L-P5C and fixed NADH, relative to wild-type
HsPYCR2. Profound effects on thermostability and secondary structure
characteristics of the Arg251Cys mutant were determined by thermal shift assays
and circular dichroism spectroscopy, respectively. Product(s) inhibition kinetics
collectively indicate NADP+ and NAD+ are mixed noncompetitive inhibitors
against NADPH and NADH, respectively, whereas L-proline is a competitive
inhibitor against L-P5C. Taken together, these findings support a sequential-

ordered binding enzyme mechanism of L-P5C binding first followed by NAD(P)Hbinding.
The ability of HsPYCR1 and 2 for reverse enzyme activity was observed
with L-T4C as the reducing substrate. Structural evidence of a HsPYCR1─L-T4C
binary complex, reverse direction saturation kinetics for both isozymes, and
inhibition kinetics showing L-proline as a competitive inhibitor versus L-T4C, all
indicate L-T4C shares the same active site as L-proline. Upon further evaluation
of reverse direction reactions, we discovered association reactions between
tris(alkyl)phosphine compounds and NAD+. Stopped-flow absorbance kinetics
demonstrated rapid and reversible NAD+─tris(alkyl)phosphine nonenzymatic
reactions with optimal absorbance at 334 nm for the reaction product. NMR
spectroscopy identified a covalent adduct between the phosphorus of tris(2carboxyethyl)phosphine or tris(3-hydroxypropyl)phosphine interacting at the C4
of the dihydronicotinamide ring of NAD+. Ultimately, this thesis dissertation
provides strong structural and kinetic insights into human pyrroline-5-carboxylate
reductase enzymes responsible for L-proline biosynthesis.
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Chapter 1

Introduction to L-proline biosynthesis in humans
INTRODUCTION
Biochemical and bioenergetic aspects of cellular metabolism rely upon the
presence and function of proteins, which are assembled based on the cellular
supply of amino acids. Among the 20 common amino acids in humans, L-proline
is distinguished as being the only proteinogenic imino acid due to both its amine
nitrogen and its side chain covalently linked to the alpha carbon as a fivemembered pyrrolidine ring. L-proline is a nonessential amino acid in humans with
L-glutamate and L-arginine serving as the primary sources for de novo
biosynthesis of L-proline as shown in Fig. 1.1.
In the 1960s, L-Δ1-pyrroline-5-carboxylate reductase (PYCR) activity was
characterized from animal sources such as rat and bovine tissues.1 The reaction
of PYCR was observed strongly favoring the direction of L-proline formation with
little appreciable reversible activity.1 It was then proposed that in mammals the
reduction of L-glutamate to L-proline proceeds through a reaction pathway that is
distinct from that of the oxidation of L-proline to L-glutamate (Fig. 1.1).1 Over the
years, structural and biochemical studies have confirmed that in human
mitochondria, L-glutamate initially is reduced to L-glutamic-γ-semialdehyde (LGSAL) by the bifunctional enzyme ALDH18A1 (synonymous with L-Δ1-pyrroline5-carboxylate synthetase (P5CS)), which possesses an ATP-dependent
glutamate-5-kinase domain and a NAD(P)H-dependent L-glutamyl-γ-5-phosphate
reductase domain (Fig. 1.1).2 Upon nonenzymatic dehydration, the open-chain LGSAL molecule undergoes ring closure to form L- Δ1-pyrroline-5-carboxylate (L-

Figure 1.1. Enzymatic reactions of L-proline and L-arginine metabolism in the mitochondrion. Background
translucent protein images are PyMol renderings of following X-ray crystal structures: dimeric TtPRODH
(PDB: 2EKG), dimeric HsPYCR1 (PDB: 5UAV), tetrameric HsALDH4A1 (PDB: 4OE5), monomer of Lglutamyl-γ-5--phosphate reductase domain of HsALDH18A1 (PDB: 2H5G), dimeric HsOAT (PDB: 2OAT),
and monomeric human Arginase (PDB: 6Q92).

2
P5C). Next, the NAD(P)H-dependent PYCR enzyme functions to reduce L-P5C
into L-proline (Fig. 1.1).3

3
A distinct pathway exists for the conversion of L-proline back to L-glutamate.
The first step of L-proline oxidation into L-P5C is catalyzed by the FADdependent enzyme L-proline dehydrogenase (PRODH).4 L-P5C is then
dehydrated nonenzymatically into L-GSAL, which is subsequently oxidized by the
NAD+-dependent enzyme ALDH4A1 (synonymous with L-GSAL dehydrogenase
(GSALDH)) to yield L-glutamate.4 L-glutamate itself has several fates, some of
which include enzymatic conversion into L-glutamine, entry into the citric acid
cycle as L-α-ketoglutarate, or directly functioning as an excitatory amino acid
neurotransmitter in the central nervous system. All of these potential fates for Lglutamate explain how L-proline metabolism is linked to overarching processes of
central metabolism such as bioenergetics, anaplerotic reactions replenishing
citric acid cycle intermediates, and cell signaling.5
The coupling of L-proline metabolism to regulatory networks suggests a
versatility beyond that of the L-proline requirement for protein synthesis. For
instance, Hancock et al. (2016) utilized a PRODH-expressing DLD colorectal
cancer cell model and mouse mitochondria to demonstrate that PRODH
mediates the transfer of electrons from L-proline directly to coenzyme Q1
(CoQ1).6 The subsequent electron transfer from CoQ1 to the electron-transport
chain (ETC) Complexes III and IV occurs during acute nutrient deprivation.6
Elevated PRODH expression can eventually lead to downregulation of ETC
component proteins through production of reactive oxygen species (ROS).6
These findings corroborate earlier observations that the initial catabolism of Lproline by PRODH modulates cellular bioenergetics and ATP generation in vivo.
In a study by Liu et al. (2015) using a P493 human B lymphoma cancer cell line,
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genetic knockdown of P5CS and all three PYCRs hindered the oxidative arm of
the pentose phosphate pathway as evidenced by a marked decrease in both
NAD+ and NADP+ levels that were not rescued by exogenous treatment with Lproline or L-P5C.7 Thus, it seems that an important function of L-proline
biosynthetic enzymes is to drive cellular bioenergetics through the pentose
phosphate pathway via shuttling of NAD(P)+, not necessarily for ATP generation
but to help provide the cell with ribose-5-phosphate for the synthesis of pyridine
nucleotides. In the context of cell signaling, D’Aniello et al. (2015) provide the first
evidence that mouse embryonic stem cell (ESC) identity depends on the
autoregulatory loop between L-Pro biosynthetic enzymes (P5CS and PYCR1)
and the Gcn2-Eif2α-Atf4 amino acid starvation response pathway.8 Herein, the
authors concluded that L-Pro starvation, either intrinsic or pharmacological
inhibition of prolyl-tRNA synthetase by halofuginone, activates autophagy and
signals massive apoptosis.8 Hence, L-Pro is a multifaceted imino acid that
influences aspects of cellular bioenergetics and cell signaling with the aid of its Lproline metabolic machinery.
The other primary source for L-proline biosynthesis is L-arginine (Fig. 1.1).
Both groups Mepham et al. (1966) and Yip et al. (1972) confirmed in rats and
goats that the enzymatic composition of the lactating mammary gland is poised
for the metabolic conversion of L-arginine into L-proline.9,10 Building upon those
findings, structural and biochemical studies have established that in human
mitochondria, L-arginine initially undergoes catalytic hydrolysis by Mn2+dependent arginase to yield urea and L-ornithine.11 Next, two half-transamination
reactions catalyzed by pyridoxal-5-phosphate-dependent enzyme L-ornithine

5
aminotransferase (OAT) converts L-ornithine and L-α-ketoglutarate substrates
into L-GSAL and L-glutamate products, respectively.12 This intersection at LGSAL reveals how L-arginine metabolism contributes to L-proline synthesis.
Within the mammalian system, glucocorticoid hormones, such as cortisol and
corticosterone,

differentially

regulate

intestinal

L-proline

and

L-ornithine

production from L-glutamine and L-arginine sources to provide substrates for the
synthesis of extracellular matrix proteins, i.e. collagen, and of polyamines.13
CLINICAL CORRELATIONS WITH ALTERED PYCR EXPRESSION AND
FUNCTION
In humans, altered PYCR expression and function has been associated with
several cancers and tumor growths, neurodegenerative diseases, and cutaneous
and connective tissue diseases. Humans have three genes encoding isozymes
PYCR1, PYCR2, and PYCRL (a.k.a. PYCR3).14 Isozymes PYCR1 and PYCR2
are mitochondrial whereas PYCRL is cytosolic, and they have varied sensitivities
to product inhibition, which contributes to their specialized function in proline
metabolism.14 The functional consequences of depleting PYCR1, PYCR2, and
PYCRL have implicated proline metabolism in various pathologies, including
cancers like melanoma, breast cancer, prostate cancer, esophageal tumors, lung
metastasis, and Kaposi’s sarcoma-associated herpesvirus (KSHV) – mediated
tumorigenesis, along with cases of acute pancreatitis, hyperprolinemia,
schizophrenia, hypomyelinating leukodystrophy type 10 with microcephaly, and
cutis laxa.5,15,16 Human PYCR1 and 2 (HsPYCR1 and 2) have been separately
implicated in specific cancers:

non-small cell lung cancer, viral-related

hepatocellular carcinoma, papillary renal cell carcinoma, melanoma, breast and

6
prostate cancers, esophageal squamous cell carcinoma, KSHV – mediated
tumorigenesis,

lung

adenocarcinoma,

and

colorectal

cancer.15,17,18,19,20,7,21,22,23,24,25 Also, studies have shown all three human PYCR
isozymes are transcriptionally up-regulated by the c-MYC oncogene in many
types of cancers.5,15,7 A study by Olivares et al. (2017) found that the collagen in
the extracellular matrix of the tumor microenvironment of pancreatic ductal
adenocarcinoma cells serves as a critical nutrient reserve of L-proline that fuels
the citric acid cycle and prolongs tumor cell survival under restrictive nutrient
conditions.26 Thus, L-proline biosynthesis promotes tumorigenesis particularly
through the activity of HsPYCR1 and 2.
Another set of pathologies linked to L-proline biosynthesis concerns
neurodegenerative and psychiatric diseases. For instance, animal-based studies
have revealed that alterations in the reactions of L-arginine and L-proline
metabolism that are involved in neurotransmission have been identified as strong
contributors to the progression of schizophrenia.27 In Zaki et al.’s (2016) study on
PYCRs in lethal microcephaly and failure to thrive pathologies, HsPYCR2 was
proposed to promote redox cycling of NAD(P)H/NAD(P)+ to support cellular
growth and

neuronal development.28 In a landmark study, Nakayama et al.

(2015) found that in human patients affected with specific neurological
phenotypes of hypomyelination and microcephaly, there was a strong genetic
linkage with individual HsPYCR2 missense mutations R119C and R251C.29
Despite the phenotypic overlap between autosomal recessive disorders of
HsPYCR1 and 2 mutations in terms of microcephaly, global developmental delay,
and joint hyperlaxity, mutations in HsPYCR1 uniquely lead to cutis laxa type IIB

(OMIM #

612940)30,31

hypomyelinating
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whereas mutations in HsPYCR2 uniquely lead to genetic

leukodystrophy

type

10

with

microcephaly

(OMIM

#

616420).28,29,32 Therefore, dysfunctions in HsPYCR2 are more strongly
associated with neurodegenerative diseases than dysfunctions in HsPYCR1.
Cutaneous and connective tissue diseases have been associated with
HsPYCR1 dysfunctions. Collagen is a structural scaffold protein found in all
connective tissue, bone, and the extracellular matrix of the human body. The
most abundant amino acid in collagen is L-proline, thus collagen is often
considered as a L-proline reservoir. Studies on the role of collagen in fibrotic
diseases and tumorigenesis are therefore often linked to L-proline metabolism.33
In a study by Reversade et al. (2009), cultured skin fibroblasts were examined
from individuals with mutations in HsPYCR1 and afflicted with autosomal
recessive cutis laxa.31 The mutations in HsPYCR1 were shown to cause aberrant
mitochondrial morphology and dysfunction.31 These observations provided new
insights into how HsPYCR1 deficiency could contribute to progeroid changes in
connective tissues besides disrupting L-proline biosynthesis.31 In addition to Lproline biosynthesis, important research has focused on understanding posttranslational modifications of L-proline in collagen. Prolyl-4-hydroxylase and
prolyl-3-hydroxylase have a non-heme iron center that catalyzes the addition of
an oxygen atom at the C4 and C3 positions of the pyrrolidine ring of peptidyl Lproline, respectively, using L-α-ketoglutarate and O2. Early work by Englard et al.
(1986), involved in vivo studies supporting a mechanism proposed by HanauskeAbel et al. (1982) in which L-ascorbate from the endoplasmic reticulum lumen
acts as an effective reductant of the iron center to replenish the ferrous form after
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each catalytic cycle of the prolyl hydroxylase

enzymes.34

SUMMARY
Although L-proline is a nonessential amino acid in humans, its importance
spans the realms of protein synthesis, bioenergetics, structural scaffolding in the
extracellular environment, and cell signaling.5 De novo biosynthesis of L-proline
stems from two major sources:

L-glutamate and L-arginine. Dysfunctional

expression or activity of HsPYCR1 and 2 have been linked to human pathological
conditions including various cancers and tumors, neurodegenerative and
psychiatric disorders, and cutaneous and connective tissue diseases. Taken
together, this dissertation aims to provide a clear understanding of the molecular
mechanisms of L-proline biosynthesis with structural and functional in vitro
characterization of human PYCR1 and PYCR2.
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Chapter 2

Kinetic Analysis of wild-type HsPYCR1 and Thr238 Active Site Mutant

Portions of this research were originally published in the Journal of Biological
Chemistry:
Christensen, E. M., Patel, S. M., Korasick, D. A., Campbell, A. C., Krause, K. L.,
Becker, D. F., and Tanner, J. J. Resolving the Cofactor Binding Site in the Proline
Biosynthetic Enzyme Human Pyrroline-5-Carboxylate Reductase 1. J. Biol.
Chem. (2017); 292 (17): 7233-7243. © the American Society for Biochemistry
and Molecular Biology. Used with permission.
ABSTRACT
Pyrroline-5-carboxylate reductase (PYCR) is the final enzyme in L-proline
biosynthesis, catalyzing the NAD(P)H-dependent reduction of L-pyrroline-5carboxylate (L-P5C) into L-proline (L-Pro). Mutations in the PYCR1 gene alter
mitochondrial function and cause the connective tissue disorder cutis laxa.
HsPYCR1 is overexpressed in multiple cancers, and the HsPYCR1 knock-out
suppresses tumorigenic growth, suggesting that HsPYCR1 is a potential cancer
target. However, inhibitor development has been stymied by limited mechanistic
details for the enzyme, particularly in light of a previous crystallographic study
that placed the cofactor-binding site in the C-terminal domain rather than the
anticipated Rao-Rossmann fold of the N-terminal domain. To fill this gap, we
report X-ray crystallographic, sedimentation-velocity, and kinetics data for human
PYCR1. Structures of the binary complexes of HsPYCR1 with NADPH or Lproline determined at 1.9 Å resolution provide insight into cofactor and substrate
recognition. We see NADPH bound to the Rao-Rossmann fold, over 25 Å from
the previously proposed C-terminal site. The 1.85 Å resolution structure of a
ternary complex containing NADPH and an L-P5C/L-Pro analog, namely Ltetrahydro-2-furoic acid (L-THFA), provides a model of the Michaelis complex
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formed during hydride transfer. Sedimentation velocity shows that PYCR1 forms
a concentration-dependent decamer in solution, consistent with the pentamer-ofdimers assembly seen crystallographically. Steady-state kinetic and mutational
analysis along with product inhibition kinetic analyses confirmed several features
seen in the crystal structure, including the importance of a hydrogen bond
between Thr238 and the substrate as well as limited cofactor discrimination
between NADPH and NADH.
INTRODUCTION
L-proline, a unique imino acid that lacks a primary amino group, is a key
building block of proteins and plays an important role in stress protection and
redox balance of cells across multiple kingdoms of life.1,2,3 From a biosynthetic
standpoint, the two biological sources of L-glutamate and L-arginine converge on
enzyme L-pyrroline-5-carboxylate (L-P5C) reductase (P5CR, EC 1.5.1.2), which
catalyzes the final reduction of L-P5C into L-proline (L-Pro) using NAD(P)H. In
humans, P5CR is known as PYCR. The human genome contains three
homologous PYCR genes, PYCR1, PYCR2, and PYCRL (also known as
PYCR3). The various human PYCR (HsPYCR) isoforms have specialized roles in
L-Pro biosynthesis and different subcellular localizations. A study of PYCRs in
melanoma cells showed that both HsPYCR1 and 2 function primarily in the Lglutamate-to-L-proline pathway, whereas HsPYCRL functions mainly in the Larginine-to-L-proline pathway.4 HsPYCR1 and 2 localize to mitochondria,
whereas HsPYCRL is cytosolic.4,5 Other studies have shown that HsPYCR1 and
2 are recoverable from the cytosol, suggesting the possibility that the enzymes
associate with the outer mitochondrial membrane.6
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HsPYCR has been implicated in various cancers and has emerged as a
potential therapeutic target. A study of mRNA profiles from 1,981 tumors
identified PYCR1 as one of the most consistently overexpressed metabolic genes
across 19 different cancer types.7 Additional studies highlight an abundance of
HsPYCR1 in melanoma cells as compared with healthy melanocytes, indicating
this enzyme as a potential therapeutic target in skin cancer treatment.4,8 Similarly,
depletion of PYCR1 in different types of cancers, such as breast, prostate, and
renal cell carcinoma, is associated with diminished cell proliferation and
tumorigenic growth.4,9,10,11
Deficiencies in PYCR are also linked to inherited metabolic disorders. Certain
mutations in the PYCR1 gene cause the autosomal recessive connective tissue
disorder cutis laxa.5 The decrease in HsPYCR1 activity is thought to impair
mitochondrial function, leading to developmental defects through increased
apoptosis.5 Mutations in the PYCR2 gene cause a developmental disorder of the
brain characterized by microcephaly, hypomyelination, and reduced white
matter.12 As with cutis laxa, the pathogenicity of the disorder involves
mitochondria-induced apoptosis in the central nervous system.12
Although X-ray crystal structures of P5CRs from microorganisms and a plant
species have been characterized13,14,15, before this work, only one X-ray
structural study has been characterized and discussed previously on human
P5CR. Fourteen years ago, Meng et al. (2006) reported 3.1 Å crystal structures of
HsPYCR1 complexed with NADPH and NADH.16 A major conclusion of that study
was that the NAD(P)H cofactor binds to the C-terminal domain rather than in the
canonical site within the N-terminal Rao-Rossmann fold domain.16 This result is
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notable because it contradicts other P5CR structures and departs from the
accepted structure-function paradigm of Rao-Rossmann fold enzymes, which
asserts that the cofactor binds to the N-termini of the strands of the RaoRossmann dinucleotide-binding fold.17,18
Herein we reexamine the structure of HsPYCR1 at high resolution to better
establish the location of the active site and to elucidate the interactions
responsible for cofactor and substrate recognition. X-ray crystal structures of
binary complexes of HsPYCR1 with NADPH and L-Pro have been determined at
1.9 Å resolution. The structure of a ternary complex with NADPH and the
L-P5C/L-Pro analog L-tetrahydro-2-furoic acid (L-THFA) has been obtained at
1.85 Å resolution. Furthermore, we present Furthermore, we present analytical
ultracentrifugation analysis of PYCR1 in solution and steady-state kinetic data of
the wild-type and active-site mutant enzymes for the forward reaction of L-P5C
reduction into L-Pro, along with product inhibition kinetic analyses. In contrast to
Meng et al.’s (2006) study, our electron density maps unequivocally identify the
location of the cofactor-binding site and show that HsPYCR1 follows the
canonical structure-function paradigm of Rao-Rossmann fold enzymes.
MATERIALS AND METHODS
Expression and purification of HsPYCR1
DNA encoding human mitochondrial PYCR1 transcript variant 1 (NCBI
RefSeq number NP_001269209.1) in pET-24b(+) with codons optimized for
expression in Escherichia coli was synthesized by GenScript Biotech Corp. The
construct encodes residues 1–300 of the full-length 319-residue protein plus an
N-terminal hexahistidine tag and tobacco etch virus protease cleavage site. This
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construct was designed for enhanced crystallization based on unpublished PDB
entry 2IZZ.
The HsPYCR1 construct was transformed into BL21(DE3)-competent E. coli
cells and plated onto LB agar containing 50 µg/ml kanamycin. A starter culture of
Luria broth medium, shaken overnight at 37 °C and 250 rpm, was used to
inoculate two 1 L cultures. After 2 h of shaking at 37 °C and 250 rpm, the larger
cultures were induced with 0.5 mM isopropyl thiogalactopyranoside and grown
with continued shaking at 18 °C overnight. Centrifugation at 3,000 x g for 20 min
at 4 °C was used to collect the cells, which were then resuspended in 50 mM
HEPES, pH 7.8, 300 mM NaCl, 10 mM imidazole, and 5% (w/v) glycerol (buffer
A). The resuspended pellet was stored at 80 °C until ready for purification.
A mixture of DNase I, lysozyme, and GoldBio ProBlock protease inhibitor
mixture was added to thawed cells and stirred at 4 °C for 20 min. After lysing cells
via sonication, cell debris was removed by centrifugation at 16,000 rpm for 1 h at
4 °C. The resulting supernatant was passed through a 0.45 µm Millex-HV syringe
filter and loaded onto a 5 ml HisTrap Ni2+-nitrilotriacetic acid column (GE
Healthcare) pre-equilibrated in buffer A using an AKTA Pure chromatography
instrument. The column was washed with buffer A supplemented with 30 mM
imidazole and eluted with 300 mM imidazole. The fractions containing PYCR1 as
determined by SDS-PAGE were collected and dialyzed at 4 °C overnight into
dialysis buffer containing 300 mM NaCl, 2% (w/v) glycerol, 50 mM HEPES, pH
7.5. Following dialysis, the protein was concentrated to 5 ml using a centrifugal
concentrator (Amicon Ultra-15) and then further purified on a HiLoad 16/600
Superdex 200 size-exclusion column (GE Healthcare) using a column buffer with
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the same composition as the dialysis buffer. The His-tag was not removed.
Crystallization of HsPYCR1, crystal soaking, and X-ray diffraction data collection
Experimental conditions for growing crystals of HsPYCR1, soaking them with
ligands, and X-ray diffraction of crystals with tabulated values of diffraction data
collection and refinement statistics are fully explained in Christensen et al.
(2017).19 In brief, the sitting drop vapor diffusion technique was used for the
crystallization of HsPYCR1, and then diffraction-quality crystals in the space
groups P21212 and C2 were grown.19 Ligand-free P21212 protein crystals were
more amenable for ligand soaking to prepare binary complexes of HsPYCR1 with
NADPH bound, HsPYCR1 with L-proline bound, and ternary complex of
HsPYCR1 with NADPH and the L-P5C/L-proline analog of L-THFA bound,
whereas the C2 protein crystal form was examined as the ligand-free enzyme.19
X-ray diffraction data were collected on Advanced Light Source beamline 4.2.2 at
Lawrence Berkeley National Laboratory using a Taurus-1 detector in shutterless
mode, and the initial phases of crystal diffractions were calculated with molecular
replacement using PHASER.19,20
Analytical ultracentrifugation
Sedimentation-velocity experiments were conducted with a Beckman XL-I
analytical ultracentrifuge using an An50Ti rotor and a two-sector cell. Sample
sedimentation was continuously monitored at 20 °C using Rayleigh interference
optics at 35,000 rpm for a total of 300 scans spaced at 2-min intervals. To
observe the concentration dependence of oligomerization, sedimentation-velocity
experiments were performed at two different protein concentrations (0.8 and 6.0
mg/ml) as determined by the Pierce BCA protein assay.

Sedimentation-velocity data were processed using

Sedfit,21
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assuming a partial

specific volume of 0.73 ml/g. Analysis of the data in Sedfit allowed for the
determination of apparent sedimentation coefficient (c(S)) and molecular mass
(c(M)) distributions. The approximate frictional ratio for decameric HsPYCR1 was
determined by allowing the value to vary in the c(S) calculation of the 6.0 mg/ml
protein sample. The frictional ratio was refined to a value of 1.94. This value was
applied to the analysis of the 0.8 mg/ml protein sample for consistency in
decamer peak identification. Analyzed data were normalized and plotted using
Origin 2016.
Kinetic measurements
All HsPYCR1 kinetic data were collected in triplicate using a Varian Cary BIO
50 UV-visible spectrophotometer (Agilent Technologies) following procedures
adapted from previous studies.4,14,22,13,23 PYCR enzyme activity assays were
performed by measuring the L-P5C-dependent oxidation of NADPH (SigmaAldrich) or of NADH (Sigma-Aldrich) at 340 nm and at 380 nm, using millimolar
extinction coefficients 6.22 mM-1 cm-1 and 1.314 mM-1 cm-1, respectively.4,24 DLP5C was synthesized according to the protocol by Williams and Frank,25 which
involved the metaperiodation of DL-5-hydroxylysine hydrochloride at 4 °C with
the reaction product purified by Dowex 50WX4 cation exchange column
chromatography using 1 M HCl to elute the fractions of DL-P5C. Additional
details concerning the synthesis and mass spectrometry characterization of DLP5C are provided in Appendix Chapter 1. DL-P5C was neutralized to pH 7.5 with
1 M Tris-HCl (pH 9.0) buffer immediately before assays. NADH and NADPH
stock concentrations were spectrophotometrically determined at 340 nm. Assays
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(600-µl total volume) were performed in 1.5 mL rectangular polystyrene cuvettes
(1 cm pathlength) (USA Scientific) at 37 °C in 0.1 M Tris-HCl (pH 7.5) reaction
buffer, 0.01% Brij-35 detergent (Santa Cruz Biotechnology), 1 mM EDTA
disodium salt (Fisher), using 0.006 and 0.06 µM HsPYCR1 wild-type and mutant
T238A enzymes. For assays in which DL-P5C was varied, the ionic strength was
maintained at approximately 450-480 mM Tris+Cl- at each DL-P5C concentration
by adding a balance of 1 M Tris-HCl (pH 7.5) buffer.26
Enzyme activity was calculated from the linear portion of the initial
absorbance decrease using the Beer-Lambert-Bouguer law.27,28,29 Assays were
performed in triplicate and data were expressed as mean ± standard deviation.
Data were fit by nonlinear regression to the Henri-Michaelis-Menten equation
using SigmaPlot 12.0 (version 12.0.0.182, Systat Software) to estimate the
maximal reaction velocity limit (Vlim) and the apparent Michaelis-Menten constant
(KM app) values (value ± standard error). The KM app for L-P5C was assumed to be
half the KM

app

value for the racemic DL-P5C mixture. The apparent catalytic

turnover rate (kcat

app)

and substrate specificity constant or catalytic efficiency

values (kcat app/KM app) were calculated from Vlim and KM app. Product(s) inhibition
kinetics were analyzed by global fitting of the data to different inhibition models
using the Enzyme Kinetics Wizard Module in SigmaPlot 12.0 and by HanesWoolf plot analysis. For NAD+ product inhibition, the data fit best to a mixed
inhibition (Full) model with enzyme-inhibition constants KIC app and KIU app = α(KIC
app)

(α = 0.4728). The mixed inhibition model had the highest squared correlation

coefficient (R2)-ranking among eight tested inhibition models. For L-Pro product
inhibition, the highest R2-ranking model was competitive inhibition (Full) (KIC app).
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RESULTS
Tertiary and quaternary structure of HsPYCR1
High-resolution crystal structures of HsPYCR1 revealed that the protomer
consists of an N-terminal α/β domain and a C-terminal α domain (Fig. 2.1A).

Figure 2.1. Structures of the PYCR1 protomer and dimer. A, structure of the
protomer of the ternary complex with NADPH and with the L-proline/L-P5C
analog of L-THFA. The N-terminal NAD(P)H-binding domain is colored according
to secondary structure, with β-strands in pink and α-helices in blue. The Cterminal oligomerization domain is colored gray. NADPH appears in gold sticks.
L-THFA is shown as cyan sticks. β-strands are labeled 1–8; α-helices are labeled
A–M. Helix-disrupting Pro-178 is shown. B, structure of the dimer. The α-helices
of the C-terminal domain are labeled H–M for the gray protomer and H’–M’ for the
purple protomer. NADPH and L-THFA are colored gold and cyan, respectively.
The arrow represents the 2-fold axis of the dimer.
The N-terminal domain features the classic Rao-Rossmann dinucleotide-binding
fold, which consists of a pair of βαβαβ motifs that interact across a pseudo-2-fold
axis to form a six-stranded parallel β-sheet with strand order 321456.30,31 An
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additional βαβ substructure follows strand 6 such that the full β-sheet of the Nterminal domain has eight β-strands, with the last two β-strands antiparallel to the
Rao-Rossmann β-strands. β-strand 8 of the N-terminal domain connects to the Cterminal domain, which consists of a bundle of six α-helices. The C-terminal
domain plays a major role in oligomerization. For example, the C-terminal domain
mediates dimerization (Fig. 2.1B). In the dimer, the C-terminal domains of two
protomers form an interlocking bundle of α-helices. Overall, the domain
architecture of HsPYCR1 is typical for P5CRs.13
The oligomeric state of HsPYCR1 in solution was determined with analytical
ultracentrifugation using sedimentation-velocity. Initial studies performed at 0.8
mg/ml (24 µM) revealed a distribution of apparent sedimentation coefficient that
exhibits a series of peaks in the range 1–7.5 S (Fig. 2.2A).

Figure 2.2. Oligomerization of PYCR1 in solution. A, apparent sedimentation
coefficient distribution determined at 6.0 mg/ml (solid line) and 0.8 mg/ml (dashed
line). B, molecular mass distribution determined at 6.0 mg/ml (solid line) and 0.8
mg/ml (dashed line).
The corresponding distribution of molecular masses reveals multiple species in
solution spanning from ~30 to 350 kDa (Fig. 2.2B). Because the theoretical
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molecular mass of a monomer is 34 kDa, the c(M) distribution is consistent with
the presence of multiple oligomeric states ranging from monomer to decamer. To
further investigate the possibility that decamer formation is concentrationdependent,

sedimentation

velocity

was

also

performed

at

the

higher

concentration of 6.0 mg/ml (180 µM). This experiment yielded a sedimentation
coefficient distribution with a single peak at 7.47 S (Fig. 2.2A), corresponding to a
molecular mass of 350 kDa (Fig. 2.2B). Thus, at a concentration of 180 µM,
HsPYCR1 is almost entirely decameric. These results are consistent with P5CR
forming a self-association equilibrium in solution.
Analysis of crystal packing with PDBePISA32 reveals a pentamer-of-dimers
assembly in both crystal forms (Fig. 2.3), consistent with the decamer observed
in sedimentation-velocity experiments.

Figure 2.3. The PYCR1 pentamer-of-dimers decamer. A, two orthogonal views of
the decamer, with each chain differently colored. B, two orthogonal views of the
decamer, with the N-terminal domains colored blue and the C-terminal domains
colored gray. Note that the C-terminal domains mediate all protein-protein
interactions in the decamer.
This assembly is also present in other P5CR crystal structures from a variety of
organisms.13,14,15 The consistency of this assembly across space groups and
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kingdoms suggests the decamer is a fundamental structural property of P5CRs.
The decamer is a pentamer-of-dimers assembly that resembles an
“hourglass-shaped barrel”13 when viewed perpendicular to the 5-fold axis (Fig.
2.3). The dimers are arranged such that the N-terminal domains form pentameric
rings at the top and bottom of the barrel, and the C-terminal domains form a
cylinder that connects the two rings. A notable feature of the decamer is that most
of the interfacial surface area results from the interaction between C-terminal
domains, whereas the N-terminal domains are relatively isolated from other
protomers (Fig. 2.3B).
Identification of the NAD(P)H-binding site
Electron density maps revealed the location and conformation of NADPH
bound to HsPYCR1 (Fig. 2.4).

N230

Figure 2.4. Electron density and interactions for NADPH bound to PYCR1.
The cage represents a simulated annealing (Fo - Fc) map contoured at 3σ.
Selected α-helices and β-strands are labeled in accordance with Fig. 2.1. α-helix
K (purple) is from the opposite protomer of the dimer. The conserved water
molecule of the Rao-Rossmann dinucleotide-binding fold is colored green.33
In the enzyme─NADPH binary complex structure, the density is very strong in
two of the five chains in the asymmetric unit, allowing modeling of the complete
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cofactor with occupancy of 1.0 (chains C and E). We note that high occupancy of
NADPH appears to be correlated with the stabilization of residues 34–40, which
form a loop that interacts with the adenosine portion of NADPH. Density for this
loop is very strong in chains C and E but much weaker in chains A, B, and D. The
loop was omitted in chain A.
NADPH binds at the C-termini of the strands of the Rao-Rossmann
dinucleotide-binding fold (Fig. 2.4).

The cofactor adopts an

extended

conformation with the pyrophosphate poised above the N-terminus of the first αhelix of the Rao-Rossmann fold (αA). The adenosine group interacts with the first
βαβαβ motif, whereas the nicotinamide riboside contacts the second βαβαβ
motif. In summary, NADPH adopts the canonical pose expected for nicotinamide
adenine dinucleotides bound to Rao-Rossmann fold domains.33
NADPH forms several noncovalent interactions with the enzyme (Fig. 2.4).
The ribose hydroxyls and pyrophosphate hydrogen bond exclusively with protein
backbone atoms. Only two side chains participate in hydrogen bonding with
NADPH. Asn56 hydrogen bonds with the adenine ring, whereas Ser34 interacts
with the 2’-phosphoryl group. Nonpolar side chains help position the bases of
NADPH, with Pro35, Val70, and Ile78 contacting the adenine and Leu11 packing
against the nicotinamide.
The carboxamide of NADPH has a 2-fold rotational degeneracy at the
resolution of our structures; however, hydrogen bonding can be used to deduce
the correct orientation of this group. The carboxamide amino group has been
modeled so it forms an intramolecular hydrogen bond with the pyrophosphate
and another hydrogen bond with the backbone carbonyl of Asn230 (Fig. 2.4). In
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contrast, rotation by 180° places the carboxamide carbonyl next to obligate
hydrogen bond acceptors, resulting in no hydrogen bonds.
The L-proline-binding site
The structure of HsPYCR1 complexed with the product L-proline was
determined at 1.90 Å resolution from a crystal that had been soaked in 1.8 M Lproline (Fig. 2.5). The electron density allowed modeling of L-proline in the active
site of all five chains with occupancy of 1.0.

Figure 2.5. The L-proline-binding site. A, electron density and interactions for Lproline (cyan) bound to PYCR1. The cage represents a simulated annealing (Fo Fc) map contoured at 3σ. The two protomers of the dimer are colored purple and
gray. Note that L-proline binds in the dimer interface, and a hydrogen bonding
water molecule in the vicinity of the carboxylate of L-proline and Ser233 is
colored red. Selected α-helices are labeled in accordance with Fig. 2.1. B, spacefilling representation of the L-proline-binding site highlighting nonpolar residues
that contact the methylene groups of L-proline.
L-proline was also modeled into an election density feature on the surface of the
protein near Thr137. The adventitious binding of L-proline to the protein surface
is common when used in high concentration as a cryoprotectant, as is the case
here.34
L-proline binds in a section of the dimer interface where the αK-αL loop of one
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protomer meets α-helices H, I, and M of the other protomer (Figs. 2.1B and 2.5A).
The carboxylate and imino groups of L-proline are anchored to the αK-αL loop via
several hydrogen bonds, some of which are mediated by a water molecule (Fig.
2.5A). Of note is the hydrogen bond between Thr238 and the imine nitrogen of Lproline. It has been proposed that this conserved Thr residue functions in
catalysis by donating a proton to the imine nitrogen atom of L-P5C.13
The roof of the binding site provides nonpolar contacts for the methylene
groups of L-proline. These contacts include Ala97 of the Rao-Rossmann fold and
the kink between α-helices H and I (Fig. 6B). The kink is caused by the presence
of conserved Pro178 and appears to be a common feature of P5CRs because it
is also present in structures of P5CR from microorganisms.14 Within the kink, the
carbonyls of residues 174 and 175 splay outward to avoid a steric clash with the
Cδ of Pro178, and as a result, these groups do not form (i to i + 4) hydrogen
bonds, and the helical structure is disrupted. Thr171 and Gly175 of the kink
region provide nonpolar contacts with the methylene groups of L-proline. These
interactions bury the carboxylate face of L-proline, leaving the other face solventexposed and available for catalysis (Fig. 2.5B).
The ternary complex with NADPH and L-THFA
The structure of HsPYCR1 complexed with NADPH and L-THFA was
determined at 1.85 Å resolution (Fig. 2.6). The electron density is very strong for
both ligands in all five chains, allowing the inclusion of the ligands in the model at
an occupancy of 1.0. This is the first structure of any P5CR that mimics the
enzyme─NADPH─L-P5C Michaelis complex.
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Figure 2.6. Structure of the ternary complex of PYCR1 with NADPH and L-THFA.
The cage represents a simulated annealing (Fo - Fc) map contoured at 3σ.
NADPH and L-THFA are colored gold and cyan, respectively. Water molecules
are colored red. The two protomers of the dimer are colored purple and gray. Two
orthogonal views are shown. Selected α-helices are labeled in accordance with
Fig. 2.1A.
The structure shows that dimerization is essential for catalytic activity.
NADPH interacts with the Rao-Rossmann fold of one protomer, and L-THFA
binds in the αK-αL loop of the opposite protomer of the dimer (Fig. 2.1B). NADPH
adopts the same conformation as in the binary enzyme-NADPH complex,
whereas L-THFA occupies the aforementioned L-proline site. Water-mediated
hydrogen bonding appears to play a role in stabilizing the ternary complex,
because five water molecules with strong electron density connect L-THFA,
NADPH, and the protein (Fig. 2.6). The ring of L-THFA stacks in parallel with the
nicotinamide ring such that C5 of L-THFA, which represents the hydride acceptor
atom of L-P5C, is 3.7 Å from C4 of the nicotinamide ring. The structure is
consistent with a direct hydride-transfer mechanism.
Henri-Michaelis-Menten kinetics and product(s) inhibition Hanes-Woolf kinetics
Steady-state kinetics assays showed that HsPYCR1 utilizes both NADH and
NADPH cofactors (Fig. 2.7, A-C). When keeping L-P5C fixed (3.5 mM) while
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B

D

C

E

Figure 2.7. Initial velocity data for PYCR1 wild-type and T238A mutant. (A) varied
NADH (0-660 µM) and fixed DL-P5C (3.5 mM) with 0.006 µM HsPYCR1. (B)
varied NADPH (0-2000 µM) and fixed DL-P5C (3.5 mM) with 0.06 µM HsPYCR1.
(C) varied DL-P5C (0-3.5 mM) and fixed NADPH (500 µM) with 0.06 µM
HsPYCR1. (D) HsPYCR1 T238A mutant (0.06 µM) with varied NADPH (0-1200
µM) and fixed DL-P5C (3.5 mM). (E) HsPYCR1 T238A mutant (0.06 µM) with
varied DL-P5C (0-3.5 mM) and fixed NADPH (500 µM). Assays were performed
at 37 °C in 0.1 M Tris-HCl (pH 7.5) reaction buffer. Data (mean ± standard
deviation) are plotted as variable substrate concentration (µM) versus initial
reaction velocity of NAD(P)+ product formation (µM s-1) with non-linear leastsquares fits to the Henri-Michaelis-Menten equation from which the kinetic
parameters reported in Table 2.1 were derived. Apparent substrate inhibition is
observed with wild-type HsPYCR1 and varied NADPH (panel B) but the data
could not be fit satisfactorily to an equation for general substrate inhibition.
varying the dinucleotide concentration, KM app values of 70 and 283 µM for NADH
and NADPH were obtained (Table 2.1). The kcat app value was nearly 3-fold higher
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Table 2.1. Steady-state kinetic parameters for PYCR1a

kcat app
(s-1)

(kcat app/KM app )
(M-1 s-1)

70 ± 11
283 ± 119
667 ± 88f

218 ± 8
74 ± 8
31 ± 2

(31 ± 5.) x 105
(2.6 ± 1.1) x 105
(0.47 ± 0.07) x 105

159 ± 47
2887 ± 774f

23 ± 2
14 ± 3

(1.4 ± 0.4) x 105
(0.05 ± 0.02) x 105

Enzyme

Varied
Fixed
Substrate Substrate

KM app (µM)

Wild-typeb

NADH
NADPH
DL-P5C

DL-P5Cd
DL-P5Cd
NADPHe

T238Ac

NADPH
DL-P5C

DL-P5Cd
NADPHe

aValue

± std error are the apparent best-fit parameters from non-linear leastsquares fit of the data to the Henri-Michaelis-Menten equation using SigmaPlot
12.0 (version 12.0.0.182, Systat Software). Data plotted as the (mean ± SD) of
n=3 technical replicates.
bFinal enzyme concentration of 0.006 µM (for varied NADH with fixed DL-P5C)
and 0.06 µM in remaining assays.
cFinal enzyme concentration of 0.06 µM in the assay.
dDL-P5C concentration fixed at 3500 µM.
eNAD(P)H concentration fixed at 500 µM.
fReported value is the concentration of L-P5C, which is assumed to be half the
concentration of the DL-P5C racemic mixture.
higher with NADH, resulting in a 12-fold greater catalytic efficiency (kcat app/KM app)
relative to NADPH (Table 2.1). A previous study reported a 6.5-fold higher
catalytic efficiency of HsPYCR1 with NADH over NADPH.4 Kinetic values of kcat
app

as 31 s-1 and KM

app

as 667 µM L-P5C were determined for wild-type

HsPYCR1 from assays varying L-P5C while keeping NADPH fixed (Table 2.1,
Fig. 2.7C).
The importance of Thr238 was tested with the site-directed mutation T238A. It
has been proposed that this universally conserved residue functions in catalysis
by donating a proton to the imine nitrogen of L-P5C.13 This proposition was based
on the observation of a hydrogen bond between the hydroxyl group of the
conserved Thr and the imine nitrogen of the product L-proline in P5CR structures

from

microorganisms14,
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an interaction that is also seen in HsPYCR1 (Fig. 2.5A).

The analogous hydrogen bond to L-THFA is also present in the ternary complex
(Fig. 2.6).
Kinetic parameters for the T238A mutant enzyme were determined by varying
NADPH and L-P5C (Fig. 2.7, D and E). Values of kcat app as 23 s-1 and 14 s-1 with
KM

app

as 159 µM and 2887 µM for NADPH and L-P5C, respectively, were

determined (Table 2.1). Because the KM app is near the upper concentration of LP5C available, a kcat app/KM app value of 16,700 M-1 s-1 was also estimated from the
slope of the linear region ([S] << KM app) of the Henri-Michaelis-Menten plot. The
nearly 10-fold lower kcat

app/K

M

app

value of the T238A mutant relative to wild-type

HsPYCR1 with L-P5C is consistent with the proposed role of Thr238 hydrogen
bonding to the substrate.
The binding order of L-P5C and NADPH to HsPYCR1 was evaluated by
product(s) inhibition studies.35 The inhibition of HsPYCR1 by NADP+ was first
examined by varying NADPH and holding DL-P5C constant. Table 2.2 shows that
increases in NADP+ concentration (0-15 mM) results in a decreasing trend in

kcatapp and a slightly lower apparent KM. With increasing NADP+ concentration,
trends of both increasing values of (1/KMapp) and (1/Vlim) support the model of
mixed inhibition by NADP+ (Table 2.2 and Figure 2.8, A and B).35 Global fitting of
the data to a mixed inhibition model provided estimates of apparent competitive
(KIC) and uncompetitive (KIU) inhibition constants for NADP+ (Table 2.2). L-proline
inhibition of HsPYCR1 was evaluated by varying DL-P5C (0-5500 µM) and
holding NADPH fixed. Table 2.3 shows that with increasing L-proline
concentration
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C

B

D

Figure 2.8. Product(s) inhibition kinetics of wild-type HsPYCR1. Henri-MichaelisMenten plots of assays performed at (A) different NADP+ concentrations (0-15
mM) while varying NADPH and holding DL-P5C constant (5000 µM) and (C) at
different L-proline concentrations (0-5 mM) while varying DL-P5C and holding
NADPH constant (500 µM). Hanes-Woolf plots of the data in panels B and D for
inhibition of HsPYCR1 by (A) NADP+ and (C) L-proline, respectively. Data
plotted as (mean ± SD) of n=3 technical replicates with non-linear least-squares
fits to the Henri-Michaelis-Menten equation and linear regression fits to the
Hanes-Woolf equation using SigmaPlot 12.0.
Table 2.2. Steady-state kinetic parameters for NADP+ product inhibition of
HsPYCR1a,b,c
NADP+
(mM)

KMapp

0

587 ± 92

22.7 ± 0.2

(38.7 ± 6.1) x 103

5

426 ± 91

9.7 ± 1.1

(22.7 ± 5.5) x 103

10

501 ± 98

7.1 ± 0.8

(14.1 ± 3.2) x 103

15

284 ± 30

4.6 ± 0.2

(16.1 ± 1.9) x 103

(µM)

kcat app
(s-1)

(kcat app/KM app )
(M-1 s-1)

KIC app (mM)

KIU app (mM)

8.28 ± 1.36d

3.92 ± 0.64d
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Value ± Std error are reported for the apparent best-fit parameters of non-linear leastsquares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical
replicates.
b
Final enzyme concentration of 0.06 µM was used for the assays.
c
DL-P5C concentration was fixed at 5000 µM while NADPH concentration was varied 0580 µM.
dApparent inhibition constants, K app (competitive inhibition) and K app (=α(K app))
IC
IU
IC
(uncompetitive inhibition) were estimated by fitting data (25-580 µM NADPH) to the
Mixed Inhibition (full) model with α=0.4728 using the Enzyme Kinetics Wizard Add-In on
SigmaPlot 12.0 (version 12.0.0.182, Systat Software).
a

Table 2.3. Steady-state kinetic parameters for L-proline product inhibition of
HsPYCR1a,b,c
L-proline
(mM)

KM app (µM)d

kcat app (s-1)

(kcat app/KM app )
(M-1 s-1)

0

1463 ± 176

17.4 ± 1.0

(11.9 ± 1.6) x 103

1

1664 ± 219

17.0 ± 1.1

(10.2 ± 1.5) x 103

2.5

1725 ± 210

15.7 ± 0.9

(9.1 ± 1.2) x 103

5

2898 ± 396

12.6 ± 1.0

(4.3 ± 0.7) x 103

KIC app (mM)

2.61 ± 0.25e

aValue

± Std error are reported for the apparent best-fit parameters of non-linear leastsquares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical
replicates.
bFinal enzyme concentration of 0.06 µM was used for the assays.
cNADPH concentration was fixed at 500 µM while DL-P5C concentration was varied 05500 µM.
dReported value is the concentration of L-P5C, which is assumed to be half the
concentration of the DL-P5C racemic mixture.
eApparent competitive inhibition constant, K app, was estimated by fitting data (250-5500
IC
µM DL-P5C) to a competitive inhibition (full) model using the Enzyme Kinetics Wizard
Add-In on SigmaPlot 12.0 (version 12.0.0.182, Systat Software).

(0-5 mM), the value of KMapp increased whereas Vlim remained fairly unchanged
consistent with competitive inhibition by L-proline.35 Best fits of the data to a
competitive inhibition model yielded an apparent KIC value of 145 µM L-proline
(Table 2.3). Hanes-Woolf plots of the NADP+ and L-proline inhibition data also
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show linear regressions consistent with mixed and competitive inhibition,
respectively (Figure 2.8, B and D). In these plots, linear trends converging at a
common negative horizontal axis intercept with an increasing slope (1/Vlim) effect
(Figure 2.8B) indicates NADP+ is a mixed noncompetitive inhibitor35 of HsPYCR1
with respect to NADPH. Parallel linear trends with an increasing vertical axis
intercept (KMapp/Vlim) effect (Figure 2.8D) indicate L-proline is a competitive
inhibitor35 with respect to L-P5C. Taken together, these modes of inhibition by
each product ligand support a sequential-ordered binding mechanism of L-P5C
binding first to the enzyme followed by NADPH.
DISCUSSION
In this work, we describe the first high-resolution structures of a human PYCR
isozyme. Notably, the complex of HsPYCR1 with NADPH and the L-P5C/L-Pro
analog of L-THFA is the first structure of a relevant ternary complex for any
P5CR. This structure provides new information about the mechanism of the
enzyme. Considering it to represent the E─NADPH─L-P5C Michaelis complex,
the structure implies that L-P5C binds with its ring approximately parallel to the
nicotinamide ring with C2 of L-P5C close to C4 of NADPH, as expected for a
hydride-transfer mechanism. The donor-acceptor distance inferred from the
structure is 3.7 Å, whereas the expected distance in the transition state for
hydride-transfer reactions is ~2.7 Å.36 It is possible that fluctuations of the
enzyme are needed to achieve the transition state from the configuration
represented in the crystal structure. Alternatively, our structure represents the
product complex (E─NADP+─L-Pro) rather than the substrate complex.
The structure also immediately suggests the stereochemistry of hydride
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transfer. Because the B-side of the nicotinamide of NADPH contacts the implied
substrate, HsPYCR1 is predicted to catalyze the transfer of the pro-4S hydrogen
to L-P5C. This assignment agrees with a previous prediction based on
superimposing

separate

structures

of

P5CR─NADP+

and

P5CR─L-Pro

complexes.13 To date, we are not aware of any reports of the determination of the
stereochemistry of P5CR by kinetic isotope effect measurements.
It has been suggested that a conserved Thr or Ser in the active site functions
as a general acid that donates a proton to the imine nitrogen of L-P5C.13 Ser and
Thr are not usually considered to be general acid/base catalysts due to their high
pKa values. It is possible for the protein micro-environment to lower the pKa of an
active site residue so it can function as a general acid, as occurs for Lys199 of
the NAD-malic enzyme37 and Arg69 of Sin resolvase.38 However, the active site
of HsPYCR1 does not have a preponderance of positively charged residues that
could depress the pKa of the proposed Thr residue. We mutated Thr238, which
forms a hydrogen bond to the imine nitrogen of L-proline in our structure (Fig.
2.5A). The mutation to Ala did not substantially diminish the kcat app, suggesting
that Thr238 is not essential for catalysis, whereas the kcat

app/K app
M

of T238A

mutant enzyme with varied L-P5C was 10-fold lower relative to wild type,
indicating that the loss of Thr238 impacts L-P5C binding. The observed T238A
mutant’s kcat app as 14 s-1 may be due to a small acid or proton donor such as a
water molecule that could enter and occupy the space devoid of steric bulk from
the side chain of Thr at residue 238, thus allowing a proton abstraction by the
imine nitrogen of L-P5C that affords some catalytic activity to occur. To rule out
this possibility and to determine if the polarity present in the side chain hydroxyl
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group of Thr is critical for catalytic activity, a prudent course of action would be an
isosteric mutation that removes the polar side chain group as in a Thr238Val
mutation. For reference, we note that mutation of Lys199 to Ala in the NAD-malic
enzyme decreases Vlim by 105-fold magnitude.37 Thus, it is concluded that Thr238
does not function as the general acid in HsPYCR1 but appears to have important
interactions with the imine nitrogen of L-P5C, as corroborated by the structural
and kinetic data.
Product(s) inhibition kinetics studies revealed L-Pro behaving as a
competitive inhibitor and NADP+ behaving as a mixed inhibitor against wild-type
HsPYCR1 enzyme, which is diagnostic of a sequential binding order with L-P5C
binding first to the enzyme followed by NADPH. This binding order is atypical of
the general family of dehydrogenase enzymes, i.e. lactate dehydrogenase, which
first binds NAD+/NADH before the second substrate.39 The proposed binding
order is supported by the X-ray crystal structure of HsPYCR1 in complex with LTHFA and NADPH (Fig. 2.6), which shows that L-THFA, an analog of both Lproline and L-P5C, is buried within the active site. The binding site for L-THFA
would be obstructed if NADPH were to bind first, thus supporting the sequential
binding order of the smaller L-P5C molecule followed by binding of the larger
NAD(P)H molecule. These findings are consistent with previous studies in which
bacterial (S. pyogenes) and plant (A. thaliana) P5CRs were also proposed to
follow a sequential-ordered binding mechanism with L-P5C binding prior to
NAD(P)H.13,40 Having the sequential-ordered binding mechanism of HsPYCR1
established will help guide development of new inhibitors and/or substrate
analogs as molecular probes for modulating HsPYCR1 activity.
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The noncanonical dinucleotide-binding site of HsPYCR1 proposed by Meng et
al. (2006)16 is not supported by the experimental data. The original NAD(P)H
cofactor ligand density was poor, the difference density was uniformly and
strongly negative, and the PDB_REDO pipeline essentially removed the
contribution of the cofactor and Glu ligands by elevating their temperature factors
to non-physical values. The NAD(P)H cofactor also had poor geometry and
formed several bad contacts, all of which are inconsistent with a well-defined
ligand-binding site.
This is in sharp contrast to the highly conserved nature of dinucleotide-binding
sites in other Rao-Rossmann fold proteins. First reported in the 1970s, the RaoRossmann fold consists of repeated βα motifs and comprises six (typically)
parallel β-strands with α-helices packed on either side of the β-sheet.30,41,42 The
dinucleotide binds with an extended conformation in the cleft found at the Ctermini of the strands, with the pyrophosphate interacting with the N-terminus of
αA and the Gly-rich β1-αA loop. Each base interacts with the opposing faces of
the β-sheet, forming a network of polar and non-polar interactions. A previous
analysis of 102 Rao-Rossmann fold protein structures representing 43 enzymes
and 40 species demonstrated a remarkably high consistency of the binding site
structure and cofactor conformation.33 In fact, the binding site is so consistent that
a conserved water molecule bridging the Gly-rich β1-αA loop and the
pyrophosphate could effectively be considered part of the dinucleotide-binding
motif.33 Indeed, this water molecule is present in our structures (Fig. 2.4). In this
context, it is surprising that a completely novel dinucleotide-binding mode for
HsPYCR1 was proposed with almost no discussion of the important way in which
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the site deviated from conventional wisdom.
Strong evidence from other structural studies also points to the mistaken
nature of the unconventional binding site16 of Meng et al. (2006). The core
structural elements of HsPYCR1 are superimposable with those of available
bacterial P5CR structures, and the dinucleotide ligands in the bacterial enzyme
structures conform to the classic paradigm for Rao-Rossmann fold proteins.13
Furthermore, the PDB contains an unpublished human PYCR1 structure (PDB
code 2IZZ) that contains NAD+ bound in the same location as our structure and
bacterial P5CR structures. All of the above structural work also supports the
conclusion that the binding site described by Meng et al. (2006)16 is incorrect.
Incorrect ligand-binding site notwithstanding, there are positive aspects to the
work of Meng et al. (2006). They were the first to establish that the fold of
HsPYCR1 is consistent with homologous enzymes. Also, they documented the
oligomeric state as a pentamer of intertwined dimers. These contributions to the
literature remain valid. Nevertheless, the record must be corrected regarding the
erroneous NAD(P)H-binding-site, and we recommend that correction take place.
We also recommend that the recent in silico analysis of cutis laxa HsPYCR1
mutants, which is based on the incorrect active site, be reevaluated with the
correct HsPYCR1 structure.43
Our results might explain why the canonical dinucleotide-binding site was
unoccupied in the Meng et al. (2006) structures. To obtain complexes, Meng et
al. (2006) soaked crystals in 0.3 mM NADH or NADPH.16 Our measurements with
HsPYCR1 indicate a KM app of 0.07 mM for NADH and 0.3 mM for NADPH (Table
2.1). Thus, the dinucleotide concentrations used by Meng et al. (2006)16 may not
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have been high enough for saturation.
Many examples of incorrectly built structures or misplaced ligands have
appeared in the crystallographic literature over the past few years.44,45,46,47 Some
have arisen from updates in genomic databases that revealed older structures
solved with incorrect sequences.44,48,49 Others are due to the very large number
of new structures appearing each year coupled with the fact that many of them
come from laboratories with little crystallographic experience.50 Further, there is
pressure now to produce faster, more numerous, and more novel results in
science,51 and ligand-binding density would be an important source of novelty.
Finally, reviewers are often judging structures without access to coordinate files
and electron density maps, making detailed verification of ligands difficult. Taken
together, this leads to a risk of inappropriate ligand placement.
It has been suggested that the risk of errors in ligand placement could be
mitigated by utilizing currently available structural tools.52,53 These tools
emphasize the inspection of electron density, stereochemistry, and ligand
environment.45,52 We suggest that the historical context of the ligand site also be
considered. In the case of a family like Rao-Rossmann dinucleotide-binding
proteins, which contain a highly conserved fold, strong proof should be required
of the authors before proposing a completely new binding site.
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Chapter 3

Kinetic and Structural Characterization of the Enzyme Mechanism
of wild-type HsPYCR2 and Disease Variants
ABSTRACT
Pyrroline-5-carboxylate reductase (PYCR) catalyzes the final step of L-proline
biosynthesis by reducing L-P5C into L-proline using NAD(P)H as the hydride
donor (Fig. 3.1). In humans, three isoforms (PYCR1, PYCR2, and PYCRL) are
known. Human PYCR1 and PYCR2 are localized in the mitochondrion and share
84% amino acid sequence identity, yet interestingly different disease symptoms
are found in patients that have mutations in PYCR1 or PYCR2. Recent genomewide association and clinical studies have revealed that homozygous mutations
in human PYCR2 lead to postnatal microcephaly and hypomyelination, including
hypomyelinating leukodystrophy type 10. To uncover biochemical and structural
insights into human PYCR2, we characterized the steady-state kinetics of wildtype enzyme along with two mutant variants, Arg119Cys and Arg251Cys, that
were previously identified in patients with microcephaly and hypomyelination.
Here we establish the substrate binding order for the human PYCR2 mechanism
and report the biochemical penalties of the PYCR2 disease variants. Structural
insights into human PYCR2 were also inferred by examining the X-ray crystal
structure of human PYCR1. From this model, Arg119 and Arg251 are predicted
to be important for the catalytic activity and structural stability of PYCR2,
respectively, which supports our kinetic assays showing a 164-fold loss in
catalytic activity for the Arg119Cys mutant relative to wild-type enzyme. The
Arg251Cys mutation has a profound effect on the thermostability and secondary
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structure of human PYCR2 as determined by fluorescence-based thermal shift
assays and circular dichroism, respectively. The PYCR2 disease variants are
concluded to impair PYCR2 function in patients by significantly lowering catalytic
activity (Arg119Cys) and stability (Arg251Cys).

Figure 3.1. Enzymatic reactions of L-proline metabolism in the mitochondrion.
Structural images are PyMol renderings of the following X-ray crystal structures:
dimeric TtPRODH (PDB code 2EKG), dimeric HsPYCR1 (PDB code 5UAV),
tetrameric HsALDH4A1 (PDB code 4OE5), and monomer of the L-glutamyl-γ-5phosphate reductase domain of HsALDH18A1 (PDB code 2H5G).
INTRODUCTION
Delta-1-pyrroline-5-carboxylate reductases (PYCRs or P5CRs) have been
identified as important housekeeping enzymes of L-proline (L-Pro) biosynthesis
and are broadly distributed across all three domains of life (eukaryota, bacteria,
and archaea).1 L-proline is synthesized from L-glutamate by the sequential action

of

L-Δ1-pyrroline-5-carboxylate
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synthase (a.k.a. aldehyde dehydrogenase 18A1,

ALDH18A1) and PYCR as shown in Fig. 3.1. L-proline is converted back to Lglutamate

via

L-proline

dehydrogenase

(PRODH)

and

L-glutamic-γ-

semialdehyde dehydrogenase (GSALDH) (a.k.a. aldehyde dehydrogenase 4A1,
ALDH4A1) as shown in Fig. 3.1. Both pathways share the intervening L-pyrroline5-carboxylate (L-P5C)/L-glutamic semialdehyde (L-GSAL) equilibrium step.
In terms of the current state of knowledge for human PYCR (HsPYCR, EC
1.5.1.2), a 2012 study on L-proline biosynthesis from melanoma tissue extracts
characterized three separate human genes encoding isozymes PYCR1, PYCR2,
and PYCRL (a.k.a. PYCR3).2 Subcellular localization studies identified HsPYCRL
as a cytosolic enzyme whereas HsPYCR1 and HsPYCR2 were identified as
mitochondrial enzymes.2 Pairwise global sequence alignment3 of HsPYCR1
(NCBI ref seq NP_008838.2, UniProtKB P32322) and HsPYCR2 (NCBI ref seq
NP_037460.2, UniProtKB Q96C36) indicates 84.4% amino acid sequence
identity between the two proteins. To date, structural knowledge of PYCR
consists of 20 total X-ray crystal structures from seven organisms (Homo

sapiens, Bacillus cereus, Coxiella burnetii, Streptococcus pyogenes, Neisseria
meningitides, Plasmodium falciparum, and Medicago truncatula) deposited in the
Research Collaboratory for Structural Bioinformatics-Protein Data Bank.4 Thus
far, two sets of X-ray crystal structures of human PYCR have been reported in
the literature.5, 6 The most recent is a 1.85 Å X-ray crystal structure determined by
Christensen et al. (2017) of the ternary complex of HsPYCR1 + NADPH + Lproline analog, L-tetrahydro-2-furoic acid (L-THFA) (PDB code 5UAV).6 The
structure by Christensen et al. resolved the location of the enzyme active site with

NADPH binding in the canonical Rao-Rossmann motif

GXGXXA/G7
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at the N-

terminus, which is consistent with known X-ray crystal structures of PYCR from
plants and bacteria.8 Although progress has been made on the structural and
functional characterization of HsPYCR1, considerably less is known about
HsPYCR2, which is the focus of this work.
L-proline biosynthesis has been implicated in different types of cancers.
Besides supporting protein synthesis, L-proline biosynthesis has been shown to
promote tumorigenesis by providing NAD(P)+ redox equivalents to support
aerobic glycolysis and the oxidative branch of the pentose phosphate pathway.9
Upregulation of HsPYCR2 has been found in different cancers such as
melanoma, breast, prostate, esophageal tumors, lung metastasis, Kaposi’s
sarcoma and primary effusion lymphoma, and cervical cancer.2,10,11,12,13 In a
mass spectrometry-based screening of metabolites in tissue sections from 256
esophageal squamous cell carcinoma (ESCC) patients, Sun et al. (2019) found a
significant upregulation of L-Pro metabolism in the cancer region compared to the
normal epithelium and muscle regions.11 Immunohistochemistry staining of the
ESCC tissue sections identified HsPYCR2 as the most enriched metabolic
enzyme in the cancer region, consistent with increased L-proline found in the
same tissue region.11 In two separate human melanoma cell lines, tumor cell
death was induced by silencing HsPYCR2 expression, indicating a critical role for
HsPYCR2 in cancer cells.14
More recently, Choi et al. (2020) verified a role for HsPYCR2 in Kaposi’s
sarcoma cells. With GST-tag pull down assays and mass spectrometry analysis,
the

authors

showed

that

Kaposi’s

sarcoma-associated herpesvirus K1
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oncoprotein binds endogenous human PYCR2 to commandeer L-proline
biosynthesis for increased intracellular L-Pro concentration that promotes in vitro
3D spheroid culture and in vivo tumorigenesis.12 From a kinetic standpoint, the
authors also demonstrated that the presence of viral K1 protein not only activated
and enhanced PYCR2 enzymatic affinity with L-P5C substrate with a 4-fold
decrease in the KM value, but also the viral K1 protein curtailed L-Pro product- or
ATP-mediated competitive inhibition of PYCR2.12 In the clinical setting of one
hospital in Bangkok, Thailand, Keeratichamroen et al. (2020) recently conducted
a pilot study examining changes in disease-relevant proteins in 31 patients with
human papilloma virus (HPV)-associated cervical cancer compared with 16
healthy control patients using immunoaffinity-depleted serum processing of blood
samples followed by liquid chromatography mass spectrometry analysis.13
Through the use of capillary electrophoresis-based western blot analysis and
receiver operating characteristic curves data analysis to quantify serum levels of
the candidate protein biomarkers for the detection of HPV-associated cervical
cancer, the authors identified high expression levels of PYCR2 in patients with
advanced-stage III-IV cervical cancer compared to either patients with earlystage I-II cervical cancer or with HPV positive normal controls, in a statistically
significant manner.13 In lieu of the current standard of practice for cervical cancer
screening tests including the Papanicolaou smear, visual inspection with acetic
acid, HPV DNA testing, and liquid-based cytology, the authors conjecture that
this unprecedented association between PYCR2 expression levels and cervical
cancer in tandem with the quantification of five other serum protein biomarkers
(A1AT, TTR, ApoA-I, VDBP, and MMRN1) can serve as a minimally invasive yet
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highly sensitive and specific screen for the detection of HPV-associated cervical
cancer.13
Autosomal recessive disorders of HsPYCR1 and HsPYCR2 have been
specifically linked to hypoprolinemia, cutis laxa and progeroid syndrome,
microcephaly, and neurological disorders. More specifically, mutations in
HsPYCR1 generally lead to cutis laxa type IIB (OMIM # 612940)15 whereas
mutations in HsPYCR2 are uniquely linked to genetic hypomyelinating
leukodystrophy type 10 with microcephaly (OMIM # 616420).16,17,18 Thus, it has
been suggested that PYCR1 mutations are most strongly associated with skin
disorders while PYCR2 mutations appear more prominent in neurological
disorders.18 In a study by Zaki et al. (2016) of HsPYCR2 mutations in patients
with lethal microcephaly, loss of HsPYCR2 was proposed to impair mitochondria
function and disrupt oxidative balance, namely NAD(P)+ levels.18 Thus it appears
HsPYCR2 not only helps drive the cellular supply of L-proline, but it also performs
redox cycling of NAD(P)H/NAD(P)+ to support cellular growth, which can have
profound effects in different disease contexts such as in cancers with upregulated
HsPYCR2 or neurological disorders associated with HsPYRC2 variants.
The need to investigate HsPYCR2 and disease variants stems in part from a
study by Nakayama et al. (2015) which showed that two families of human
patients were affected by the same allelic autosomal-recessive condition in the

PYCR2 gene.17 Two HsPYCR2 variants, R119C and R251C, were each identified
by a genome-wide association study to have a statistically significant linkage to
the observed neurological traits of hypomyelination and microcephaly in the
patients. These findings, along with the growing recognition of HsPYCR2 being
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implicated in different cancers (non-small cell lung cancer, viral-related
hepatocellular carcinoma, papillary renal cell carcinoma, melanoma, breast and
prostate cancers, and esophageal squamous cell carcinoma, Kaposi’s sarcoma,
and cervical cancer)19,20,21,14,9,11,12,13 motivated our investigation of the kinetic
mechanism of wild-type HsPYCR2 and the biochemical penalties of the clinically
relevant R251C and R119C mutations on HsPYCR2 function. Here we report the
steady-state kinetic parameters of HsPYCR2 wild-type and mutants R251C and
R119C along with thermostability and secondary structure analysis. Product(s)
inhibition studies of wild-type HsPYCR2 indicate a sequential-order binding
mechanism with L-P5C binding first.
MATERIALS AND METHODS.
Materials and Reagents
Milli-Q Ultrapure water was used for all experiments. The following reagents
were purchased from Millipore-Sigma: DL-5-hydroxylysine hydrochloride, sodium
metaperiodate, Dowex 50WX4 hydrogen form (200-400 mesh) cation exchange
resin, NaH2PO4, ε-amino-N-caproic acid, N-tosyl-L-phenylalanine chloromethyl
ketone, bovine serum albumin, nicotinamide adenine dinucleotide phosphate
reduced form (NADPH), nicotinamide adenine dinucleotide reduced form
(NADH), and ammonium fluoride (NH4F). The following reagents were from
Fisher Scientific: LB Agar Miller, ampicillin, yeast extract, NaOH, NaCl, 2-[4-(2hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), and ethylenediamine
tetraacetic acid (EDTA) disodium salt. Glycerol and tryptone were purchased
from Research Products International. Reagents β-octyl-D-glucopyranoside (βOG) and L-proline were from Combi-Blocks. Ethanol (190- or 200-proof) was
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from Decon Labs. Tris(hydroxymethyl)aminomethane (Tris), glycine, isopropyl βD-thiogalactopyranoside (IPTG), phenylmethylsulfonyl fluoride (PMSF), leupeptin
hemisulfate, and NAD+ were purchased from Gold Biotechnology. Imidazole and
(O)2-aminobenzaldehyde (o-AB) were purchased from Acros Organics, and
hydrochloric acid (HCl) 34-37% OmniTrace was purchased from EMD-Millipore.
DL-P5C synthesis
DL-P5C was synthesized according to the protocol by Williams and Frank,22
which involved the metaperiodation of DL-5-hydroxylysine hydrochloride at 4 °C
with the reaction product purified by Dowex 50WX4 cation exchange column
chromatography using 1 M HCl to elute the fractions of DL-P5C. Synthesized DLP5C was quantified using the o-AB assay in which DL-P5C and o-AB react to
form a yellow conjugate that is measured at 443 nm (ε443 = 2590 M-1 cm-1).23 DLP5C stock solutions were stored in 1 M HCl at 4 °C. DL-P5C as the main reaction
product was confirmed by liquid chromatography-electrospray ionization-multiple
reaction monitoring (LC-ESI-MRM) mass spectrometry. Additional details
concerning the synthesis and mass spectrometry characterization of DL-P5C are
provided in Appendix A.
Site-Directed Mutagenesis of HsPYCR2
The DNA sequence encoding human (Homo sapiens) PYCR2 transcript
variant 1 (NCBI RefSeq NM_013328.3) was subcloned into the pKA8H vector at
the BamHI and NdeI sites with a N-terminal 8x-Histidine tag (pKA8H/HsPYCR2).
The pKA8H/HsPYCR2 construct includes an ampicillin resistance marker gene
and was used as a template for generating mutants R119C and R251C. We used
a modified protocol from the GeneTailor Site-Directed Mutagenesis System
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(Invitrogen, Life Technologies) to introduce mutations via overlapping mutagenic
and non-mutagenic sequence PCR-based reactions. Primers were generated
using New England BioLabs NEBaseChanger online tool and Eurofins Genomics
oligonucleotide primer synthesis services. Forward mutagenic primers consisted
of an overlapping region, the mutation site, and an extended region, whereas the
reverse non-mutagenic primers consisted of a complementary overlapping region
and an extended region. The 21-bp forward 5ʼ-TGGGGGCTTCTGCTCTCTGCT3ʼ and reverse 5ʼ-CTCTCTAGAAAGTGCAGGGCG-3ʼ primers were used for
generating

the

R251C

mutant,

and

CAAAGTGATTTGCTGCATGACCAACACAC-3ʼ

the

29-bp

forward

5ʼ-

and

18-bp

reverse

5ʼ-

GGGGCTGGCTGGAATGCC-3ʼ primers were used for generating the R119C
mutant. The triplet codon of the mutation site is underlined in bold for each
forward primer. The wild-type and mutant constructs were confirmed by DNA
sequencing of the entire PYCR2 gene insert.
Expression and purification of HsPYCR2 wild-type and mutants
The pKA8H/HsPYCR2 constructs for wild-type and the R251C and R119C
mutant proteins were transformed into E. coli BL21 (DE3) pLysS competent cells
(Novagen-EMD Millipore Sigma) for recombinant protein expression. Cells were
grown on LB Agar Miller plates containing 50 μg/ml ampicillin and 34 μg/ml
chloramphenicol (Chem-Impex International). Starter cultures from the growth
plates were then made in LB broth, grown overnight and used to inoculate six 1
L-cultures of Terrific Broth (TB) media (prepared from recipe in Sambrook et al.
(1989) consisting of tryptone, yeast extract, glycerol, and water)24, which also
contained 50 μg/ml ampicillin and 34 μg/ml chloramphenicol. The 1-L cultures
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were grown at 37 °C (180 rpm) until reaching an optical density at 600 nm
(OD600) ≈ 0.8-1.0. The temperature was then lowered to 18 °C and IPTG (0.4 mM
final concentration) was added to the cultures to induce recombinant protein
expression. After induction with IPTG for 10 h (18 °C, 180 rpm), cultures were
then treated with 100 μg/ml chloramphenicol with continued shaking at 180 rpm
at 18 °C for an additional 2 h. The chloramphenicol treatment was found to
improve the solubility of the HsPYCR2 proteins, as chloramphenicol was
previously reported to enhance chaperone-assisted folding of target proteins.25
Cells were then harvested by centrifugation (5400 x g) (Avanti J-E High-Speed
Centrifuge, Beckman Coulter) for 20 min at 4 °C. Cell pellets were stored at -80
°C. Upon thawing, the cell pellets were resuspended in NPI-5 cell lysis buffer (5
mM imidazole, 500 mM NaCl, 50 mM NaH2PO4, pH 7.5) containing 500 μM
Tris(3-hydroxypropyl)phosphine (THPP) reducing agent (Strem Chemicals),
0.01% TritonX-100 detergent (Amresco), 0.01% Brij-35 polyoxyethylene
detergent (Santa-Cruz Biotechnology), 10 mM β-OG, and five protease inhibitors
(ε-amino-N-caproic acid, phenylmethylsulfonyl fluoride, leupeptin hemisulfate, Ntosyl-L-phenylalanine chloromethyl ketone and N-α-p-tosyl-L-lysine chloromethyl
ketone). The cell suspension was then sonicated for 5 min with 5 sec on and 15
sec off pulse settings using a Sonic Dismembrator (Model F 550, Fisher
Scientific). The resulting cell lysates were centrifuged (30960 x g) for 1.5 h at 4
°C to obtain the supernatant with the HsPYCR2 protein.
HsPYCR2 proteins were purified at 4 °C by immobilized metal affinity column
chromatography using a Ni2+-NTA Superflow resin (Qiagen). A stepwise gradient
of 5 mM, 60 mM, and 500 mM imidazole in 50 mM NaH2PO4-based column
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buffers was used to elute the HsPYCR2. Eluted fractions were analyzed by
sodium dodecyl sulfate poly-acrylamide gel electrophoresis (SDS-PAGE) using
(β)2-mercaptoethanol (Acros Organics) as a reducing agent. Fractions containing
HsPYCR2 were pooled and dialyzed (10 kDa molecular weight cutoff (MWCO)
Dialysis Snakeskin Tubing, ThermoFisher Scientific-Pierce Biotech) into 50 mM
HEPES (pH 7.5) buffer containing 250 mM NaCl, 0.5 mM EDTA, 500 μM
THPP, and 10 % (v/v) glycerol. HsPYCR2 proteins were concentrated using an
ultrafiltration stirrer cell (Model 8050, Amicon, EMD Millipore-Sigma) and a 5 kDa
PLCC low bind 44.5 mm diameter ultrafiltration disc (EMD Millipore-Sigma) at 4
°C until the protein solution volume was reduced to approximately 5 ml. Aliquots
of 1 ml were then placed into 2 ml microtubes and flash-frozen in liquid nitrogen.
The tube lids were subsequently pierced with fine needle and the frozen samples
were then further concentrated by freeze-dry vacuum lyophilization (FreeZone
Bulk Tray Dryer, Labconco) for 3-5 h until the volume was reduced to 250 μl. The
resulting concentrated protein was next exchanged into fresh 50 mM HEPES (pH
7.5) buffer as described above by microdialysis using inverted 15kDa MWCO
Tube-O-Dialyzer tubes (G Biosciences-Geno Technology). Protein concentration
was quantified by the 660 nm Pierce Protein Dye Assay (ThermoFisher ScientificPierce Biotech) as per manufacturer’s instructions. Finally, all protein samples
were

flash-frozen in liquid nitrogen in 500 μl aliquots and stored at -80 °C.

Proteins were analyzed by SDS-PAGE under reducing conditions on a 4-20 %
gradient gel and visualized using Bio-Safe Coomassie Blue G250 stain (Fig. 3.2).
The N-terminal 8x-His tag was retained in all the purified HsPYCR2 proteins. A
more thorough description of methods and procedures used for HsPYCR2
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protein purification can be found in Appendix B.

Figure 3.2. SDS-PAGE of HsPYCR2 enzymes. HsPYCR2 wild-type (2 µg), and
R251C (10 µg) and R119C mutant (2 µg) enzymes (each in 50 mM HEPES (pH
7.5) buffer containing 250 mM NaCl, 0.5 mM EDTA, 10% (v/v) Glycerol, 500 µM
THPP reducing agent) were mixed with denaturing loading dye buffer (50 mM
Tris-HCl pH 6.8, 2% SDS, 10% Glycerol, 0.02% Bromophenol Blue, and 10%
β(2)-Mercaptoethanol). Samples were thermally denatured at 100 oC and then
loaded onto a 4-20% gradient precast polyacrylamide-Tris-Gly HCl, 10-well MP
TGX gel (Bio-Rad). After the electrophoresis of the gel, it was stained with BioSafe Coomassie Blue G250 (Bio-Rad). The PageRuler Prestained Protein
Ladder (ThermoFisher Scientific) was used as reference to estimate the
molecular weight of the HsPYCR2 wild-type and mutant enzymes (each
containing an N-terminal (8x)His-tag). The predicted molecular weight of the
HsPYCR2 polypeptides is 36.1 kDa, which is consistent with the observed band
(black arrow) immediately above the 35 kDa marker.
Kinetic characterization of HsPYCR2 enzymes
Kinetics assays of HsPYCR2 were performed at 37 °C in 0.1 M Tris-HCl (pH
7.5) reaction buffer containing 0.01% Brij-35 detergent and 1 mM EDTA using a

protocol modified from previous

studies.26,8,27,28
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The catalytic activity of HsPYCR2

wild-type and mutants R251C and R119C were monitored by measuring the LP5C-dependent oxidation of NAD(P)H at 340 nm and at 380 nm, using millimolar
extinction coefficients 6.22 mM-1 cm-1 and 1.314 mM-1cm-1, respectively.29,2 The
concentrations of NADPH and NADH along with NADP+ (VWR International) and
NAD+ in 10 mM Tris-HCl pH 8 buffer, were spectrophotometrically determined
and stored at -80 °C. DL-P5C substrate solution stored at 4 °C in 1 M HCl, was
neutralized to pH 7.5 just prior to enzyme assays by adding 1 M Tris-HCl (pH 9.0)
buffer. NAD(P)H was varied (0-580 μM) while holding DL-P5C fixed at 5000 μM
and, DL-P5C was varied (0-5500 μM) while holding NAD(P)H fixed at 500 μM.
NAD+ product inhibition assays were performed by holding DL-P5C constant
(5000 μM) while varying NADH (0-580 µM) at different NAD+ concentrations (0500 µM). L-Pro inhibition assays were conducted by holding NADH constant (500
µM) and varying DL-P5C (0-5500 µM) at different L-Pro concentrations (0-500
µM). For assays in which DL-P5C was varied, the ionic strength was maintained
at approximately 450-480 mM Tris+Cl- at each DL-P5C concentration by adding a
balance of 1 M Tris-HCl (pH 7.5). The final assay volume was 600 μl in 1.5 ml
rectangular polystyrene cuvettes (1 cm pathlength) (USA Scientific). Reactions
were prewarmed at 37 °C and initiated by adding the enzyme last. The
absorbance decrease due to oxidation of NAD(P)H was monitored at 340 and
380 nm in a Varian Cary Bio 50 UV-Vis Spectrophotometer (Agilent
Technologies) against blanks from which the varied substrate had been omitted.
Final concentrations of enzyme used in the assays were 0.06 µM wild-type, 0.6
µM R251C mutant, and 3 µM R119C mutant.
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Enzyme activity was calculated from the linear portion of the initial
absorbance decrease using the Beer-Lambert-Bouguer law.30,31,32 Assays were
performed in triplicate and data were expressed as mean ± standard deviation.
Data were fit by nonlinear regression to the Henri-Michaelis-Menten equation
using SigmaPlot 12.0 (version 12.0.0.182, Systat Software) to estimate the
theoretical maximal velocity limit (Vlim) and the apparent Michaelis-Menten
constant (KM

app)

values (value ± standard error). The KM

assumed to be half the KM

app

for L-P5C was

value for the racemic DL-P5C mixture. The

apparent catalytic turnover rate (kcat
catalytic efficiency values (kcat

app

app)

app/K app)
M

and substrate specificity constant or
were calculated from Vlim and KM

app.

Product(s) inhibition kinetics were analyzed by global fitting of the data to
different inhibition models using Enzyme Kinetics Wizard Module in SigmaPlot
12.0 and by Hanes-Woolf plot analysis. For NAD+ product inhibition, the data fit
best to a mixed inhibition (Full) model with enzyme-inhibition constants KIC app and

KIU

app

= α(KIC

app)

(α = 0.4112). The mixed inhibition model had the highest

squared correlation coefficient (R2)-ranking among eight tested inhibition models.
For L-Pro product inhibition, the highest R2-ranking model was competitive
inhibition (Full).
Thermal Stability Assays
Thermofluor assays were used to determine the thermal stabilities of wild-type
HsPYCR2 and the mutants. Thermal stabilities of wild-type, R251C, and R119C
were measured in 50 mM HEPES (pH 8.0) buffer containing 150 mM NaCl, 0.5
mM EDTA, 500 µM THPP reducing agent, and 10 % (v/v) glycerol. Assays were
performed in a 50 μl reaction volume using white 8-strip 0.2 ml PCR tubes with
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individual flat optically clear caps (Phenix Research Products). The reaction
mixtures included 6.4 µM of HsPYCR2 wild-type and mutant enzymes, various
single additions and combinations of 1 mM NADH, 1 mM DL-P5C (pH 7.5), 1 mM
NAD+, and 1 mM L-Pro (pH 8.0), and the reaction volume balanced with 100 mM
potassium phosphate (pH 7.0) buffer. Sypro Orange fluorescent dye (λex = 470
nm, λem = 570 nm, Molecular Probes) was added last at (25X) final concentration
strength, and then the PCR tubes were covered with aluminum foil to protect from
light during mild agitation using a rocking shaker for 4 h at 4 °C.
Next, a mini plate spinner (Model MPS C1000, LabNet) was used for 60 sec
at 2500 rpm to force liquid contents towards the bottom of the tubes. Sample
tubes were then loaded into an iCycler chassis (Bio-Rad) to initiate data
collection using the MyiQ Single-Color Real-Time PCR Detection System with
optics module (CCD camera bandpass optical Filter 2 position at (λex = 485 ± 20
nm, λem = 530 ± 30 nm)) using iQ5 Optical System software (Bio-Rad, version
2.1). Thermal denaturation curves were recorded using a 10 min thermal
equilibration period at 20 °C followed by increasing temperature increments at
0.2 °C per 15 sec from 20-90 °C. The instrument’s software provided overlay
plots of relative fluorescence units (RFU) vs. temperature (T) and of (–d(RFU)/dT)
vs. T. From the raw numerical data, mean values of triplicate control blank curves
without the enzyme were subtracted from corresponding mean values of
quadruplicate curves with the enzyme for data analysis using Microsoft Excel
2017 and SigmaPlot 12.0.
The data was fit to a non-linear Boltzmann model:
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𝑓𝑓 =
where f

𝑦𝑦0 + (𝑎𝑎 − 𝑦𝑦0)

�1 + 𝑒𝑒

−(𝑥𝑥−𝑥𝑥0)
�
�
𝑏𝑏

�

is the fluorescence intensity at temperature x, y0 and a are

pretransitional and posttransitional fluorescence intensities, respectively, and b is
a slope factor. Analysis of the Boltzmann model fit curve facilitated determination
of x0 as the melting point temperature (Tm) that occurs at the midpoint of inflection
in the unfolding transition of (RFU vs. T) plots. Statistical comparisons between
paired groups of data were performed using Student’s t-test calculations in
Microsoft Excel 2017 with p < 0.05 and at 95% confidence level considered
statistically and significantly different.
Circular Dichroism (CD) Spectroscopy
Wild-type HsPYCR2 and mutants R251C and R119C were microdialyzed into
10 mM NaH2PO4 (pH 8.0) containing 250 mM NH4F buffer for 16 h at 4 °C. Then,
1200 µl of each protein sample (final concentration 4 µM) was loaded into an
individual 0.01 cm-optical length micro-cylindrical Suprasil cell (Starna Cells) and
spectra in the far UV wavelength range of 180-260 nm were collected at 22 °C
using a CD spectrophotometer (Jasco, Model J-815) with Spectra Manager
software (Jasco, version 2.10.01). Averaged baseline scans of buffer alone were
measured before averaged sample scans of each protein sample. Instrument
scanning parameters were 0.5 nm data pitch interval, standard sensitivity, 4-sec
data integration averaging time, bandwidth = 1.00, continuous scan mode with
scanning speed of 100 nm/min, baseline correction = baseline measured, and
accumulation scans = 16. The raw data was converted into Mean Residue
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2

-1

Ellipticity (θ, in units deg cm dmol ) using the following equation:
Mean Residue Ellipticity =
1 deg
(CD Jasco value in units mdeg) × � 3
�
⎞
10 mdeg
⎟
1 µmol
1 mol
10 dmol
1L
1m3
(0.01 cm pathlength) × (4 µM) × �
(340
� × � 6
� × �
� × � −3 3 � × � 6 3� ×
aa residues)
1 mol
1 µM ∙ 1 L
10 µmol
10 m
10 cm
⎝
⎠
⎛
⎜

Secondary structure elements (8 individual components) for each protein

were determined from a mathematical fit to the experimental CD spectra (190250nm) using the online BeStSel algorithm.33 The CD spectra (plotted as Mean
2

-1

Residue Ellipticity (θ) in units deg cm dmol vs. Wavelength (λ) in units nm) and
corresponding high tension (HT) voltage spectra of HsPYCR2 wild-type and
mutants R119C and R251C

(codes CD0006228000, CD0006229000, and

CD0006230000, respectively) have been deposited in the publicly accessible
Protein Circular Dichroism Data Bank (http://pcddb.cryst.bbk.ac.uk).
RESULTS
Steady-state Kinetic Parameters of HsPYCR2 Wild-type and Mutants
In previous studies, the enzymatic activity of the inherited HsPYCR2 mutants
leading to microcephaly and hypomyelination in human patients was not
reported. Proline levels in patients were found to be normal by plasma amino
acid analysis, suggesting proline depletion was not a biochemical factor in the
pathophysiology.17,18,34 However, cells harboring the HsPYCR2 mutants exhibited
higher apoptosis rates under oxidative stress and were characterized by a lower
mitochondrial membrane potential.17 To provide further insight into the
biochemical penalties of the R119C and R251C mutations, we determined the
steady-state kinetic parameters of HsPYCR2 wild-type and mutants with respect
to L-P5C and NAD(P)H substrates.

61
Table 3.1 provides the kinetic parameters for HsPYCR2 wild-type and
mutants R251C and R119C.
Table 3.1. Steady-state kinetic parameters for HsPYCR2a
Enzyme
Wild-typeb
R251Cc
R119Cd
Wild-typeb
R251Cc
R119Cd

(kcat app/KM app )
(M-1 s-1)

Varied
Substrate

Fixed
Substrate

DL-P5C

NADHe

1509 ± 69g

61.3 ± 1.4

(41 ± 2) x 103

DL-P5C

NADPHe

994 ± 134g

26.0 ± 1.5

(26 ± 4) x 103

DL-P5C

NADHe

1315 ± 291g

3.2 ± 0.3

(2.4 ± 0.6) x 103

DL-P5C

NADPHe

1499 ± 152g

3.1 ± 0.1

(2.1 ± 0.2) x 103

DL-P5C

NADHe

317 ± 90g

0.08 ± 0.01

(0.25 ± 0.08) x 103

DL-P5C

NADPHe

334g,h

0.13h

0.4h x 103

NADH

DL-P5Cf

298 ± 73

47.9 ± 5.3

(161 ± 44) x 103

NADPH

DL-P5Cf

216 ± 17

24.0 ± 0.7

(111 ± 9) x 103

NADH

DL-P5Cf

953 ± 321

5.9 ± 1.4

(6.2 ± 2.5) x 103

NADPH

DL-P5Cf

119 ± 10

1.8 ± 0.1

(15 ± 1) x 103

NADH

DL-P5Cf

34 ± 5

0.015 ± 0.001

(0.44 ± 0.07) x 103

NADPH

DL-P5Cf

537h

1.5h

2.8h x 103

KM app (µM)

kcat app (s-1)

aValue

± std error are the apparent best-fit parameters from non-linear least-squares fit
of the data to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version
12.0.0.182, Systat Software). Data plotted as the (mean ± SD) of n=3 technical
replicates.
bFinal enzyme concentration of 0.06 µM in the assay.
cFinal enzyme concentration of 0.6 µM in the assay.
dFinal enzyme concentration of 3 µM in the assay.
eNAD(P)H concentration fixed at 500 µM.
fDL-P5C concentration fixed at 5000 µM.
gReported value is the concentration of L-P5C, which is assumed to be half the
concentration of the DL-P5C racemic mixture.
h(Values) are the apparent best-fit parameters from non-linear least-squares fit of the
data (single replicate, n=1) to the Henri-Michaelis-Menten equation using SigmaPlot
12.0.

Wild-type HsPYCR2 did not show a strong preference for NADH or NADPH when
keeping L-P5C fixed as indicated by similar apparent kcat/KM values of (160 ± 44)
x 103 M-1 s-1 and (111 ± 9) x 103 M-1 s-1, respectively. Accordingly, wild-type

HsPYCR2 displayed similar kcat/KM
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values when varying L-P5C and keeping

NADH or NADPH constant. These findings contrast with a previous study by De
Ingeniis et al. in which HsPYCR2 was reported to have 2.5-fold higher activity
with NADH relative to NADPH.2 Both HsPYCR2 mutants R251C and R119C
exhibit substantially lower activity relative to the wild-type enzyme. Figure 3.3
shows Henri-Michaelis-Menten plots of the kinetic data in which L-P5C is varied
and NADH is held constant.

Figure 3.3. Steady-state kinetics of HsPYCR2. Overlay of Henri-MichaelisMenten kinetics traces of 0.06 µM wild-type HsPYCR2 (dark blue), 0.6 µM R251C
mutant (dark gray), and 3 µM R119C mutant (dark orange) enzymes. Assays
were performed in 0.1 M Tris-HCl (pH 7.5) reaction buffer at 37 °C with varying
DL-P5C (0-5500 µM) concentration and holding NADH fixed at 500 µM. Each
data trace is plotted as (mean ± SD) of three technical replicates with non-linear
least-squares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0.
The kcat app values with L-P5C as the varying substrate were 19-fold and 766-fold
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lower for R251C and R119C mutants, respectively, than wild-type HsPYCR2.
Similarly, significant lower activities were observed with the mutants when
NADPH was held fixed. The resulting kcat app/KM app values for R251C and R119C
were estimated to be 12-fold and 104-fold lower, respectively, than the wild-type
enzyme. The apparent kcat/KM values when varying NADH and holding L-P5C
fixed were 26-fold and 366-fold lower than wild-type HsPYCR2 for R251C and
R119C mutants, respectively. Thus, the R119C mutation clearly has the most
significant impact on HsPYCR2 activity.
This loss of catalytic activity may be explained by inference from the
homologous structure of the ternary complex HsPYCR1 + NADPH + L-THFA
(PDB code 5UAV),6 in which the Arg119 site occurs near the posterior wall of the
enzyme’s active site (Fig. 3.4). Mutation at sites Arg119 or Arg251 may have
disrupted the conformation flexibility of the HsPYCR2 structure, perhaps in
vicinity of the cofactor substrate binding site, thus leading to decreased kinetics of
cofactor substrate entrance and egress.36 When performing the R119C mutant
enzyme activity assays with DL-P5C and NADPH substrates, we encountered an
obstacle of limited amounts of R119C mutant enzyme to carry out more technical
replicates, yet we still suspect that the drastic loss of catalytic activity is due to
this mutation in proximity to the enzyme’s active site.
Product(s) Inhibition and Substrate Binding Order
The binding order of L-P5C and NADH to HsPYCR2 was evaluated by
product(s) inhibition studies.37 The inhibition of HsPYCR2 by NAD+ was first
examined by varying NADH and holding DL-P5C constant. Table 3.2 shows that
increases in NAD+ concentration (0-500 µM) results in a decreasing trend in
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Figure 3.4. Illustration of Arg119 and Arg251 impacting α-helices H and I in
PYCR. Diagram was prepared with PyMOL35, showing a surface rendering with
transparency and clipped away perspectives of the dimeric view (light pink and
deep blue surfaces are partner monomers) of the experimental X-ray crystal
structure of HsPYCR1 + NADPH + L-THFA (PDB code 5UAV).6 Mutations at
conserved sites R119 and R251 (shown as green and light gray stick figures,
respectively) in HsPYCR2 enzyme perhaps locally destabilize α-helices H and I
(residues Glu164 - Lys194). In reference to the Arg119 site on the posterior wall
of the active site containing NADPH and L-THFA (shown as orange and yellow
stick figures, respectively, the latter of which is in proximity (2.6 Å) to the deep
blue monomer’s side chain hydroxyl group of Thr238 active site residue) within
the same (light pink) protein monomer, a side-chain guanidinium nitrogen of
Arg119 may be hydrogen-bonded within close proximity (2.9 Å) to the side chain
carboxyl oxygen of Glu164 (shown as magenta stick figure), which projects from
the α-helix H backbone. In reference to the other (deep blue) protein monomer’s
Arg251 site, its side chain guanidinium nitrogen may be hydrogen-bonded within
close proximity (2.8 Å) to the side chain carboxyl oxygen of the same (light pink)
protein monomer’s Asp186 (shown as magenta stick figure), which projects off of
the α-helix I backbone and may be affecting the α-helical H and I kink region’s
Pro178 site (shown as deep teal stick figure).

kcat

app

and a slightly lower apparent KM. With increasing NAD+ concentration,

trends of both increasing values of (1/KM

app)

and (1/Vlim) support the model of

mixed inhibition by NAD+ (Table 3.2 and Figure 3.5, A).38 Global fitting of the data
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Table 3.2. Steady-state kinetic parameters for NAD+ product inhibition of
HsPYCR2a,b,c

KM app (µM)

kcat app (s-1)

(kcat app/KM app)
(M-1 s-1)

0

298 ± 73

47.9 ± 5.3

(161 ± 44) x 103

100

259 ± 53

37.3 ± 3.2

(144 ± 32) x 103

250

209 ± 31

26.5 ± 1.5

(127 ± 20) x 103

500

211 ± 15

19.1 ± 0.5

(90.5 ± 7.0) x 103

NAD+
(µM)

KIC app (µM)

KIU app (µM)

792 ± 248d

326 ± 102d

Value ± std error are reported for the apparent best-fit parameters of non-linear leastsquares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical
replicates.
bFinal enzyme concentration of 0.06 µM in the assays.
cDL-P5C concentration was held constant at 5000 µM and NADH concentration was
varied from 0-580 µM.
app (competitive inhibition) and K app (= α (K app))
dApparent inhibition constants, K
IC
IU
IC
(uncompetitive inhibition) were estimated by fitting the data to the Mixed Inhibition (full)
model with α = 0.4112 using the Enzyme Kinetics Wizard Add-In on SigmaPlot 12.0
(version 12.0.0.182, Systat Software).
a

to a mixed inhibition model provided estimates of apparent competitive (KIC) and
uncompetitive (KIU) inhibition constants for NAD+ (Figure 3.5, A). L-proline
inhibition of HsPYCR2 wild-type was evaluated by varying DL-P5C (0-5500 µM)
and holding NADH fixed. Table 3.3 shows that with increasing the L-proline (0500 µM) the value of KM

app

increased whereas Vlim remained fairly unchanged

consistent with competitive inhibition by L-proline (Table 3.3 and Figure 3.5, C).38
Table 3.3. Steady-state kinetic parameters for L-proline product inhibition of
HsPYCR2a,b,c
L-proline
(kcat app/KM app )
KM app (µM)d
kcat app (s-1)
KIC app (µM)
(µM)
(M-1 s-1)
0

1509 ± 69

61.3 ± 1.4

(40.6 ± 2.1) x 103

100

2126 ± 147

52.6 ± 2.0

(24.7 ± 1.9) x 103
103

250

1627 ± 272

34.5 ± 2.8

(21.2 ± 4.0) x

500

3149 ± 590

42.3 ± 4.9

(13.4 ± 3.0) x 103

145 ± 8e
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Value ± std error are reported for the apparent best-fit parameters of non-linear leastsquares fit to the Henri-Michaelis-Menten equation using SigmaPlot 12.0 (version
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical
replicates.
b
Final enzyme concentration of 0.06 µM in the assays.
c
NADH concentration was held constant at 500 µM while DL-P5C concentration was
varied 0-5500 µM.
dReported value is the concentration of L-P5C, which is assumed to be half the
concentration of the DL-P5C racemic mixture.
e
Apparent competitive inhibition constant, KIC app, was estimated by fitting the data to the
Competitive Inhibition (full) model using the Enzyme Kinetics Wizard Add-In on
SigmaPlot 12.0 (version 12.0.0.182, Systat Software).
a

A

C

B

D

Figure 3.5. Product(s) inhibition kinetics of wild-type HsPYCR2. Henri-MichaelisMenten plots of assays performed at (A) different NAD+ concentrations (0-500
µM) while varying NADH and holding DL-P5C constant (5000 µM) and (C)
different L-proline concentrations (0-500 µM) while varying DL-P5C and holding
NADH constant (500 µM). Hanes-Woolf plots of the data in panels A and C for
inhibition of HsPYCR2 by (B) NAD+ and (D) L-proline. Data are plotted as (mean
± SD) of three technical replicates with non-linear least-squares fits to the HenriMichaelis-Menten equation and linear regression fits to the Hanes-Woolf
equation using SigmaPlot 12.0.
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Best fits of the data to a competitive inhibition model yielded an apparent KIC
value of 145 µM L-proline (Figure 3.5, C). Hanes-Woolf plots of the NAD+ and LPro inhibition data also show linear regressions consistent with mixed and
competitive inhibition, respectively (Figure 3.5, B and D). In these plots, linear
trends converging at a common negative horizontal axis intercept with an
increasing slope (1/Vlim) effect (Figure 3.5, B) indicates NAD+ is a mixed
noncompetitive inhibitor39 of HsPYCR2 with respect to NADH. Parallel linear
trends with an increasing vertical axis intercept (KMapp/Vlim) effect (Figure 3.5, D)
indicate L-proline is a competitive inhibitor39 with respect to L-P5C. Taken
together, these modes of inhibition by each product ligand support the proposed
sequential-ordered binding mechanism shown in Figure 3.6.37
(A)

(B)

L-P5C

E

(P)

NADH

E• L-P5C

E• L-P5C• NADH

NAD

E• L-Pro• NAD+

(Q)
+

L-Pro

E• L-Pro

E

Figure 3.6. Cleland diagram of the proposed sequential-ordered binding
mechanism of HsPYCR2. First (A) and second (B) substrates bind in order to
HsPYCR2 and, following the chemical step, the first (P) and second (Q) products
are released in sequential order.
Because PYCR has been reported to catalyze the reverse reaction with Lproline and NAD+,40,41 we thought it would be prudent to test whether HsPYCR2
exhibits reversible activity which would interfere with the above product inhibition
assays. No formation of NAD(P)H was observed over 10 min (Fig. 3.7). Thus,
HsPYCR2 activity is only detected in the forward direction toward L-proline
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production.
A

B

Figure 3.7. Test for HsPYCR2 reverse activity with L-proline. Absorbance traces
of HsPYCR2 wild-type enzyme (0.6 µM final concentration) with L-proline (10
mM) and (A) 1 mM NAD+ or (B) 1 mM NAD(P)+. Assays (600 µL total volume)
were performed in 0.1 M Tris-HCl (pH 7.5) containing 0.01% Brij-35 detergent,
and 1 mM EDTA at 37 °C and absorbance at 340 nm was monitored for 10 min.
Thermal Stability of HsPYCR2 Wild-type and Mutants
The thermal unfolding of HsPYCR2 proteins was measured in the absence
and presence of all combinations of substrates and products to examine
HsPYCR2 stability and the functional consequences of the R119C and R251C
Table 3.4 Melting point (Tm) values of HsPYCR2 determined by
Thermofluor assays
Ligand(s)c

Tm (°C)a
Wild-typed

R251Cd

R119Cd

None

69.2 ± 0.1†

54.2b

67.6 ± 0.1£

NADH

69.0 ± 0.1

54.9b

66.4 ± 0.1

DL-P5C

69.0 ± 0.1

53.4 ± 0.1

67.2 ± 0.1

NADH + DL-P5C

53.2 ± 0.1†

55.4b

54.9 ± 0.1£

NAD+

69.6 ± 0.1

53.0 ± 0.2

67.6 ± 0.1

L-Pro

69.4 ± 0.1§

52.9 ± 0.1§‡

67.6 ± 0.1‡

NAD+ + L-Pro

69.3 ± 0.1֎

56.6b

67.4 ± 0.1֎
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Melting point temperatures (Tm) are reported as value ± std error and were determined
from the apparent best fit estimates of dynamic curve fits to a user-defined sigmoidal, 4
parameter equation modeled as the Boltzmann equation in SigmaPlot 12.0 (version
12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=4 technical
replicates.
b
Melting point temperatures reported as the local minimum value from the plot of (–
d(RFU)/dT vs. T) using SigmaPlot 12.0 (version 12.0.0.182, Systat Software) with data
plotted as (mean ± SD) of n=4 technical replicates.
c
Each ligand concentration was 1 mM in the assays.
d
Enzyme concentration was 6.4 µM in all the assays.
†
According to Student's t-statistic, wild-type (none) and wild-type (NADH + DL-P5C) Tm
values are statistically different at 95% confidence level (n=4).
§
According to Student's t-statistic, wild-type (+ L-Pro) and R251C mutant (+ L-Pro) Tm
values are statistically different at 95% confidence level (n=4).
‡According to Student's t-statistic, R251C mutant (+ L-Pro) and R119C mutant (+ L-Pro)
Tm values are statistically different at 95% confidence level (n=4).
֎According to Student's t-statistic, wild-type (NAD+ + L-Pro) and R119C mutant (NAD+ +
L-Pro) Tm values are statistically different at 95% confidence level (n=4).
£According to Student's t-statistic, apo-R119C mutant and R119C mutant (NADH + DLP5C) Tm values are statistically different at 95% confidence level (n=4).
a

mutations. HsPYCR2 unfolding was monitored using the Sypro orange reporter dye
which increases in fluorescence emission at 610 nm upon binding to surface-exposed
hydrophobic-patches as the protein unfolds.42 The thermal unfolding traces for

HsPYCR2 wild-type and mutants are in shown in Figure 3.8 and the
corresponding melting point temperatures (Tm) are summarized in Table 3.4.
Wild-type HsPYCR2 and the mutant R119C exhibited similar Tm values whereas
A

C
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Figure 3.8. Thermal stability assays of HsPYCR2. Relative fluorescence intensity
units (RFU) vs. T (°C) from Thermofluor assays are shown for (A) HsPYCR2
wild-type, and mutant enzymes (B) R251C and (C) R119C. The legend indicates
the different combinations of substrate and product ligands (1 mM) each trace.
(D) A derivative plot of the thermal shift data for HsPYCR2 wild-type (dark blue),
R251C mutant (dark grey), and the R119C mutant (dark orange) in the presence
of 1 mM L-proline. The local trough minimum indicates the melting point
temperature (Tm) for each enzyme. All Thermofluor assays were performed with
6.4 µM enzyme.
the R251C mutant displayed a Tm value (54.2 °C) that was nearly 15 °C lower
than the wild-type enzyme (69.2 °C). Unfortunately, some of the unfolding
transitions could not be fit to the Boltzmann Equation model used for Tm
determinations, particularly for several R251C mutant curves (Fig. 3.8, B).
To verify the lower melting point temperatures of R251C, the data was also
visualized as -d(RFU)/dT vs. T plots (Fig. 3.9). Figure 3.8, panel D shows a plot
of wild-type HsPCYR2, R251C, and R119C in the presence of L-proline which
clearly shows local minimum values of the troughs confirming significantly leftshifted Tm values for the R251C mutant (ranging 53-56 °C) indicating lower
thermostability relative to HsPYCR2 wild-type (Tm ≈ 69 °C) and the R119C
mutant (Tm ≈ 67 °C).
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Figure 3.9. Fluorescence-based protein thermal shift profiles of R251C mutant
enzyme with no ligand or combinations of substrate ligands or product ligands.
Thermofluor assay traces of (-d(RFU)/dT) vs. T (°C) for 6.4 µM R251C mutant
enzyme with (A) no ligand, (B) 1 mM NADH, (C) 1 mM DL-P5C, (D) 1 mM NADH
+ 1 mM DL-P5C, (E) 1 mM NAD+, (F) 1 mM L-Pro, and (G) 1 mM NAD+ + 1 mM
L-Pro. Local minima of the troughs in the plots represent melting point (Tm)
determinations. The trough minima of the traces are annotated.
Adding substrates individually had no effect on the thermal stability of the
HsPYCR2 enzymes, however, the combination of NADH and DL-P5C induced
significantly lower (95% confidence level, n=4) Tm values for the wild-type
enzyme (53.2 °C) and the R119C mutant (54.9 °C). Incubation of the HsPYCR2
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enzymes with products had no effect on the observed Tm values. Because the
observed effect on Tm is only observed when both substrates (NADH + DL-P5C)
are present, the ternary complex of HsPYCR2-P5C-NADH may induce a
conformational change during catalytic turnover that is less stable than the
enzyme alone.
Secondary Structure of HsPYCR2 Wild-type and Mutants
The CD spectra of HsPYCR2 wild-type and mutants are shown in Figure 3.10.
The CD spectrum of the R119C mutant was typical of a protein with strong αhelical character whereas the spectrum of wild-type HsPYCR indicates less αhelical character. Most notably, the R251C mutant displays the lowest amount of
α-helical character of the HsPYCR2 proteins.
To provide more insight into the observed differences in the CD spectra,
secondary structure analysis was performed using the β-structure selection
(BeStSel) method that takes into account the twist of β-structures.33 BeStSel
accommodates for the spectral diversity of β-structures which is sometimes a
drawback of CD spectroscopy, and was recently shown to outperform 11 other
secondary structure estimation algorithms.33 Figure 3.10, panels B-D show
secondary structural analysis of HsPYCR2 wild-type, and the mutants R251C
A
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Figure 3.10. Secondary structure analysis of HsPYCR2 wild-type and mutant
enzymes. (A) CD spectra of HsPYCR2 wild-type (dark blue), and the mutants
R251C (dark grey) and R119C (dark orange) (4 µM each). Secondary structure
analysis of (B) HsPYCR2 wild-type, and the mutants (C) R251C and (D) R119C.
The experimental CD spectrum of each protein was fit with the BeStSel
algorithm33 and analyzed for eight secondary structure components: α-helix,
regular; α-helix, distorted; left-hand twisted antiparallel β-strand or sheet; relaxed
antiparallel β-strand or sheet; right-hand twisted antiparallel β-strand or sheet;
parallel β-strand or sheet; turns; and other (310-helix, π-helix, β-bridge, bend,
loop/irregular, and other invisible regions). The different secondary structure
component contributions to the CD spectrum of each protein are expressed as a
normalized percent.
and R119C, respectively. The overlay traces of the BeStSel algorithm fits to the
experimental CD spectra (190-250 nm) of HsPYCR2 wild-type, R251C, and
R119C shown in Fig. 3.11 exhibited high calculated values of Pearson correlation
coefficients43 of 0.9928, 0.9975, and 0.9790, respectively, suggesting a strong
reliability of the secondary structure estimations for each protein (Table 3.5).
A

B

C

Figure 3.11. BeStSel algorithm fits to experimental CD spectra of HsPYRC2
proteins. Shown is the overlay of the experimental CD spectra (solid line) and the
best-fit CD spectra (dotted line) generated by the BeStSel algorithm.33 Data are
plotted as Molar Circular Dichroism (Δε) in units M-1 cm-1 versus wavelength for
(A) HsPYCR2 wild-type, (B) R251C mutant, and (C) R119C mutant enzymes.
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The BeStSel structural explanations for the observed CD spectra indicate that
the R119C mutant has an overall α-helical character (fαR + fαD) that is over 2-fold
(14.9 %) higher than HsPYCR2 wild-type (6.3 %) (Figure 3.10, B and D and
Table 3.5). The R251C mutant is estimated to have substantially lower α-helical
character than HsPYCR2 wild-type but has 2-fold (44.9%) higher antiparallel βstrand character (fβAnti1 + fβAnti2 + fβAnti3) than the wild-type enzyme (20.6 %)
(Figure 3.10, B and C and Table 3.5) .
DISCUSSION
In this work, functional and structural characterization of HsPYCR2 mutants
R119C and R251C was provided to gain insight into how these mutations may
contribute to hypomyelinating leukodystrophy type 10, an autosomal recessive
neurological disorder. Different clinical studies have found that patients with
inborn genetic errors in the PYCR2 gene initially possess normal growth
parameters and brain anatomy at birth, but then progressively develop
microcephaly, hypomyelination, and failure to thrive complications that lead to
cognitive and motor deficits that eventually terminate their lives in childhood.34,44
Zaki et al.’s (2016) study of 14 affected individuals ascertained that the patients
harbored either a stop codon mutation that results in depletion of PYCR2 or one
of five missense mutations in the dimerization domain, such as Arg199Trp and
Cys232Gly.18 Expression levels of missense PYCR2 mutants were not found to
be significantly decreased relative to wild-type PYCR2, however, based on
coimmunoprecipitation experiments of PYCR2 in 293T cells, the authors reported
on impaired protein multimerization of the patient protein variants,18 indicating the
mutant proteins may not form a proper oligomeric structure, which for human
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PYCR1 is a

pentamer-of-dimers.6

More recently, Escande-Beillard et al. (2020) developed a Pycr2-/- mouse
model, in which both PYCR2 and incidentally PYCR1 protein expression was
limited, indicating that the loss of PYCR2 was not compensated by the
engagement of PYCR1 activity to counteract the pathogenesis of recessive
hypomyelinating

leukodystrophy

type

10.44

Upon

performing

liquid

chromatography-tandem mass spectrometry of Pycr2-/- mouse brain tissue
samples, analysis of several amino acids that behave as neurotransmitters was
unremarkable except for substantially and significantly high levels of glycine, an
excitatory neurotransmitter, in all tested brain regions. Based on marked neuronal
and

oligodendroglial

morphological

changes

indicative

of

axonopathy,

hypomyelination, and premature apoptosis found in both brain MRI scans of
HLD10 patients and immunofluorescence analysis of Pycr2-/- mouse brain
tissues, the authors remarked that PYCR2 deficient patients and mice showed
signs of cerebral hyperglycinemia with encephalopathy.44 Using proximity-based
BirA-protein

label

proteomics

on

primary

human

cell

lines,

serine

hydroxymethyltransferase (SHMT2), the rate-limiting mitochondrial enzyme
responsible for glycine synthesis, was not only found among the top five PYCR
protein-protein interaction candidates, but endogenous protein expression (as
well as mRNA levels in mice) of SHMT2 were significantly upregulated in the
absence of PYCR2.44 Further immunofluorescence staining and quantitative
analyses demonstrated that knockdown of SHMT2 could rescue both axonal
beading and reduced neurite length (phenotypes of axonal injury) of cultured
Pycr2-/- mouse neurons.44
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Here we show two missense mutations (R251C and R119C) in the PYCR2
gene that are linked to HLD10 marked by axonal injury and microcephaly, impair
HsPYCR2 catalytic activity. The observed loss in activity results from different
underlying causes in the two mutants. Currently X-ray crystal structures of
HsPYCR2 are not available. However, Arg119 and Arg251 are conserved in
HsPYCR1, thus allowing their structural contributions to be examined. The
structure of HsPYCR1 in complex with NADPH and L-THFA (PDB code 5UAV) is
shown in Figure 3.4.6 Arg119 (green sticks) and Arg251 (light gray sticks) are
from different protomers but interact with Glu and Asp residues of one protomer
on α-helices H and I, which are split by a kink formed by Pro178. The active site
is formed at the dimer interface with Thr238 of one protomer (see chapter two,
Fig. 2.6) forming a key hydrogen bonding interaction with the ring oxygen of LTHFA, which is synonymous with the imine nitrogen of L-P5C or L-Pro. Arg119
resides on a β-strand of the Rao-Rossmann fold with its side chain guanidinium
group within 2.9 Å to the side chain carboxylate groups of Glu164 of α-helix H of
the same protomer. Thereby, Arg119 likely helps stabilize α-helix H which has a
critical role in shaping the active site.6 The loss of enzyme activity in the R119C
mutant of HsPYCR2 is likely related to disrupting the active site environment.
Why the R119C would exhibit enhanced α-helical character as observed by CD
spectroscopy is not clear from the structure of HsPYCR1.
As shown in Figure 3.4, the partner protomer’s (deep blue) Arg251 site has its
side chain guanidinium nitrogen within close proximity (2.8 Å) for a hydrogen
bond with the side chain carboxyl oxygen of the other protomer’s (light pink)
Asp186 of α-helix I. Thus, Arg251 contributes to interactions at the dimerization
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interface between the two protomers. The dramatic decrease in thermal stability
and α-helical content of the R251C mutant relative to wild-type HsPYCR2
indicates that Arg251 has an important structural role. The loss of the Arg251Asp186 interaction in the R251C mutant may destabilize α-helices L and K,
thereby changing the orientation of Thr238 and negatively impacting the active
site. Escande-Beillard et al. (2020) rationalized that substitution of residue
Glu246 into Val with a bulkier side chain most likely results in steric hindrance
with the partner monomer at the dimer interface of human PYCR2, thus
disrupting catalytic function as observed with the Glu246Val mutant enzyme.44
With respect to the Tm values determined here for HsPYCR2, the values are
higher than typically observed for human proteins. In a survey of 18 human
proteins within the enzyme classes of sulfotransferases, methyltransferases, and
isomerases, Vedadi et al. (2006) reported melting point temperatures ranging
from 34-58 °C using differential scanning fluorimetry.45 The Tm values estimated
for HsPYCR2 wild-type and R119C mutant are above that conventionally
expected for human enzymes, however, the observed Tm for HsPYCR2 wild-type
alone (69 °C) is consistent with a previously reported thermal inactivation of
HsPYCR1 in which the enzyme activity dropped to 50% within 10 min at 68 °C.5
Product(s) inhibition kinetics studies revealed L-Pro behaving as a
competitive inhibitor and NAD+ behaving as a mixed inhibitor against wild-type
HsPYCR2 enzyme, which is diagnostic of a sequential binding order with L-P5C
binding first to the enzyme followed by NADH (Fig. 3.6). This binding order is
atypical of the general family of dehydrogenase enzymes, i.e. lactate
dehydrogenase, which first binds NAD+/NADH before the second substrate.46
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Figure 3.12. Single dimer ball-space-filling model views of enzyme-ligand(s)
complexes. Illustrations were prepared with PyMOL35 as renderings of
homologous HsPYCR1 experimental X-ray crystal structure that support our
proposed sequential-binding order mechanism of HsPYCR2. (A and D) 1.92 Å
structure of HsPYCR1 + L-Pro (PDB code 5UAT)6 as lime green and sea blue
partner monomers shown with buried L-Pro product ligand (purple sticks and
dots) in a single active site zoomed in on right panel B, (B and E) 1.90 Å structure
of HsPYCR1 + NADPH (PDB code 5UAU)6 as black and light blue partner
monomers shown with bound NADPH substrate ligand (orange sticks and dots)
in a single active site zoomed in on right panel D, and (C and F) 1.85 Å structure
of HsPYCR1 + NADPH + L-THFA (PDF code 5UAV)6 as salmon pink and dark
blue partner monomers shown with buried L-THFA analog ligand (yellow sticks
and dots) together with bound NADPH substrate ligand (orange sticks and dots)
in a single active site zoomed in on right panel F.
The proposed binding order is supported by X-ray crystal structures of HsPYCR1
in complex with THFA and NADPH (Fig. 3.12), which shows that L-THFA, which
is an analog of both L-proline and L-P5C, is buried within the active site. The
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binding site for L-THFA would be obstructed if NADPH were to bind first, thus
supporting the sequential binding order of the smaller L-P5C molecule followed
by binding of the larger NAD(P)H molecule. Specifically, Figure 3.12, panels C
and F show that NADPH is more solvent exposed which would facilitate the
sequential release of NADP+ followed by L-proline. These findings are consistent
with previous studies in which bacterial (S. pyogenes) and plant (A. thaliana)
P5CRs were also proposed to follow a sequential-ordered binding mechanism
with L-P5C binding prior to NAD(P)H.27,47 Having the sequential-ordered binding
mechanism of HsPYCR2 established will help guide development of new
inhibitors and/or substrate analogs as molecular probes for modulating HsPYCR2
activity.
Interestingly, serum levels of L-proline in healthy adult humans are reported to
range from 125-633 µM with mean levels around 270 µM.48,49 The competitive
inhibition constant determined here for L-proline (KIC app= 145 ± 8 µM) as well as
that previously reported for HsPYCR2 by De Ingeniis et al. (KI = 96 µM)2, is within
physiological L-proline concentrations suggesting that HsPYCR2 is susceptible to
product feedback inhibition by L-proline. Because concentrations of normal
human fasting plasma L-P5C and of L-P5C released into extracellular medium by
cultured human skin fibroblasts have been observed << 100 µM50,51 and the
apparent KM determined here for L-P5C is (1509 ± 69 µM), HsPYCR2 is likely
operating under V/KMapp conditions and thereby sensitive to feedback regulation
by L-proline.
On a more clinical note, previous studies which have profiled blood and
plasma metabolites of HsPYCR2-deficient patients have reported no significant

decreases

in L-proline

.17,18

However, it

remains unknown
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what the

concentrations of L-proline are in the relevant affected neurological tissue and
cerebrospinal fluid (CSF) of these patients. In Escande-Beillard et al. (2020)’s
study, the authors mentioned that no L-proline deficiency in blood or brain tissues
was found in Pycr2-/- mice.44 Yet, progressive neurological deterioration
associated with another enzyme (P5CS) deficiency is marked by hypoprolinemia
and lower urea cycle intermediates (e.g., ornithine, citrulline, arginine) that cannot
be

treated

by

fortified

amino

acid

supplements.52,53

Unsuccessful

supplementation therapies may be due to a number of complications such as low
bioavailability, high clearance rates, different intestinal absorption and plasma
kinetics between amino acids derived from amino acid supplements and whole
protein, as well as inadequate delivery to affected tissues.54 Thus, L-proline
serum levels in HsPYCR2 deficient patients may not be an adequate biochemical
marker to determine whether HsPYCR2 deficiency causes abnormal L-proline
bioavailability in patients, especially in the CSF. On a broader scope, EscandeBeillard et al. (2020) proposed loss of PYCR2 may lead to SHMT2 upregulation
as the direct cause of cerebral hyperglycinemia in HLD10 patients, which triggers
excitotoxicity by activation of N-methyl-D-aspartate (NMDA) receptors leading to
hypomyelination and axonal damage; thus, perhaps therapeutic NMDA receptor
antagonists or other treatments aimed at lowering cerebral glycine levels might
be of benefit to PYCR2-deficient patients.44
In conclusion, we have shown that HsPYCR2 mutants R119C and R251C
result in impaired enzyme function and structural stability, thus potentially leading
to disrupted L-proline biosynthesis and metabolic dysfunctions that contribute to
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hypomyelinating leukodystrophy type 10 with microcephaly.
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Chapter 4

L-thioproline oxidation: Novel Enzyme Function Discovered for
human PYCR1 and 2
ABSTRACT
L-thioproline (L-thiazolidine-4-carboxylate, L-T4C) is a cyclic sulfur imino acid
analog of L-proline (L-Pro) found in multiple kingdoms of life. The oxidation of LT4C leads to L-cysteine (L-Cys) formation in bacteria, plants, mammals, and
protozoa. The conversion of L-T4C to L-Cys in bacterial cell lysates has been
attributed to proline dehydrogenase and L-Δ1-pyrroline-5-carboxylate (P5C)
reductase (PYCR) but detailed kinetic studies have not been conducted. Here,
we characterize the dehydrogenase activity of human PYCR isozymes 1 and 2
with L-T4C using NAD(P)+ as the hydride acceptor.

Both PYCRs exhibit

significant L-T4C dehydrogenase activity, however, PYCR2 displayed nearly 10fold higher catalytic efficiency (136 M-1 s-1 versus 13.7 M-1 s-1) than PYCR1.
Interestingly, no activity was observed with L-Pro and the analog DL-thiazolidine2-carboxylate (DL-T2C), indicating that the sulfur at the 4-position is critical for
PYCRs to utilize L-T4C as a substrate. Structural insights into L-T4C binding
interactions were gained by solving a 2.30 Å X-ray crystal structure of a (PYCR1
+L-T4C) complex. L-T4C was found to occupy the same binding site as L-Pro, an
observation that was corroborated by inhibition kinetics that showed L-Pro is a
competitive inhibitor of PYCR1 (KIC app = 15.7 mM) with respect to L-T4C. Taken
together, the evidence assigns a novel enzyme function to human PYCRs, thus
we propose that PYCR should be classified as a bifunctional enzyme with a new
name, L-thiazolidine-4-and-L-pyrroline-5-carboxylate oxidoreductase (TPCOR).
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INTRODUCTION
L-thiazolidine-4-carboxylate (L-T4C) is a metabolite known to occur in various
organisms throughout nature from protozoa, bacteria, plants, and mammals.1,2,3,
4,5

L-T4C is an analog of L-Pro (Figure 4.1) thought to derive from L-Cys from the

mitochondrial reaction of L-Cys and formaldehyde.2
A

B

C

D

Figure 4.1. Chemical structures of L-Pro, analogs, and L-Cys. (A) L- Pro, (B) DLT2C, (C) L-T4C, and (D) L-Cys.
L-T4C has been reported to have toxic effects in certain organisms when applied
exogenously such as in bacteria and plants. For instance, the toxic effects of LT4C in Escherichia coli are typically attributed to its misincorporation into proteins
via the bacterial prolyl-tRNA synthetase, which does not discriminate between LPro and L-T4C.6,7 Elthon et al. (1984) presented evidence that L-T4C treatment
strongly influences the accumulation of L-Pro, an important cellular osmolyte and
source of energy critical for plant survivability when not in excess, by specific
inhibition of L-Pro oxidation in mitochondria isolated from etiolated barley
(Hordeum vulgare) shoots.5 The toxic effects of L-T4C have been exploited in its
use as an anti-infection agent against various diseases. For instance, Magdaleno
et al.’s (2009) study analyzed the effects of L-T4C on parasitic cell viability of the
non-infectious epimastigote forms of Trypanosoma cruzi and on the infection of
mammalian CHO-K1 cells by T. cruzi, which leads to the pathology of Chaga’s

disease in host

cells.8
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According to their findings, L-T4C significantly reduced

parasitic cell viability and T. cruzi infection rates in CHO-K1 cells.8 These results
led to the suggestion that L-T4C may be a viable treatment against Chaga’s
disease.
A mechanism by which cells diminish L-T4C toxicity is to convert it to L-Cys,
thereby not only removing the L-proline analog but also mobilizing the sulfur into
a useable form. Utilizing L-T4C as a source of L-Cys has been shown to be
required for the survival of the protozoan Entamoeba histolytica, which relies on
L-Cys as the principal low-molecular-weight thiol due to the lack of glutathione.9
Using stable isotope labeling and mass spectrometry, Jeelani et al. (2014)
demonstrated that L-T4C was the major source of L-Cys formation in cells,
thereby promoting trophozoite growth and protecting protozoan cells against
oxidative stress.9 Consistent with these metabolite findings, lysates of E.

histolytica were shown to convert L-T4C into L-Cys, however, the enzymes
responsible for L-T4C oxidase activity were not identified.9
The potential of L-T4C (L-thioproline) to serve as a source of L-Cys and to
trap reactive nitrogen species (RNS) has also been explored in humans for
various therapeutic applications. The first demonstration of the therapeutic
potential of L-thioproline can be traced to Mackenzie et al.’s (1957) report on
finding L-thioproline is about five times more potent than L-cysteine in preventing
massive pleural effusions and death in thiourea-treated rats.2 From a chemical
structure standpoint, L-T4C’s sulfur atom is protected in a ring moiety (Fig. 4.1,
C) that only opens and liberates a sulfhydryl group upon uptake into the liver,
whereas the sulfur in L-Cys is fully exposed (Fig. 4.1, D) and readily reactive as a

nucleophile prior to cellular

uptake.2
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From several clinical reports in the 1960s-

1980s, oral tablet or intravenous administration of L-thioproline given to patients
suffering from infectious hepatitis, liver insufficiency, or chronic liver cirrhosis
demonstrated limited benefits primarily to remedying cell necrosis and correcting
levels of transaminase and alkaline phosphatase enzyme activities.10 Under the
moniker of generic Timonacic, L-thioproline (brand names:

Hepalidine,

Heparegen, etc.) has been used for the treatment of hepatic and biliary diseases,
particularly in France.10
Despite the interest in L-T4C as a therapeutic L-Cys source in humans or an
oxidative stress protectant in various organisms such as protozoa and plants,
detailed kinetic studies with L-T4C have yet to be conducted. Two enzymes that
have been implicated in L-T4C metabolism from numerous studies are L-proline
dehydrogenase (PRODH) and L-Δ1-pyrroline-5-carboxylate (P5C) reductase
(PYCR). Genetic knockout studies in E. coli and activity assays with bacterial cell
lysates suggests PYCR may have a significant role in converting L-T4C into LCys, but the individual contributions of PRODH and PYCR are unclear.11,7
Here, we set out to determine the ability of the human PYCR enzymes to
catalyze the oxidation of L-T4C. The known function of PYCR is to catalyze the
last step in L-Pro biosynthesis by NAD(P)H-dependent reduction of L-P5C into LPro. In this study, we characterized the ability of PYCR to catalyze the reverse
reaction of reducing NAD(P)+ with L-Pro and analogs, L-T4C and DL-T2C (Figure
4.1) at biologically relevant pH 7.5. We report human PYCR1 and 2 do not exhibit
any enzyme activity with L-Pro or DL-T2C, however, notable activity was
observed with L-T4C as a substrate. PYCR2 was found to have an apparent
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catalytic efficiency with L-T4C of nearly 10-fold higher than PYCR1. A 2.30 Å
experimental X-ray crystal structure of the binary complex (PYCR1+L-T4C) was
solved, which implies molecular details for the hydride transfer step from L-T4C
to NAD(P)+. L-Pro was also shown to be a competitive inhibitor of PYCR1 with
respect to L-T4C, indicating that L-T4C occupies the L-proline-binding site. In
summary, the experimental evidence gathered here assigns a novel enzyme
function to human PYCRs, thus expanding its physiological role.
MATERIALS AND METHODS
Materials, Reagents, and Enzymes
MilliQ-Ultra purified water was used for the preparation of all buffers and
chemicals in the experiments. The same reagents mentioned in chapter three
were accessed and used for these studies, including the purchases of Lthiazolidine-4-carboxylic
Millipore-Sigma.

acid

and

DL-thiazolidine-2-carboxylic

acid

from

Human PYCR1 was graciously provided by Dr. John J.

Tanner’s group after following an expression and purification procedure as
described previously in chapter two.12 A detailed description of the expression
and purification conditions for human PYCR2 is provided in appendix chapter B.
Kinetic characterization of PYCR reverse activity.
The majority of reaction components and reaction conditions from the
methods described in chapters two and three remain consistent in these studies,
yet there are some notable exceptions. For instance, stock solutions of L-T4C,
DL-T2C, and L-Pro were each adjusted to pH 7.5 using 6 M NaOH prior to
performing the assays. Assays were performed at 37 °C in 0.1 M Tris-HCl (pH
7.5) reaction buffer containing 0.01% Brij-35 detergent, 1 mM NAD(P)+ (pH 8.0), 1
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mM EDTA (pH 7.5), and different test substrate compounds of 10 mM L-proline
(pH 7.5), 10 mM L-T4C (pH 7.5), and 10 mM DL-T2C (pH 7.5). The reaction
components were pre-warmed for 5 min in a 1.5 mL microtube at 37 °C and then
transferred to a 1 cm path length polystyrene rectangular cuvette (USA
Scientific). The assay (600 µl total volume) was initiated by adding PYCR1 or 2
enzyme (0.6 µM final concentration) and reaction progress was monitored at 340
nm using a Varian Cary 50-UV/VIS spectrophotometer at room temperature for
10 min duration.
For reverse direction steady-state kinetics, the parameters kcat and KM for LT4C were determined by holding NADP+ fixed (1 mM) while varying L-T4C (0-25
mM). In assays varying L-T4C, 1 M Tris-HCl (pH 7.5) buffer was added to each
assay to maintain an ionic strength of approximately 450-460 mM Tris+Cl-. Lproline inhibition studies were performed under the same conditions with 0.6 µM
PYCR1 enzyme (final concentration) with NADP+ fixed (1 mM) and L-T4C varied
(0-25 mM) at different concentrations of L-proline (0-20 mM).
For both steady-state kinetics and ligand inhibition kinetics, the reaction
components were all pre-warmed for 5 min, combined in a 1.5 ml microtube,
positioned in a 37 °C water bath for 5 min, then transferred into a cuvette with the
addition of enzyme to initiate the reaction. Each cuvette measurement had been
zeroed against blanks omitting L-T4C, and all assays were performed in triplicate.
Initial velocities were calculated from the linear increase in absorbance within a
one minute window in the initial 2.5 min and quantifying NAD(P)H formation (ε340
= 6.22 mM-1 cm-1)7,13 according to the Beer-Lambert-Bouguer law.14,15,16 Data
(mean ± standard deviation) are plotted as variable substrate concentration in
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units mM (horizontal axis) versus initial reaction velocity of NAD(P)H product
formation in units µM s-1 (vertical axis). The data were fit by nonlinear regression
analysis to the Henri-Michaelis-Menten equation using SigmaPlot 12.0. Ligand
inhibition data was analyzed by Henri-Michaelis-Menten and linear Hanes-Woolf
plots. The apparent enzyme-inhibitor dissociation constant (KIC) was determined
by a fit of the data to a Competitive Inhibition (Full) Model, which was the highestranked R2 inhibition model of the Enzyme Kinetics Wizard Add-In module in
SigmaPlot 12.0.
RESULTS
A

C

B

D

Figure 4.2. PYCR reverse activity with L-Pro and analogs. Final enzyme
concentration was 0.6 µM for each assay. Progress of the reaction was
monitored for 10 min by following the absorbance at 340 nm. Time-course
absorbance profiles of PYCR1 reverse activity with (A) 1 mM NADP+ + 10 mM LPro or with (B) 1 mM NAD+ + 10 mM L-Pro or its analog L-T4C or DL-T2C. Timecourse absorbance profiles of PYCR2 reverse activity with (C) 1 mM NADP+ + 10
mM L-Pro or with (D) 1 mM NAD+ + 10 mM L-Pro or its analog L-T4C or DL-T2C.
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PYCR reverse activity with L-Pro, L-T4C, and DL-T2C
The ability of PYCR to catalyze the reduction of NAD(P)+ with L-proline, LT4C, and DL-T2C was examined at pH 7.5 for 10 min. The results shown in Fig.
4.2 and Table 4.1 demonstrate that NADPH formation is only observed in PYCR
reverse activity assays using L-T4C as the substrate. Thus, neither PYCR1 nor
PYCR2 can catalyze the reverse reaction of L-proline oxidation and NAD(P)+
reduction, consistent with the forward reaction toward L-proline biosynthesis
being strongly favored by PYCRs.
Table 4.1. Human PYCR reverse activity with L-Pro and its analogsa
Enzymeb

PYCR1

PYCR2

Substratec

NAD(P)H formation
(µM s-1)e

Cofactord

A340 nm/min

L-Pro

NADP+

-0.0006

0

L-Pro

NAD+

0.0059

~0

L-T4C

NAD+

0.0438

0.1175

DL-T2C

NAD+

0.0004

~0

L-Pro

NADP+

-0.0082

0

L-Pro

NAD+

-0.0017

0

L-T4C

NAD+

0.0374

0.1003

DL-T2C

NAD+

-0.0015

0

aEnzyme

activity assay involved measurement for the change in absorbance at
340 nm over 10 min time duration.
bFinal enzyme concentration of 0.6 µM in assay.
cFinal concentration of 10 mM for L-Pro, L-T4C, and DL-T2C.
dFinal NAD(P)H concentration of 1 mM.
eInitial reaction velocity of NAD(P)H formation calculated with ε
NAD(P)H at 340 nm =
−1
−1
6.22 mM cm .
In terms of quantitative comparisons of reverse activity, PYCR1 shows nearly
3.5-fold higher reaction velocity with 10 mM L-T4C in the presence of 1 mM NAD+
compared to the corresponding value in the presence of 1 mM NADP+.
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Conversely, PYCR2 shows nearly 2.5-fold higher reaction velocity with 10 mM LT4C in the presence of 1 mM NADP+ compared to the corresponding value in the
presence of 1 mM NAD+.
Steady-state kinetics analysis of PYCR reverse activity with L-T4C
The apparent steady-state kinetic parameters kcat and KM were then determined
for L-T4C by keeping NADP+

fixed while varying the L-T4C substrate. Henri-

Michaelis-Menten plots of the data are shown in Fig. 4.2 for PYCR1 and PYCR2.
A

B

Figure 4.3. Steady-state kinetics analysis of PYCR reverse activity with L-T4C.
Final enzyme concentration of 0.6 µM (A) PYCR1 and (B) PYCR2 were used.
Data are plotted as (mean ± SD) of three technical replicates and fit to the HenriMichaelis-Menten equation by non-linear least-squares regression in SigmaPlot
12.0.
Table 4.2. Steady-state kinetics analysis of PYCR reverse activitya with L-T4C
(kcat app/KM app )
(M-1 s-1)

Enzymeb

Varied
Substrate

Fixed
Substratec

KM app (mM)

kcat app (s-1)

PYCR1

L-T4C

NADP+

18.9 ± 2.9

0.26 ± 0.02

13.7 ± 2.3

PYCR2

L-T4C

NADP+

6.8 ± 0.9

0.92 ± 0.04

136 ± 19

a(Value

± Std error) are the apparent best-fit parameters from non-linear leastsquares fit of the data to the Henri-Michaelis-Menten equation using SigmaPlot
12.0 (version 12.0.0.182, Systat Software). Data plotted as the (mean ± SD) of
n=3 technical replicates.
bFinal enzyme concentration is 0.6 µM.
cFinal NADP+ concentration fixed at 1 mM.
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Both PYCR1 and PYCR2 achieved saturation kinetics with L-T4C substrate for
nonzero maximal limiting reaction velocities (Vlim) of 0.16 µM s-1 and 0.55 µM s-1,
respectively. PYCR2 exhibited higher catalytic activity than PYCR1 with kcatapp
approaching 1 s-1 (Table 4.2). The nearly 4-fold higher kcatapp and 3-fold lower

Kmapp values for PYCR2 result in a 10-fold higher catalytic efficiency with L-T4C
relative to PYCR1 (Table 4.2).
Structural and ligand inhibition kinetics analysis of L-T4C binding in PYCR1
A

B

Figure 4.4. Superimposed X-ray crystal structures of PYCR1─L-T4C and
PYCR1─L-Pro binary complexes. (A) Ball-space-filling model of dimeric
superimposed structures of PYCR1─L-T4C (purple blue and wheat partner
protomers) and PYCR1─L-Pro (lime green and hot pink partner protomers)
binary complexes. The active site is formed at interface of partner protomers with
L-T4C (cyan sticks) and L-Pro (gray sticks) present deep in active site. (B)
Ribbon cartoon model of superimposed structures with zoomed-in view of active
site showing hydrogen bond interaction (2.7 Å) between side chain hydroxyl
group of Thr238 and imine nitrogen (blue colored atom) of L-T4C, analogous to
hydrogen bond interaction (3.4 Å) between side chain hydroxyl group of Thr238
and imine nitrogen (blue colored atom) of L-Pro. Illustrations of the 2.30 Å X-ray
crystal structure of the PYCR1─L-T4C complex and of the 1.90 Å X-ray crystal
structure of PYCR1─L-Pro complex (PDB code 5UAU)12 were made with
PyMol.17 The X-ray crystal structures of human PYCR1 soaked with 50 mM LT4C in the former case and soaked with 1.8 M L-Pro in the latter case, were both
graciously provided by Dr. John J. Tanner and Dr. Emily Christensen.
To further characterize L-T4C as a substrate of PYCR, structural and kinetic
evidence was generated to support that L-T4C binds in the same active site
region of PYCR1 as L-proline and consequently as the L-P5C substrate. In
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previous studies (see chapter three) with PYCR1, a 1.90 Å X-ray crystal structure
of the binary complex of PYCR1+L-Pro was solved (PDB code 5UAU).12 The
structure, along with evidence from product inhibition kinetics, showed that L-Pro
and L-P5C occupy the same binding site near NADPH in PYCR1. As shown in
Fig. 4.4, our collaborators (Dr. Emily Christensen and Dr. John J. Tanner) solved
a 2.30 Å X-ray crystal structure of L-T4C complexed with PYCR1. The electron
density of L-T4C is observed in the same active site binding pocket as previously
shown for L-Pro. Additionally, the highly conserved active site residue Thr238’s
side chain hydroxyl group forms a 2.7 Å hydrogen bond interaction with the imine
nitrogen of L-T4C, which is analogous to hydrogen bond interaction (3.4 Å)
between side chain hydroxyl group of Thr238 and imine nitrogen of L-Pro in the
superimposed structure of the PYCR1─L-Pro binary complex. Thus, L-T4C
appears to bind to the PYCR1 active site in a manner similar to L-proline.
In tow with this structural interpretation, we performed ligand inhibition kinetics
with L-proline to test whether L-T4C binds to the same site as L-proline in
PYCR1. Upon holding NADP+ concentration constant at 1 mM and varying L-T4C
substrate (0-25 mM) at different L-proline concentrations (0-20 mM), the apparent

KM (KMapp) for L-T4C was observed to trend upward while the apparent kcat
(kcatapp) stayed relatively constant (Table 4.3 and Fig.4.5). With increasing L-Pro
concentration, trends of an overwhelming increasing value of the KMapp with a
fairly unchanging value of the Vmax agree well with the model of competitive
inhibition with an apparent competitive inhibition constant (KIC app) of 15.7 mM LPro (Fig.4.5, A

and Table 4.3).18 Hanes-Woolf plot analysis of the L-proline

inhibition data shows a parallel linear pattern that is consistent with competitive
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inhibition (Figure 4.5, B). In particular, the increasing vertical axis intercept
(KMapp/Vmax) effect shown in Figure 4.5, panel B indicates L-Pro is a competitive
inhibitor19 with respect to the L-T4C substrate.
Table 4.3. Steady-state kinetic parameters for L-proline ligand inhibition of
PYCR1 with varied L-T4Ca,b,c

KM app (mM)

kcat app (s-1)

(kcat app/KM app )
(M-1 s-1)

0

18.9 ± 2.9

0.26 ± 0.02

13.7 ± 2.3

5

32.0 ± 6.3

0.27 ± 0.35

8.4 ± 11.1

10

35.1 ± 6.9

0.26 ± 0.35

7.5 ± 10.1

20

36.8 ± 7.6

0.23 ± 0.03

6.3 ± 1.6

L-proline
(mM)

KIC app (mM)

15.7 ± 1.1d

a(Value

± Std error) are reported for the apparent best-fit parameters of nonlinear least-squares fit to the Henri-Michaelis-Menten equation using SigmaPlot
12.0 (version 12.0.0.182, Systat Software) with data plotted as (mean ± SD) of
n=3 technical replicates.
bFinal enzyme concentration is 0.6 µM.
cNADP+ concentration was fixed at 1 mM while L-T4C concentration was varied
0-25 mM.
dApparent competitive inhibition constant, K app, was estimated by globally fitting
IC
the data (0.5-25 mM) to a competitive inhibition (full) model using the Enzyme
Kinetics Wizard Add-In on SigmaPlot 12.0 (version 12.0.0.182, Systat Software).
A

B

Figure 4.5. L-Pro ligand inhibition kinetics of PYCR1 with varied L-T4C substrate.
(A) Henri-Michaelis-Menten plots of assays performed at different L-proline
concentrations (0-20 mM) while varying L-T4C (0-25 mM) and holding NADP+
concentration constant (1 mM). (B) Hanes-Woolf plot of the (2-25 mM) data in
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panel A. Final enzyme concentration of 0.6 µM PYCR1 was used. Data are
plotted as (mean ± SD) of n=3 technical replicates with non-linear least-squares
fits to the Henri-Michaelis-Menten equation and linear regression fits to the
Hanes-Woolf equation using SigmaPlot 12.0.
DISCUSSION
The kinetic data shown here directs attention to the chemical importance of

Figure 4.6. Proposed catalytic mechanism of L-T4C initial oxidation by PYCR.
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sulfur in the structure of L-proline analogs. As depicted in Fig. 4.1, the insertion of
the sulfur atom at the C4 position of the pyrrolidine ring of L-Pro enables
oxidation of L-T4C whereas sulfur at the C3 position of the pyrrolidine ring of LPro, as in DL-T2C, does not enable oxidation of the L-proline analog. A reaction
mechanism for the oxidation of L-T4C by PYCR is proposed in Fig. 4.6. The
mechanism involves a hydride transfer from the C2 position in L-T4C to NADP+
followed by nonenzymatic hydrolysis to form products L-cysteine and formate
(which later becomes formaldehyde). The sulfur being adjacent to the C2 position
likely lowers the pKa of the hydrogen atoms at C2 and promotes electron
delocalization between the N1 and C2 atoms. These electronic factors must be
sufficient enough to enable PYCR to catalyze hydride transfer from the C2 of LT4C to NADP+. In DL-T2C, the sulfur is too far removed from the site of hydride
transfer to have an impact, thus no activity is observed with this L-proline analog.
Both PYCR1 and PYCR2 catalyze the oxidation of L-T4C at a significant rate,
however, PYCR2 exhibits a 10-fold higher catalytic efficiency than PYCR1.
When comparing the L-T4C oxidative and L-P5C reductive enzyme activities,
PYCR1 and PYCR2 both exhibit >103-fold higher catalytic efficiency in the
forward direction reaction with L-P5C (as shown in data from chapter three)
consistent with the main function of PYCRs in L-proline biosynthesis.
L-T4C has long been studied as an anti-aging therapeutic. For example,
dietary supplementation with L-T4C (2.0 g/kg) in mice was shown to increase
median and maximal life span by approximately 10–29% in both genders and
improve neuromuscular coordination and exploratory function.20 The mechanisms
by which L-T4C enhances lifespan in mice appear to be multifaceted and likely
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involve the protection of mitochondrial function. Navarro et al. (2007) found that
L-T4C-supplemented diets given to mice ad libitum resulted in approximately 51–
74% curtailment of aging-related reductions of brain mitochondrial enzyme
activities of NADH-dehydrogenase, cytochrome c oxidase, and mitochondrial
nitric oxide synthase in old and senescent mice.20
Other anti-aging effects of T4C include its ability to act as an in vivo protector
against protein aggregation and as a scavenger of reactive nitrogen and oxygen
species, and N-nitroso compounds. In a recent mouse study by Lyu et al. (2020),
L-T4C significantly diminished aggregation of oxidized bovine serum albumin
(BSA), possibly by directly interacting with BSA via hydrogen bonds and van der
Waals interactions.21 In the same study, the ability of L-T4C to prevent oxidative
damage in brain tissue was tested against five other antioxidants. L-T4C showed
the highest antioxidant effects in oxidized isolates of mouse brain tissue with a
nearly 1.4-fold drop in malondialdehyde content (readout for membrane lipid
peroxidative damage) and nearly 1.3-fold increase in superoxide dismutase
enzyme activity (readout for cellular antioxidant activity).21
Over the years, L-T4C’s high capacity for trapping reactive nitrogen species
and N-nitroso compounds has been exploited on the drug market for protection
against liver diseases and gastrointestinal disorders. In mammals, many
carcinogenic N-nitrosamines (e.g., N-nitrosomorpholine) are endogenously
formed inside the acidic stomach by the reaction between amines and nitrite,
which originates from nitrate produced by two primary sources: bacterial flora in
the oral cavity and activated macrophages.22 It has also been established that
endogenously produced N-nitrosothioproline and N-nitrosoproline comprise the

majority of excreted N-nitroso compounds found in

urine.22
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However, in vitro

reaction kinetics show that N-nitrosation of L-T4C into N-nitrosothioproline occurs
103 times faster than that of L-proline into N-nitrosoproline.23 Miwa et al.’s (1989)
in vitro study reported that the incubation of 5 mM morpholine with activated
murine macrophages resulted in the formation of 1.06 pM N-nitrosomorpholine,
which could be strongly curtailed by treatment with 5 mM L-T4C.22 These results
led Miwa et al. (1989) to propose that L-T4C can trap nitrosating-compounds
produced by activated macrophages in non-human and human animals.22 In a
more recent study of pathology with Barrett’s esophagus and development of
esophageal cancer, Kumagai et al. (2004) evaluated the nitroxide scavenging
efficacy of L-T4C using a surgically made duodenal reflux model in rats.
Experimental treatment of 0.5% L-T4C was used to examine whether L-T4C
could lower reactive nitrogen species (e.g., nitric oxide and peroxynitrite, and Nnitroso compounds) present in the contents of the gastroduodenal reflux and
thereby minimize pathology.24 Upon histological examination, the L-T4C treated
rats had milder forms of mucosal changes with lesser degrees of inflammation
and zero presence of esophageal adenocarcinoma compared to the control
group. These exciting results suggest L-T4C inhibits the production of N-nitroso
compounds in the gastroduodenal reflux contents, a property of potential
therapeutic benefit in esophageal cancer.24
Another important aspect of L-T4C is its impact on biogenic aldehydes. L-T4C
has been suggested to be a source of formaldehyde, presumably through its
metabolism by L-proline dehydrogenase and PYCR. Garnier et al. (1980)
assessed the clinical toxicity of L-T4C in patients and concluded that overdosage
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of L-T4C overwhelms the metabolic capacity of the liver, thereby leading to LT4C distribution throughout the body including the cerebrospinal fluid (CSF). It
was proposed that metabolic degradation of L-T4C in the intrameningeal tissue
results in the release of toxic formaldehyde, which causes the acute central
nervous system (CNS) symptoms of epileptic seizures and convulsions.25 In a
separate study investigating the therapeutic potential of L-T4C in cancer,
Newman et al. (1980) showed that the toxicity of L-T4C administered at 400
mg/kg to mice and rats could be counteracted by barbiturate anesthesia with no
acute CNS symptoms of epileptic seizures and convulsions.26 Thus, it was
proposed that the acute toxic effects of L-T4C in animals may not be a direct
consequence of formaldehyde released from L-T4C, but rather the inactivation of
important biogenic aldehydes by L-T4C, particularly in the brain.10 From high
performance liquid chromatography (HPLC) and mass spectrometry experiments,
Susillo et al. (1989) reported on the involvement of L-cysteine in the brain
metabolism of biogenic aldehydes, i.e. 5-hydroxyindole-3-acetic acid (5’-HIAAL),
by forming L-thiazolidine-4-carboxylic acid derivatives, perhaps as a control
measure to limit labile biogenic aldehydes by the rapid intracellular inactivation of
the compounds.27 Essentially, the metabolic transformation of indoleamines into
biologically inactive L-T4C derivatives is catalyzed by two enzymes located in
separate subcellular compartments of neuronal cells.27 Monoamine oxidase
located in the outer mitochondrial membrane converts 5-hydroxytryptamine (5HT) into biogenic aldehyde (5’-HIAAL) and then carbon-sulfur lyase in the cytosol
cleaves off the cysteinyl moiety from the spontaneously formed condensation
product of (L-cysteine + 5’-HIALL), namely (4R)-2-[3’-( 5’-hydroxyindoly1)-
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methyl]-1,3-thiazolidine-4-carboxylic acid (5’-HITCA), to liberate a reactive free
aldehyde 5’-HIAA product.27
In summary, we show here that PYCR1 and PYCR2 exhibit activity with LT4C that is likely to be biologically significant and contribute to the physiological
effects reported thus far with L-T4C. The 2.30 Å X-ray crystal structure of the
PYCR1+L-T4C complex shows that L-T4C binds in the active site of PYCR1
which is consistent with the mechanism shown in Fig. 4.6 with hydride transfer
from L-T4C to NADP+. L-proline ligand inhibition kinetic studies corroborate the
interpretation of the structural data and indicate that L-T4C and L-proline occupy
the same binding pocket in PYCR1. Whether L-cysteine and formaldehyde also
bind to PYCR1 is not known, but would be an important question to pursue in
future research. A key underlying point of our findings is that human PYCRs
function as a metabolic lynchpin that links L-Pro biosynthesis with L-Cys
formation. In conclusion, a new enzyme activity is assigned to human PYCRs.
We thus propose that PYCR be renamed for its bifunctional activities as Lthiazolidine-4-and-L-pyrroline-5-carboxylate oxidoreductase (TPCOR).
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Chapter 5

Cautionary tale of using tris(alkyl)phosphine reducing agents with
NAD+-dependent enzymes
ABSTRACT
Protein purification protocols typically include disulfide bond reducing agents
to thwart unwanted thiol oxidation and protein aggregation. Various disulfide
bond reducing agents include dithiothreitol, β-mercaptoethanol, glutathione, and
phosphine compounds such as tris(2-carboxyethyl)phosphine (TCEP) and tris(3hydroxypropyl)phosphine (THPP). Δ1-pyrroline-5-carboxylate (P5C) reductase
(PYCR) catalyzes the final step of L-proline (L-Pro) biosynthesis by reducing LP5C into L-Pro using NAD(P)H as a hydride donor. When probing the ability of
PYCR to operate in the reverse direction of L-Pro oxidation using NAD+, we
observed a rapid non-enzymatic reaction between NAD+ and reducing agents
TCEP and THPP. The product of the reaction with TCEP exhibits a maximum
absorbance peak at 334 nm and forms with an apparent forward association rate
constant of 490.5 M-1s-1. The reaction with TCEP is reversible with an apparent
equilibrium association constant of 20.1 M-1. NMR characterization (1H-, 13C-, and
31P-NMR)

of the reaction product revealed that a covalent adduct is formed with

the phosphorus of the phosphine compound and the C4 atom of the
dihydronicotinamide ring of NAD+. The findings here serve to caution researchers
when using TCEP or THPP in experimental protocols that include NAD(P)+dependent enzymes.
INTRODUCTION
In all domains of life, L-proline is biosynthesized from L-glutamate via
three enzymatic steps with the last step catalyzed by L-Δ1-pyrroline-5-carboxylate
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(L-P5C) reductase (PYCRs or P5CRs). PYCR reduces L-P5C into L-Pro using
NAD(P)H as the hydride donor. Besides providing L-proline for protein
biosynthesis, another function of PYCR is to provide NAD(P)+ redox equivalents
for other pathways such as the oxidative branch of the pentose phosphate
pathway in plants and animals. 1 PYCR has been found to have important roles in
plant stress response, bacterial pathogenesis, and in humans, is upregulated in
different types of cancer.2,3
Studies of PYCR or P5CR from various organisms have assayed the reverse
reduction reaction of NAD(P)+ with L-Pro to characterize the kinetic activity of
PYCR. In some cases, L-proline analogs such as L-thiazolidine-4-carboxylate (LT4C) and 3,4-dehydro-L-proline were used as the substrate.4 Because the L-P5C
substrate is not commercially available and L-P5C is not amenable for long-term
storage, PYCR assays in the reverse direction are more easily deployed. In
particular, PYCR assays in the reverse direction are more readily applied in highthroughput screening of compound libraries seeking to identify small molecule
inhibitors of PYCR. We, therefore, sought to test the reverse activity of human
PYCR, namely of human isoforms 1 (HsPYCR1) and (HsPYCR2). Under our
assay conditions, however, we did not detect any reverse activity of PYCR with
NAD(P)+ and L-Pro, a finding which contrasts with previous reports on PYCRs.5,6
Amid these experiments, we unexpectedly discovered a chemical reaction
between NAD+ and reducing agents tris(3-hydroxypropyl)phosphine (THPP) and
tris(2-carboxyethyl)phosphine (TCEP). THPP and TCEP are tris(alkyl)phosphine
compounds commonly used as disulfide reducing agents during protein
purification and are thought to be more effective than dithiothreitol (DTT) and β-
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mercaptoethanol. In a direct side-by-side comparison of disulfide reducing agents
at biologically relevant pH 8.0 conditions, THPP demonstrated higher watersolubility, lower susceptibility to oxidation, and a higher ability to reduce a wide
range of disulfide substrates into their corresponding thiols than TCEP and DTT.7
THPP has also found uses in industrial wood pulp applications as an agent for
bleaching and brightness stabilization in spruce wood pulps.8
THPP and TCEP concentrations are commonly maintained at ≤ 1.0 mM
during protein purification and long-term storage of proteins. In a given enzyme
assay, the final THPP and TCEP concentrations are typically much lower due to
dilution effects upon adding the enzyme to the assay. However, THPP and TCEP
are sometimes added to the assay solution for various reasons resulting in
millimolar concentrations of the phosphine compound. Examples would include
enzyme

activity

assays,

biological

binding

experiments,

and

protein

crystallization.
Here, we report evidence of a rapid chemical reaction between NAD+ and
tris(alkyl)phosphine compounds THPP and TCEP under conditions commonly
used for kinetic and structural studies of enzymes. Stopped-flow kinetics show
the reaction product with the main UV absorbance peak at 334 nm that is rapidly
formed upon mixing NAD+ and TCEP. One-dimensional and two-dimensional
NMR demonstrate that the reaction product is a covalent adduct formed between
the phosphorus of the phosphine compound and the C4 atom of the
dihydronicotinamide ring of NAD+. Altogether, our findings here serve as a
cautionary note when using TCEP and THPP in biological assays and structural
studies of NAD(P)+-dependent oxidoreductases.
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MATERIALS AND METHODS.
Materials and Reagents.
MilliQ-Ultra purified water was used for the preparation of all buffers and
chemicals in the experiments. The following reagents were purchased from
Millipore-Sigma:

NaH2PO4, ε-amino-N-caproic acid, N-tosyl-L-phenylalanine

chloromethyl ketone, bovine serum albumin, pyruvate, L-lactate dehydrogenase,
NADPH, NADH, and NH4F. The following reagents were commercially available
from

Fisher

Scientific:

NaOH,

NaCl,

2-[4(2-hydroxyethyl)piperazin-1-

yl]ethanesulfonic acid (HEPES), Na2CO3, NaHCO3, and ethylenediamine
tetraacetic acid (EDTA) disodium salt. Reagents β-octyl-D-glucopyranoside (βOG) and L-proline (L-Pro) were commercially available from Combi-Blocks.
Ethanol

(190-

or

200-proof)

Tris(hydroxymethyl)aminomethane

was

purchased

(Tris),

from

glycine,

Decon

Labs.

isopropyl

β-D-

thiogalactopyranoside (IPTG), phenylmethylsulfonyl fluoride (PMSF), leupeptin
hemisulfate, and NAD+ were purchased from Gold Biotechnology. Imidazole and

o-aminobenzaldehyde (o-AB) were purchased from Acros Organics. In terms of
tris(alkyl)phosphine

reducing

agents

used

in

this

study,

tris(3-

hydroxypropyl)phosphine (THPP) was purchased from Strem Chemicals, and the
hydrochloride salt of tris(2-carboxyethyl)phosphine (TCEP-HCl) was purchased
from ThermoFisher Scientific-Pierce Biotech.
Stock solutions of NADH and NAD+ were prepared in 10 mM Tris-HCl (pH 8)
and stored at -80 °C. NADH and NAD+ concentrations were determined
spectrophotometrically at wavelengths 340 nm (ε340 = 6.22 x 103 M-1cm-1)9 and
260 nm (ε260 = 17.37 x 103 M-1cm-1),10 respectively. Each tris(alkyl)phosphine
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reducing agent, THPP and TCEP, was prepared in 100 mM Tris-HCl (pH 7.5)
buffer and stored at -80 °C.
Enzyme expression and PYCR reverse activity assays
HsPYCR1 protein was graciously provided by Dr. John J. Tanner’s group after
following an expression and purification procedure as described previously.11
Similarly, HsPYCR2 protein was expressed from a pKA8H-PYCR2 construct in E.

coli BL21 (DE3) pLysS competent cells (Novagen-EMD Millipore Sigma), cultured
in TB liquid media and induced with 0.4 mM IPTG, followed by centrifugation for
the harvesting of cell pellets. Next, the cell pellets were resuspended in NPI-5 cell
lysis buffer (5 mM imidazole, 500 mM NaCl, 50 mM NaH2PO4, pH 7.5) also
containing 500 µM THPP, 0.01% TritonX-100 detergent (Amresco), 0.01% Brij-35
polyoxyethylene detergent (Santa-Cruz Biotechnology), 10 mM βOG, and a
mixture of five protease inhibitors. The cell suspension was then subjected to
sonication and 4 °C centrifugation, to obtain supernatants of target protein
solution for further purification by Ni-NTA Superflow (Qiagen) affinity column
chromatography.
Time-course profiles of enzymatic reactions in the direction of NADH
formation were performed at room temperature with NAD+ substrate to monitor
gain of absorbance at 340 nm over time under dark lab conditions with overhead
lights off the entire time, using a modified protocol based on previous
studies.12,9,4,13 The ability of HsPYCR1 or 2 enzyme to catalyze the reverse
reaction (L-Pro + NAD+  L-P5C + NADH) was tested in 0.1 M Tris-HCl (pH 7.5)
buffer containing 0.01% (v/v) Brij-35 detergent, 30 mM MgCl2, 5 mM L-proline
(pH 7.5), and 0.5 mM NAD+ (pH 8), and with or without tris(alkyl)phosphine
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compound (1 mM TCEP (pH 7.5) or 1 mM THPP (pH 7.5)). The reaction
components added into a 1 cm path length rectangular semi-micro, self-masking
quartz spectrophotometer cuvette (Starna Cells) were cover wrapped in
aluminum foil to protect from ambient light, placed atop a rocking platform for mild
agitation at room temperature for 15 min, and then, the reaction was initiated by
adding PYCR enzyme (0.06 µM final concentration) to achieve final assay
volume of 600 µl. Followed by immediate parafilm covering the cuvette top, we
shook it with inversion agitation to mix contents before placing the quartz cuvette
into the spectrophotometer. Reactions were monitored at 340 nm for 30 min
using a Varian Cary 50-UV/Vis spectrophotometer (Agilent Technologies) and
Cary

WinUV

Kinetics

Application

software

(version

5.0.0.999,

Agilent

Technologies).
NAD+ reactions with tris(alkyl)phosphine reagents
Reactions of NAD+ with THPP and TECP were initially performed at room
temperature and dark conditions similar to the PYCR enzyme assays above,
except no enzyme was added. Reaction components (0.5 mM NAD+ and 5 mM Lproline) were combined with 0.1 M Tris-HCl buffer (pH 7.5, 0.01% (v/v) Brij-35
detergent, 30 mM MgCl2) in the quartz cuvette for 15 min initial absorbance
monitoring followed by the addition of THPP and TCEP (1 mM final
concentration) and immediate parafilm covering the cuvette top for inversion
agitation to mix contents before placing the quartz cuvette back into the
spectrophotometer. The absorbance at 340 nm was monitored for 30 min total
using a Varian Cary 50-UV/Vis spectrophotometer.
Stopped-flow absorbance spectrophotometry of the reactions between NAD+
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and THPP or TCEP were performed in the dark with different 100 mM (pH 7.5)
reaction buffer compositions: HEPES, Tris-HCl, Na-Phosphate, and PBS. All
stopped-flow experiments were conducted on a Hi-Tech KinetAsyst Scientific SF61DX2 stopped-flow instrument equipped with a photodiode array detector and
attached to nitrogen gas pressure, where all instrument settings and data
collection was controlled and managed by Kinetic Studio software. The
temperature of the mixing chamber for all experiments was maintained at room
temperature (23 °C). NAD+ (0.5 mM after mixing) was rapidly mixed with THPP or
TCEP (25 mM after mixing) and the reaction was monitored in the stopped-flow
by multiwavelength absorption in the range of 310-702 nm, Run Time = 1 s,
Number of Scans = 100. In another set of experiments, NAD+ was held fixed at
0.5 mM (after mixing) while increasing the concentrations of THPP and TCEP (5150 mM, after mixing) in 100 mM HEPES (pH 7.5) buffer and monitoring the
reaction by single-wavelength data collection at 334 nm. The average of three
collected traces (n=3 technical replicates) was fit by non-linear least-squares
regression to a single 3 parameter exponential rise equation using SigmaPlot
12.0 (version 12.0.0.182, Systat Software). The observed rate constant (kobs)
from the single 3 parameter exponential fitting was then plotted versus THPP and
TCEP concentrations from which the apparent second-order forward association
rate constant of the reaction (k+app) was determined as the slope of linear leastsquares fit analysis. The apparent first-order reverse dissociation rate constant of
the reaction (k−app) was determined by the intercept at the vertical axis. Under the
pseudo-first-order conditions of the stopped-flow experiments ([THPP or TCEP]
>> [NAD+]), the following linear relationship holds kobs = (k+app) [THPP or TCEP] +

(k−app)

and the apparent association equilibrium constant is defined as
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=

Kaapp

(k+app/k−app).14
Nuclear Magnetic Resonance (NMR) characterization of the reaction product
For NMR measurements, the reaction of NAD+ with THPP and TCEP was
performed in 100 mM NaHCO3-Na2CO3 (pH 7.5) buffer. Reaction component
tubes were wrapped in aluminum foil to protect from ambient light. Samples were
made by reacting NAD+ (30.6 mM) or NADH (25.3 mM) with 400 mM of THPP or
TCEP and kept on ice before NMR measurements. To assign the chemical
structure to samples, we examined H2O-D2O (9:1 in volume) deuterated solventbased preparations of each reaction component individually as well as in
approximate (1:1) volume combinations of NAD+ to THPP or TCEP in separate
NMR glass capillary tubes to gather 1H-,

13C-,

and

31P-NMR

data, as well as for

the combination samples 1H-31P-HSQC-TOCSY, 1H-31P-HSQC, 1H-13C HMBC,
and 1H-13C HSQC data. The NMR spectra were acquired on a Bruker Advance
600 MHz NMR spectrometer with a 5 mm TXI or 5 mm BBO probe. All spectra
were acquired under dark lab conditions with overhead lights off the entire time
and with the samples at 4 °C.
RESULTS
Evidence of (NAD+─tris(alkyl)phosphine) association reaction
Evidence

for

a

nonenzymatic

reaction

between

NAD+

and

a

tris(alkyl)phosphine reducing reagent was adduced by several observations.
Initial assays of HsPYCR1 and 2 with L-Pro and NAD+ generated no increase in
absorbance at 340 nm over 30 min (Figure 5.1). We then included THPP and
TCEP in the reaction buffer as was done in the U.S. Patented PYCR1 inhibition
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assay

protocol.15

A rapid initial increase was observed with either TCEP or

A

B

Figure 5.1. Test for PYCR activity in the reverse direction. PYCR activity in the
reverse direction (L-Pro + NAD+  L-P5C + NADH) was assayed using 0.1 M
Tris-HCl (pH 7.5) buffer with 0.01% (v/v) Brij-35 detergent, 30 mM MgCl2, 5 mM
L-proline, 0.5 mM NAD+, with or without 1 mM TCEP or 1 mM THPP, and final
enzyme concentration 0.6 µM (A) HsPYCR1 and (B) HsPYCR2. Progress of the
reaction was monitored for 30 min by following the absorbance at 340 nm.
THPP, which then leveled off between 10-15 min and sustained absorbance
intensity up to 30 min (Figure 5.1). Suspecting that we were observing a
nonenzymatic reaction, we repeated the assay without PYCR and observed a
sharp increase in absorbance at 340 nm upon adding THPP or TCEP after 15
min with again a sustained absorbance intensity up to 30 min (Figure 5.2).
Because the observed increase in absorbance occurred rapidly upon adding
TCEP and THPP, we examined the reaction by stopped-flow absorbance
spectrophotometry. Upon rapidly mixing both TCEP with NAD+ in 100 mM
HEPES (pH 7.5) reaction buffer, a peak with a maximum absorbance at 334 nm
appeared within 200 ms (kobs of 35.4 ± 0.4 s-1) (Figure 5.3, A). The reaction was
repeated using different reaction buffers with each exhibiting a similar kobs value
(30-35 s-1) for the increase in absorbance, indicating the product formation is
independent of the buffer composition.
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A

B

Figure 5.2. Absorbance changes upon mixing NAD+ with tris(alkyl)phosphine
compounds. Nonenzymatic reactions with or without NAD+ (0.5 mM) were
incubated in 0.1 M Tris-HCl (pH 7.5) buffer with 0.01% (v/v) Brij-35 detergent, 30
mM MgCl2, and 5 mM L-proline. After 15 min, TCEP (A) and THPP (B) were
added (1 mM final concentration) and the absorbance at 340 nm was recorded
for an additional 15 min. All data points were normalized to a zero-absorbance
baseline.
A

C

B

D

Figure 5.3. Stopped-flow absorbance spectrophotometry of mixing NAD+ and
TCEP. NAD+ (0.5 mM after mixing) and TCEP (25 mM after mixing) were rapidly
mixed and multiwavelength absorbance traces were recorded. Reactions were
performed in 100 mM (pH 7.5) (A) HEPES, (B) Tris-HCl, (C) Na-Phosphate, and
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(D) PBS reaction buffer. Plots of the absorbance increase at 334 nm over 0.20 s
of time were fit to a single 3 parameter exponential equation as shown in the
inset along with the observed rate constant (kobs).
Rate constants for the observed increase in absorbance at 334 nm were then
determined for TCEP and THPP using 100 mM HEPES (pH 7.5) reaction buffer.
A

C

B

D

Figure 5.4. Stopped-flow kinetics of the (NAD+─tris(alkyl)phosphine) association
reaction. NAD+ (0.5 mM) was rapidly mixed with 50 mM (A) THPP and (C) TCEP
in 100 mM HEPES (pH 7.5) reaction buffer. Plots of the absorbance increase at
334 nm over 0.30 s of time were fit to a single 3 parameter exponential equation
are shown in the inset along with the observed rate constant (kobs). The
dependence of the observed rate constant (kobs) on THPP and TCEP
concentration was then determined by holding NAD+ concentration fixed (0.5
mM) and varying THPP and TCEP concentration (5-150 mM). Single wavelength
data were collected at 334 nm and the corresponding kobs values were
determined from single 3 parameter exponential fits of the data. The apparent
forward association (k+ app) and reverse dissociation (k- app) rate constants were
determined from the plot of kobs versus (B) THPP and (D) TCEP. Data are plotted
as (mean ± SD) of n=3 technical replicates and fit to a linear equation using
SigmaPlot 12.0. All concentrations are specified after mixing.
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Figure 5.4 shows the absorbance changes upon rapidly mixing 50 mM THPP
(panel A) or 50 mM TCEP (panel B) with NAD+. In another set of experiments,
NAD+ was then rapidly mixed with increasing concentrations of THPP or TCEP
(5-150 mM). The observed rate constants (kobs) versus THPP (panel C) and
TCEP (panel D) concentration were then plotted to determine the apparent
forward association (k+app) and reverse dissociation (k-app) rate constants. Table
5.1 summarizes the rate constants and shows that both the apparent forward
(490.5 M-1 s-1) and reverse (24.4 s-1) rate constants with TCEP are faster than
with THPP. The apparent equilibrium association constant (Kaapp), however, is
slightly higher with THPP (35.1 M-1).
Table 5.1. Pre-steady-state kinetic parameters for the
reaction of NAD+ and tris(alkyl)phosphine compounds
Kinetic parameter

THPP

TCEP

k+ app (M-1 s-1)a

230.9 ± 5.7

490.5 ± 24.8

k- app (s-1)b

6.6 ± 0.4

24.4 ± 1.7

Ka app (M-1)c

35.1 ± 2.3

20.1 ± 1.7

a(Value

± Std error) is reported for the apparent forward rate constant determined as the
slope of the plotted data fit to a linear least-squares equation using SigmaPlot 12.0
(version 12.0.0.182, Systat Software) with data plotted as (mean ± SD) of n=3 technical
replicates.
b(Value ± Std error) is reported for the apparent reverse rate constant determined as the
vertical axis intercept of the plotted data.
cApparent equilibrium association constant determined from the calculation of K app =
a
(k+app/k−app).

Characterization of the reaction product
L-lactate dehydrogenase and pyruvate were initially added to the reaction
product to test whether NADH was formed. However, no decrease in absorbance
(330-340 nm) was observed indicating that the product was not usable by L-
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lactate dehydrogenase. We also did not find evidence for NADH by mass
spectrometry analysis of the reaction product.
NMR was then used to characterize and identify the product. Initial NMR
experiments included one-dimensional (1H and

31P)

and two-dimensional (1H-31P

HSQC, 1H-31P HSQC-TOCSY) analyses. The chemical shift data from these
experiments indicated the tris(alkyl)phosphine compound’s phosphorus atom was
interacting with the C4 position of the dihydronicotinamide ring of NAD+.
Additionally, two-dimensional NMR data as shown in Fig. 5.5 with corresponding
spectral data provided in Table 5.2, indicated the reaction was reversible as the
1H-31P
31P

HSQC-TOCSY showed

31P

correlations to reaction product protons and

correlations to NAD+ protons. With the 1H-31P HSQC-TOCSY, NAD+ proton

correlations could only be observed if the phosphine compound was associating
and dissociating with the dihydronicotinamide ring during the TOCSY spinlock,
indicating reaction reversibility. Lastly, these initial experiments indicated the
reaction yielded two products with different stereochemistry, likely with the
phosphorus above or below the dihydronicotinamide ring, in a roughly 1 to 0.6
ratio.
As evident from both one-dimensional (31P) and two-dimensional (1H-31P
HSQC, 1H-31P HSQC-TOCSY) analyses, the latter of which is shown in Fig. 5.5
and Table 5.2, there were two sets of phosphorus species observed in the NAD+
and THPP reaction mixture. The phosphorus species circa 34.4 ppm were
interacting with the dihydronicotinamide ring. The phosphorus species circa -13.2
ppm were interacting with one of the ribose rings. Additionally, two-dimensional
(1H-13C HMBC) analysis of NAD+ alone and NADH alone with their spectral data
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A

B

δ (31P)

δ (31P)

δ (1H)

δ (1H)

Figure 5.5. Two-dimensional 1H-31P NMR spectra of the NAD+ and THPP
reaction mixture. Shown here is the (A) 1H-31P HSQC spectrum and (B) 1H-31P
HSQC-TOCSY spectrum. Both spectra were acquired with a J-coupling constant
of 11 Hz, and the latter spectrum with a TOCSY mixing time of 80 ms. The
assignments are summarized in Table 2 to support the chemical structures of the
reaction product and NAD+ alone as shown in Fig. 5.6, D.
summarized in Tables 5.3 and 5.4, respectively, support structural assignments
of these reference compound structures shown in Fig. 5.6, A and B.
Table 5.2. Chemical shifts from 1H-31P NMR correlation experiment† of NAD+ and THPP
reaction mixture
Label
1
2
3
4
5
6
7
8
9
10
b
d
g

δ (1H-31P HSQC,
ppm)

δ ( 1H-31P HSQCTOCSY, ppm)

3.96 (1H), minor 4.35
1.96 (m), minor 1.98
1.54 (m)
3.44 (m)

34.3, minor 34.4
34.3
34.3

34.3, minor 34.4
34.3
34.3
34.3

7.10 (d, 1H, J = 1.8 Hz), minor 7.23
(d, 1H, J = 1.8 Hz)
6.33 (at, 1H, J = 6.3 Hz), minor 6.28
(at, 1H J = 6.3)
4.51
4.67 (broad s), minor 4.69
8.91 (d, J = 6.3 Hz)
8.59 (d, J = 8.4 Hz)
9.11 (s)

34.3, minor 34.4

34.3, minor 34.4

34.3, minor 34.4

34.3, minor 34.4

δ (1H, ppm)‡

34.3
34.3
34.3
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†Chemical

shifts were determined from the HSQC and HSQC-TOCSY experiments shown in Fig.
5.5 and correspond to site labels shown in Fig. 5.6, D.
‡Listed next to each 1H-NMR chemical shift value is (multiplicity designation [s, singlet; d, doublet;
m, multiplet; etc.], J-coupling constant).
Table 5.3. Chemical shifts from 1H-13C NMR correlation experiment† of NAD+
Label
a
b
c
d
e
f
g

δ (1H, ppm)‡
1H,

5.85 (d,
J = 5.6 Hz)
1
8.9 (d, H, J = 6.6 Hz)
7.93 (at, 1H, J = 6.6 Hz)
8.57 (d, 1H, J = 8.5 Hz)

9.1 (s, 1H)

δ (13C, ppm)
98
140.3
126.6
143.6
131.6
163.2
138.0

HMBC
b, g
a, c, d, g
b, e
b, f, g

a, b, d, e, f

†Chemical

shifts were determined from the HMBC experiment and correspond to site labels
shown in Fig. 5.6, A.
‡Listed next to each 1H-NMR chemical shift value is (multiplicity designation [s, singlet; d, doublet;
etc.], J-coupling constant).
Table 5.4. Chemical shifts from 1H-13C NMR correlation experiment† of NADH
Label
A
B
C
D
E
F
G

δ (1H, ppm)‡
4.55 (d, 1H, J = 7.1 Hz)
5.73 (d, 1H, J = 8.4 Hz)
4.51 (1H)
2.35 (dd, 1H, J = 3.4, 18.8 Hz),
2.49 (d, 1H, J = 18.4 Hz)

6.68 (s, 1H)

†Chemical

δ (13C, ppm)

HMBC

93.1
121.4
103.4
19.9

B, G
A, C, D, G
B, E
B, C, E, G

97.5
170.7
136.7

A, B, D, E, F

shifts were determined from the HMBC experiment and correspond to site labels
shown in Fig. 5.6, B.
‡Listed next to each 1H-NMR chemical shift value is (multiplicity designation [s, singlet; d, doublet;
dd, doublet of doublets], J-coupling constant).

A

C

124
B

D

Figure 5.6. Chemical structures of compounds based on the assignment of NMR
spectral data. Assignments of (A) NAD+ structure, (B) NADH structure, (C) NAD+
and THPP reaction mixture structure, and (D) structures of NAD+ and THPP
reaction mixture (left) and NAD+ alone (right) have alphanumeric site labels
corresponding to chemical shift data presented in Tables 5.2-5.5.
Further experiments were conducted, on an aged sample of NAD+ and THPP,
to complete the structural assignment. These experiments included one
dimensional (13C) and two dimensional (1H-1H COSY, 1H-1H TOCSY, 1H-13C
HSQC, 1H-13C HMBC) analyses as shown in Fig. 5.7, the last of which has its
spectral data summarized in Table 5.5. Also, the reaction product of NAD+ and

C

A

δ (13C)

δ (1H)

δ (1H)

δ (1H)
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B

D

δ (13C)

δ (1H)

δ (1H)

δ (1H)

Figure 5.7. Two-dimensional NMR spectra of NAD+ and THPP reaction mixture.
Shown here is the (A) 1H-1H COSY spectrum, (B) 1H-1H TOCSY spectrum, (C)
1H-13C HSQC spectrum, and (D) 1H-13C HMBC spectrum. The assignments of
panel D are summarized in Table 5.5 to support the chemical structure of the
reaction product as shown in Fig. 5.6, C.
Table 5.5. Chemical shifts from 1H-13C NMR correlation experiment† of NAD+ and THPP
reaction mixture
Label

δ (1H, ppm)‡

1

3.96

2

1.96 (m), minor 1.98

3

1.54 (m)

4
5
6
7

3.44 (m)

8
9
10

(1H),

minor 4.35

7.10 (d, 1H, J = 1.8 Hz),
minor 7.23 (d, 1H, J = 1.8 Hz)
6.33 (at, 1H, J = 6.3 Hz),
minor 6.28 (at, 1H J = 6.3)
4.51
4.67 (broad s), minor 4.69

δ (13C, ppm)

HMBC

28.4 (J-CP = 47 Hz),
minor 28.6 (J-CP = 48 Hz)
11.3 (J-CP = 44 Hz),
minor 11.1 (J-CP = 45 Hz)
21.6 (J-CP = 4 Hz),
minor 21.8 (J-CP = 4 Hz)
59.3
168.2
94.6
139.3, minor 134.5

5, 6, 7, 8, 9

126.6, minor 132.6

1, 7, 9, 10

93.9
92.6, minor 92.3

1, 8
7, 8

3, 4
2, 4
2, 3

1, 5, 6, 8, 10

†Chemical

shifts were determined from the HMBC experiment shown in Fig. 5.7, D and
correspond to site labels shown in Fig. 5.6, C.
‡Listed next to each 1H-NMR chemical shift value is (multiplicity designation [s, singlet; d, doublet;
m, multiplet; etc.], J-coupling constant).

THPP was very similar to that of NAD+ and TCEP as determined by overlaying or
stacking the one-dimensional proton spectra as shown in Fig. 5.8.
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DISCUSSION
To our knowledge, this is the first NMR characterization of a covalent adduct
between NAD+ and TCEP or THPP. The reaction occurs at biologically relevant
concentrations of NAD+ (0.5 mM) with TCEP and THPP concentrations (1 mM)
typically used in experimental conditions. Stopped-flow kinetics indicate the
reaction is reversible and occurs on a timescale comparable to that of TCEP
reduction of disulfide bonds in DTT (43 M-1s-1), peptide substrates containing a
CXXC motif (650 M-1s-1), and oxidized cysteines in proteins (1.5 - 813 M-1s-1).16,17
We did not detect NADH formation, instead, NMR showed conclusive evidence
for a covalent adduct of the phosphorus at the C4 position of the
dihydronicotinamide ring. The reaction likely proceeds through a nucleophilic
attack of the phosphine’s phosphorus atom at the C4 position of the
dihydronicotinamide group of NAD+ similar to that of a tertiary phosphine
attacking an alkyl halide to form a phosphonium ion.
The dihydronicotinamide ring of NAD+ has electrophilic character and thereby
A
a

b

δ (1H)
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B
i

ii

Figure 5.8. Covalent Adduct Reaction Product NMR spectra and resolved
chemical structures. (A) 1H-NMR spectra stacked as (a) NAD+ with THPP and (b)
NAD+ with TCEP. (B) Chemical structures of resolved covalent adduct product
from the reaction of (i) NAD+ with THPP and (ii) NAD+ with TCEP.
is susceptible to modifications by nucleophilic species. More fundamentally,
NAD(P)+ and NAD(P)H differ from other coenzymes such as thiamine
pyrophosphate, biotin, and pyridoxal phosphate, which return to their original
forms upon completion of their catalytic cycles, whereas the pyridine
dinucleotides appear modified with stereospecific hydrogen exchange at the C4
position of the dihydronicotinamide ring, thus earning NAD(P)+ and NAD(P)H the
title of cosubstrate.18 Of biological relevance is that various sulfhydryl compounds
can form adducts at the C4 position of the dihydronicotinamide ring.19 Besides
consistent UV absorption spectra, the infrared absorption spectra of covalent
adduct compounds formed from the reaction of thiols (including benzyl
mercaptan, 2-mercaptothiazole, β-phenylethyl mercaptan, ethyl mercaptan,
thiocyanate

ion,

and

thiophenol)

with

1-substituted

NAD+

demonstrate

characteristic peak absorption at ~1560

cm-1,
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particularly due to a vinylogous

amide group that often occurs in 1,4-dihydronicotinamide molecules.19 Sulfhydryl
compounds such as cysteine and glutathione can add to the dihydronicotinamide
ring of NAD+ to form NAD+-mercaptan addition complexes with UV absorbance
maxima at 350 nm.20 It is of interest to note that the apparent association
equilibrium constants for cysteine (2.4 x 10-9 M-1) and glutathione (1.6 x 10-9 M1)20

with NAD+ are dramatically 109- to 1010-fold smaller in magnitude than the

Kaapp values for tris(alkyl)phosphine compounds with NAD+ observed here.
Another example of observed NAD+ addition reaction with a nucleophilic species
involves the bacterial NAD+-dependent enzyme urocanase, which forms a
chromophore between competitive inhibitor imidazole-propionate and NAD+ with
an observed UV absorbance peak at 335 nm.21 In this case, NMR evidence
showed that the chromophore generated from this urocanase reaction was not
NADH, but rather was a reversible complex of the inhibitor’s imidazole nitrogen
forming a covalent adduct with the C4 position of the dihydronicotinamide ring of
NAD+.21 Thus, the UV absorbance peak of 334 nm observed here for the covalent
NAD+─tris(alkyl)phosphine adducts, is similar to that previously reported for
various covalent NAD+ adduct species.
We could not find any previous reports of chemical reactivity between NAD+
and phosphine compounds. In 2017, however, Mayclin et al. from the Seattle
Structural Genomics Center for Infectious Disease resolved a 1.45 Å X-ray
crystal structure of the NADP+ cofactor-bound complex of bacterial short-chain
dehydrogenase/reductase (SDR) from Burkholderia ambifaria (Figure 5.9).22 This
structure was determined from a crystal grown in the presence of 5 mM NADP+

and 1 mM TCEP (PDB Code: 5VPS). Whereas

NADP+

129
was explicitly added to the

crystallization experiment to obtain a structure of the functional enzyme, TCEP
was included as an innocuous component of the enzyme stock solution buffer.
The electron density maps clearly showed NADP+ bound to the Rao-Rossmann
fold in the expected conformation (Figure 5.9, a). Unexpectedly, strong electron
density indicated that the C4 atom of the dihydronicotinamide ring of NADPH had
been covalently linked to the phosphorus atom of (Figure 5.9, b). The electron

Figure 5.9. Structure of Burkholderia ambifaria SDR with a NADP+─TCEP adduct
in the active site. (a) Ribbon cartoon model of the SDR protein with the adduct in
pink sticks. The inset shows electron density for the adduct (polder omit, 3.0σ).
(b) Closeup views of the adduct showing electron density for the P-C4 bond (left)
and interactions with the carboxyethyl groups of TCEP (right). The X-ray crystal
structure of SDR soaked with 5 mM NADP+ and 1 mM TCEP was graciously
provided by Dr. Stephen J. Mayclin and Dr. Thomas E. Edwards.
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density is consistent with the structure of the adduct determined from solution
NMR. Thus, TCEP and NADP+ are also capable of forming a covalent adduct in
an oxidoreductase active site. Whether the kinetics of the reaction is similar to
that in solution remains unknown. Because TCEP and NAD(P)+ can form a
complex in solution or in an enzyme active site, it raises the question as to how
many structures of NAD(P)+-dependent oxidoreductases have been impacted by
including TCEP or THPP in the crystallization milieu. Although the NADP+-TCEP
adduct was captured in SDR, the same adduct could potentially cause disorder of
the NAD(P)+ cofactor in other enzymes making it difficult to identify NAD(P)+binding interactions.
In addition to unintentional interference with crystallization and structural
studies, TCEP and THPP are also likely to cause problems with enzyme assays
and binding studies. As we observed, adding TCEP and THPP to NAD(P)+dependent assays would generate a rapid absorbance increase around 340 nm
that, without proper controls, could be misinterpreted as enzyme activity. This
would particularly be a problem with high-throughput assays that use only
endpoint measurements. With respect to binding studies, the addition of
tris(alkyl)phosphine compounds would potentially lead to lower concentrations of
free NAD(P)+, resulting in anomalous errors in the determined binding constant.
Also, the data could be convoluted by unknowingly having two species present,
NAD(P)+ and the NAD(P)+─tris(alkyl)phosphine covalent adduct. Methods that
measure changes in heat to quantify bimolecular binding events, such as
isothermal titration calorimetry, would have additional complications due to heat
contributions by NAD(P)+ reacting with TCEP or THPP during the titration.23

We

characterized

the

chemical

reaction

kinetics
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of

(NAD+─tris(alkyl)phosphine) association reactions and identified the chemical
structure of the reaction product molecule through NMR assignments. Evidence
from stopped-flow spectrophotometry and multidimensional NMR indicate that
the species formed with a UV absorbance maximum at 334 nm is a reversible
covalent adduct between the tris(alkyl)phosphine compound’s phosphorus atom
and the C4 position of the dihydronicotinamide group of NAD+. Side-by-side
comparison of TCEP and THPP shows the reaction kinetics with NAD+ are faster
with TCEP whereas THPP exhibits a 1.7-fold higher apparent equilibrium
association constant for the NAD+─tris(alkyl)phosphine covalent adduct. In
conclusion,

the

implications

of

our

data

concerning

the

(NAD+─tris(alkyl)phosphine) association reaction warrant caution be taken when
using TCEP or THPP with NAD(P)+-dependent enzymes.
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Chapter 6

Major Conclusions and Future Directions
MAJOR CONCLUSIONS
Pyrroline-5-carboxylate reductases have been identified as important
housekeeping enzymes of L-proline biosynthesis, which generate the unique
imino acid L-proline that serves as an instrumental structural component of
proteins and participates in stress protection and redox homeostasis of cells
across all three domains of life (eukaryota, bacteria, and archaea).1,2,3,4 In
chapter two, we describe the circa 1.9 Å high resolution X-ray crystal structures of
the binary complexes of HsPYCR1 with NADPH or L-Pro bound ligands that were
obtained by our collaborators. These structures unequivocally identify the
NADPH-binding site being located in the N-terminal Rao-Rossmann fold domain
of HsPYCR1. A high-resolution X-ray crystal structure of a ternary complex of
HsPYCR1 containing NADPH and an L-P5C/L-Pro analog, L-THFA, provides a
mechanistic model of the Michaelis complex formed during hydride transfer.
Functional analysis of a highly conserved active site Thr238 by site-directed
mutagenesis reveals substitution with Ala (T238A) results in a 10-fold diminution
in catalytic efficiency with varied concentrations of L-P5C relative to the wild-type
enzyme. These data suggest that the loss of Thr238 as a potential proton donor
in the enzyme active site strongly hinders catalytic activity, perhaps by loss of a
hydrogen bonding interaction with the imine nitrogen of the L-P5C substrate.
Based upon structural homology with human PYCR1, chapter three focuses
on the functional and structural consequences in wild-type HsPYCR2 enzyme of
two mutant variants, Arg119Cys and Arg251Cys, that were previously identified

in patients with microcephaly and

hypomyelination.5
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Arg119 and Arg251 are

predicted to be important for the catalytic activity and structural stability of
HsPYCR2. Henri-Michaelis-Menten kinetic analysis shows a 164-fold loss in
catalytic efficiency for the Arg119Cys mutant, with varied concentrations of L-P5C
substrate and fixed concentration of NADH cofactor, relative to the wild-type
enzyme. The dramatic loss in activity could be due to mutation of Arg119 near
the posterior wall of the enzyme’s active site leading to disrupted conformation
flexibility of HsPYCR2 near the cofactor substrate binding site, thus leading to
decreased kinetics of cofactor substrate entrance and egress.6 The Arg251Cys
mutation has a profound effect on the thermostability and secondary structure of
HsPYCR2 as determined by fluorescence-based thermal shift assays and circular
dichroism, respectively.
The binding order of L-P5C and NAD(P)H to HsPYCR1 and HsPYCR2
enzymes was evaluated by product(s) inhibition studies using L-Pro, NADP+, or
NAD+.7 Collective analysis of Henri-Michaelis-Menten kinetic data and HanesWoolf plots of linear regressions indicate NADP+ and NAD+ are mixed
noncompetitive inhibitors8 of HsPYCR1 and 2 against NADPH and NADH
substrates, respectively. L-Proline is a competitive inhibitor8 of HsPCYR1 and 2
with respect to L-P5C substrate. Taken together, these modes of product
inhibition support a proposed sequential-ordered binding mechanism for
HsPYCR1 and HsPYCR2 enzymes.7 Interestingly, serum levels of L-proline in
healthy adult humans is reported to range from 125-633 µM with mean levels
around 270 µM.9,10 The apparent competitive inhibition constants for both
HsPYCR1 and HsPYCR2 determined with L-proline (KIC app = 2.61 ± 0.25 mM and
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145 ± 8 µM, respectively) highlight HsPYCR2’s greater sensitivity to physiological
L-proline concentrations, suggesting that it is susceptible to product feedback
inhibition by L-proline. In terms of NAD+, Yang et al.’s (2007) study estimated
[NAD+] in mitochondria of HEK293 cells is 245.6 µM using MALDI-MS, which
corresponds to 2053 pmol NAD+/mg mitochondrial protein.11 NADH may be lower
than NAD+ levels (e.g., physiologic NAD+/NADH ratio ~0.1-10 in mammalian
cells)12, and intracellular concentrations of NADP+ and NADPH are even lower
than their non-phosphorylated forms wherein the NADP+ pool is predominantly in
the reduced state.13 Thus, the apparent competitive inhibition constants
determined here for both HsPYCR1 and HsPYCR2 with
respectively (KIC

app

NADP+ and NAD+,

= 8.28 ± 1.36 mM and 792 ± 248 µM) as well as the

corresponding apparent uncompetitive inhibition constants (KIU app = 3.92 ± 0.64
mM and 326 ± 102 µM) highlight again that HsPYCR2 is more susceptible to
product feedback inhibition by NAD+ than HsPCYR1. The physiologic levels of
NADP+ are not high enough to effectively inhibit HsPYCR1.
In chapter four, we performed in vitro experiments probing human PYCRmediated reverse direction reactions, which involve the reduction of NAD(P)+ into
NAD(P)H using L-Pro, L-T4C, or DL-T2C as the reducing substrate with human
PYCRs at biologically relevant pH 7.5. From these studies, we observed no
substantial reverse activity of HsPYCR1 or HsPYCR2 with L-Pro or DL-T2C,
however, substantial activity was observed with L-T4C. Upon further analysis of
Henri-Michaelis-Menten saturation kinetics, we report that HsPYCR2 exhibits an
apparent catalytic efficiency (136 M-1 s-1) with varied concentrations of L-T4C that
is nearly 10-fold higher than that of HsPYCR1 (13.7 M-1 s-1) with varied
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concentrations of L-T4C. Ligand inhibition kinetics evidence of L-Pro as a
competitive inhibitor (KIC

app

= 15.7 mM) of HsPYCR1 with respect to L-T4C

substrate. This data along with the 2.30 Å X-ray crystal structure of a
HsPYCR1─L-T4C complex highly suggests that L-T4C binds at the same active
site region as L-Pro in the enzyme. Taken together, this experimental evidence
assigns a novel enzyme function to human PYCRs. We propose PYCRs be given
the new name L-thiazolidine-4-and-L-pyrroline-5-carboxylate oxidoreductase
(TPCOR) to embody both enzyme activities.
Upon encountering a PYCR1 inhibition assay protocol that included TCEP in
the human PYCR-mediated reverse direction reaction,14 we set out to further
examine

the

enzymatic

and

nonenzymatic

reactions

between

tris(alkyl)phosphine compounds THPP or TCEP and NAD+ as detailed in chapter
five. To that end, our body of evidence of the (NAD+─tris(alkyl)phosphine)
association reaction indicates the following: (i) the chemical reaction kinetics
occurs rapidly within one second; (ii) optimal absorbance of the reaction product
was observed at 334 nm; (iii) nearly identical observed rate constants, kobs, with
four various reaction buffers show that the association reactions are not
dependent on the composition of the reaction buffer; and (iv) THPP demonstrates
an overall larger apparent association equilibrium constant with NAD+, Ka

app,

than compared to TCEP’s association with NAD+ (35.1 ± 2.3 M-1 versus 20.1 ±
1.7 M-1). NMR one-dimensional and two-dimensional spectroscopy of the nuclei
1H, 13C,

and

31P

collectively resolved the chemical structure of the (NAD+-

tris(alkyl)phosphine) association reaction product molecule as a covalent adduct
between the phosphorus of THPP or TCEP interacting at the C4 position of the

dihydronicotinamide ring of

NAD+.
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All in all, our in vitro findings concerning the

(NAD+─tris(alkyl)phosphine) association reaction serves as a cautionary tale
when using TCEP or THPP in NAD+-dependent enzyme activity assays due to
artifactual background increases in absorbance around 340 nm by the reaction
product molecule.
FUTURE DIRECTIONS
From chapters two and three, elucidation of the sequential-ordered binding
mechanism of HsPYCR1 and HsPYCR2 has the potential to guide the
development of new inhibitors and/or substrate analogs as molecular probes for
modulating human PYCR activity. For instance, D’Aniello et al. (2020) consider
HsPYCR1 to be a potential therapeutic target against cases of hepatocellular
carcinoma and breast cancer, but hitherto, no specific enzyme inhibitors have
been developed.15 However, in the context of plants and development of
herbicides specifically targeting and inhibiting plant P5CR activity, Forlani et al.
(2008) have identified inhibitors with two phosphonic groups as the main
structural feature for binding to the P5CR active site.16 In that study, the authors
kept the bisphosphonate scaffold while diligently exploring analogs of the inhibitor
(3,5-dichlorophenyl)aminomethylenebisphosphonic acid.16
Additionally, previous studies that have profiled metabolic alterations in the
blood and plasma of HsPYCR2-deficient patients found no significant decreases
in L-proline .5,17 However, it remains unknown what the concentrations of Lproline and of its related metabolites are in the relevant affected neurological
tissue and cerebrospinal fluid (CSF) of these patients. Thus, an appropriate next
step would be to examine if HsPYCR2 deficiency causes abnormal L-proline
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bioavailability in patients, especially in the CSF.
Upon observing that HsPYCR1 and HsPYCR2 utilize L-T4C as a substrate in
chapter four, the next prudent course of action should involve knockout studies of
HsPYCR1, HsPYCR2, and of both isozymes combined with L-Pro starvation
studies of human tissue cells supplied with doses of L-T4C in growth media.
From these studies, the measured endpoints of cellular L-Cys levels and the
various redox states of L-Cys could describe how L-Pro homeostasis and L-Cys
homeostasis interact at the level of PYCR bifunctional enzyme activity. From
early in vivo studies done by Mackenzie et al. (1957), L-T4C was found to be a
great sulfur replacement for L-cystine (oxidized form of L-Cys) to supplement
animals with low L-methionine diets and promote growth.18
Another set of studies could be done to explore if there is altered reactive
nitrogen species (RNS) homeostasis with overexpressed HsPYCR1, HsPYCR2,
and both isozymes. PYCR enzymes consume L-T4C, which is regarded as a
major cellular nitrite scavenger. Taking L-T4C’s capacity as a nitrite scavenger
and probe for the detection of RNS a step further, Kumagai et al. (2004)’s
duodenal contents reflux rat model with the intervention of L-thioproline curtailed
pathological tissue damage by the presence of RNS, i.e. nitric oxide and
peroxynitrite, and N-nitroso compounds in gastroduodenal reflux contents.19
Recent advances in imaging methods and visualization tools could allow for
specific detection of RNS. For instance, one method relies on an iridium(III)
complex used as a near-infrared phosphorescent probe for examining the
interplay between nitric oxide and superoxide species and for detecting
intracellular peroxynitrite levels of organisms both in vitro and in vivo.20 Another
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novel approach involves the use of a chemiluminescent molecule (oxygenembedded quinoidal pentacene) tethered to a near-infrared nanoprobe for noninvasive, in vivo, specific detection of peroxynitrite via a chemiluminescence
resonance energy transfer mechanism.21
Aside from these novel research pursuits, L-proline metabolism is intimately
linked with vital cellular processes including bioenergetics, anaplerotic reactions
replenishing citric acid cycle intermediates, and cell signaling.22 The role of PYCR
at the intersection of L-Pro and L-Cys homeostasis and the potential involvement
of PYCR in RNS balance via L-T4C would further expand our understanding of
the numerous physiological roles of PYCR enzymes. From the two major
biosynthetic routes of L-proline formation mentioned in chapter one, this work
primarily addresses the L-glutamate route with an emphasis on the final reductive
step. In conclusion, the entirety of this thesis dissertation accomplishes both
structural and kinetic characterization of human PYCR enzymes responsible for
L-proline biosynthesis.
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APPENDIX A

DL-P5C Substrate Stocks’ Chemical Synthesis Protocol
DL-P5C Synthesis
The synthesis of DL-P5C followed the method of Williams and Frank1 except
the volume of each of the following components was reduced by two-fold: DL-5hydroxylysine hydrochloride, sodium metaperiodate, glycerol, glycine, and HCl.
After performing the reaction at 4 °C, the reaction mixture was loaded onto a 1.5
cm (inner diameter) x 43.5 cm (length) borosilicate glass column (Kimble Chase)
packed with Dowex 50WX4 cation exchange resin that had been equilibrated with
2 M HCl. The column was then washed with 1 M HCl to elute the fractions. The
concentration of DL-P5C in the collected fractions was determined by diluting a 4
μl sample of each fraction into 16 μl of 1 M HCl which was then added to 180 μl of
5 mM o-AB (prepared by diluting a 500 mM o-AB stock (in 100% ethanol) into 20
mM Glycine-HCl, pH 2.0), resulting in a final 200 μl volume. DL-P5C reacts with

o-AB to form a yellow conjugate that can be detected at 443 nm (ε443 = 2590 M-1
cm-1).2 The DL-P5C/ o-AB mixtures (200 μl) were incubated at room temperature
with mild shaker agitation for 24 h in a clear polystyrene 96-well flat bottom plate
(Corning) covered in aluminum foil. Absorbance at 443 nm was then recorded
using a Synergy 2 Multi-Mode Plate-Reader (BioTek) with Gen5 Secure Reader

Control and Data Analysis software (version 2.05.5, BioTek). The concentration
of DL-P5C was determined using a modified equation of the Beer–Lambert–
Bouguer law3,4,5 which incorporates the mean absorbance of six replicates of a
blank (5 mM o-AB in 20 mM Glycine-HCl, pH 2.0), a microplate-based path
length-well volume correction factor (2.19) determined from IR absorbance

measurements6
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with 1 M HCl, and a dilution factor of 50-fold. Eluted fractions of

DL-P5C in 1 M HCl were kept long-term as stock solutions at 4 °C.
[DL-P5C] (mM) = �

((sample mean A443 − blank mean A443) × 2.19)
�
(ε443 nm = 2.590 mM-1 cm-1) × (1 cm)

× 50 (dilution factor)

Characterization of DL-P5C by Electrospray Ionization Mass Spectrometry
Liquid chromatography-electrospray ionization-multiple reaction monitoring
(LC-ESI-MRM) mass spectrometry analysis was performed to verify the presence
of DL-P5C in the samples. The LC-ESI-MRM analysis was performed on a 4000
QTrap from Sciex (Framingham, MA) operating in MRM analysis mode. The
electrospray source was optimized for positive mode with the following
parameters: declustering potential = 40 V, curtain gas = 30 L/min, ionization
potential = 5500 V, temperature = 600 °C, ion source gas 1 = 60 and ion source
gas 2 = 80. The samples were loaded into sample vials and held at 5 °C until the
injection time. An Agilent LC 1200 HPLC system was used for the separation of
the compounds, using a Waters X-Bridge Amide column (Waltham, MA) with
dimensions of 4.6 mm x 100 mm. The flow rate was maintained at 0.5 mL/min
with the gradient as follows: from 0 to 2 min 5% mobile phase A (20 mM
ammonium acetate, 20 mM NH4OH, pH = 9.5) and 95% mobile phase B
(acetonitrile); from 2 to 20 min from 5% to 70% A, at 20.2 min 95% A, at 24 min
95% A, and at 24.2 min 5% A for 16 min duration for re-equilibration purposes.
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Appendix A Figure 1. Microplate-based DL-P5C concentration determinations
and mass spectrometry analysis. The scatter plot summarizes microplate-based
DL-P5C concentration determinations via o-AB colorimetric assay of absorbance
measurements at 443 nm of one batch of chemically synthesized DL-P5C
substrate in column eluted fractions. Then, liquid chromatography-mass
spectrometry analysis was performed on three samples, prepared as (1/100)
dilutions using acetonitrile solvent, from those eluted fractions as annotated in the
scatter plot: (A) Column Wash Flowthrough sample, (B) Elution Peak #1 sample,
and (C) Elution Peak #2 sample.
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APPENDIX B

Extended Methods and Procedure for HsPYCR2 Protein Purification
Recombinant protein expression (pKA8H/PYCR2) vector DNA constructs
were

first

transformed

into

DNA

propagation

host

E. coli XL1-Blue

Supercompetent Cells (Agilent Technologies), which were grown on separate LB
Agar Miller plates containing 50 μg/ml ampicillin. Then, the recombinant protein
expression pKA8H vector DNA constructs were transformed into protein
expression host E. coli BL21 (DE3) pLysS competent cells (Novagen-EMD
Millipore Sigma), which were likewise grown on separate LB Agar Miller plates
containing 50 μg/ml ampicillin and 34 μg/ml chloramphenicol (Chem-Impex
International). Using this pKA8H expression vector construct resulted in proteins
with an N-terminal octahistidine tag followed by a tobacco etch virus protease
cleavage site.
Next, from those latter growth plates, a pipette-tip picked single colony of cells
was inoculated into 15 ml starter liquid growth culture containing TB liquid media
(prepared from the recipe in Sambrook et al. 1989 consisting of tryptone, yeast
extract, glycerol, and water),1 50 μg/ml ampicillin, and 34 μg/ml chloramphenicol.
Then starter culture was grown for 17 h overnight in an incubator-shaker at 37 °C,
180 rpm. To scale up culture size, we transferred 2.5 ml starter culture into each
of six 2 L flasks containing 1 L of TB liquid media and 50 μg/ml ampicillin to
shake at 37 °C, 180 rpm, until reaching nearly synchronized cell densities
associated with OD600 ≈ 0.8-1.0. At that point, the incubation temperature was
lowered to 18 °C and the six flasks of culture were induced with 0.4 mM IPTG for
cultures shaken at 180 rpm for 10 h. Then, we added 100 μg/ml chloramphenicol
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to the six flasks of culture to be continued shaken at 180 rpm and 18 °C for 2
additional hours to arrest ribosomal translation of bacterial proteins to further
improve the solubility of the target overexpressed recombinant protein by means
of affording the bacterial cells to divert their chaperone-assisted folding
capabilities towards the target protein without continuous generation of
aggregation-prone proteins.2
Next, we harvested cells via repeated rounds of large rotor centrifugation
(Avanti J-E High-Speed Centrifuge, Beckman Coulter) at relative centrifugal force
(5400 x g) for 20 min at 4 °C to process all 6 L of culture into two 1000-ml
centrifugation polypropylene bottles (Beckman Coulter), with supernatants
decanted off and cell pellets stored at -80 °C overnight to promote cell lysis by
freezing. Then with a metal spatula, we transferred cell pellets from both
centrifugation bottles into a common glass beaker and let pellets thaw at room
temperature on the lab countertop for 30 min. Next, the combined cell pellets
were resuspended and lysed in NPI-5 cell lysis buffer (5 mM imidazole, 500 mM
NaCl, 50 mM NaH2PO4, pH 7.5) with the addition of 500 µM Tris(3hydroxypropyl)phosphine (THPP) reducing agent (Strem Chemicals), 0.01%
TritonX-100 detergent (Amresco), 0.01% Brij-35 polyoxyethylene detergent
(Santa-Cruz Biotechnology), 10 mM βOG, and a mixture of five protease
inhibitors: (i) 500 mM ε-amino-N-caproic acid dissolved in water, (ii) 50 mM
PMSF dissolved in acetone, (iii) 2 mM leupeptin hemisulfate dissolved in water,
(iv) 8 mM N-tosyl-L-phenylalanine chloromethyl ketone dissolved in ethanol, and
(v) 13 mM N-α-p-tosyl-L-lysine chloromethyl ketone (Bachem) dissolved in water.
The cell suspension was then subjected to sonication at knob setting 6 for total
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processing time of 5 min with settings 5 s-pulse on and 15 s-pulse off, on a Sonic
Dismembrator (Model F 550, Fisher Scientific). Next, cell lysates were poured
into four 25 ml-centrifugation tubes fitted with stoppers and caps, to be subjected
to small rotor 4 °C centrifugation at relative centrifugal force (30960 x g) for 1.5 hr
before obtaining supernatants of target protein solution.
After that, the target protein was purified by application into a borosilicate
glass column (Kimble Chase) of 2.5 cm (diam.) x 24 cm (height) packed with 25ml resin bed of Ni2+-nitrilotriacetic acid Superflow resin (Qiagen) for motor-driven
pulsatile tubing flow-immobilized metal affinity column chromatography in 4 °C
cold room. The column purification proceeded with column volumes (CV) of an
increasing imidazole concentration gradient (5 CV of 5 mM  10 CV of 60 mM 
6 CV of 500 mM imidazole) of 50 mM NaH2PO4-based buffers applied into
column until final protein elution into automated glass test tube fraction collector
set at 2 ml per fraction. Next, Bio-Safe Coomassie Blue G250 Stain (Bio-Rad)
exposure-based SDS-PAGE of two precast 15-well gels 4-20 % Tris/Gly (BioRad, Mini-Protean TGX) was performed with 20 µl-aliquots of 20 eluted fraction
tubes chosen randomly from 50 total tubes, where each aliquot was chemically
reduced with SDS-Loading Buffer and (β)2-Mercaptoethanol (Acros Organics)
and thermally reduced by 10 min boil at 100 °C, all ultimately to determine which
eluted protein fractions to pool together. Next, in 4 °C cold room, the pooled
protein fractions were collected into a regenerated cellulose dialysis tubing sac
(Dialysis Snakeskin Tubing, ThermoFisher Scientific-Pierce Biotech) clipped
closed at both ends and dialyzed at moderate stir atop stirring plate for three
separate periods (24 hr5 hr5 hr) into fresh 1 L dialysis buffer (50 mM HEPES,
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250 mM NaCl, 0.5 mM EDTA, 500 µM THPP reducing agent, 10% (v/v) glycerol,
pH 7.5).
Then, we performed two methods of protein concentration:

initially

concentrating the large volume of dialyzed protein in 4 °C cold room using 5 kDa
PLCC low bind 44.5 mm diameter ultrafiltration disc (EMD Millipore-Sigma) with
an ultrafiltration stirrer cell (Model 8050, Amicon, EMD Millipore-Sigma) under
airflow N2(g)-pressure until approximately 5 ml concentrated protein obtained, and
if protein appeared visibly free of any aggregates/precipitates, then prepared 1
ml-aliquots in 2 ml microtubes that are shock-frozen in liquid nitrogen followed by
piercing tube lids with a fine needle and subjecting them to stand in a tube holder
for freeze-dry vacuum lyophilization (FreeZone Bulk Tray Dryer, Labconco)
carried out 3-5 h until approximately 250 µl concentrated protein remained in
microtubes. For these lyophilized microtube samples, we subjected them to
microdialysis in 4 °C cold room with inverted 15K MWCO Tube-O-Dialyzer tubes
(G Biosciences-Geno Technology) at moderate stir atop stirring plate for three
separate periods (24 hr5 hr5 hr) into fresh 500 ml dialysis buffer. Protein
concentration was quantified by 660 nm Pierce Protein Dye Assay (ThermoFisher
Scientific-Pierce Biotech) with bovine serum albumin standards’ curve prepared
by spectrophotometric measurements using 1 cm-path length 1.5 ml polystyrene
cuvettes (USA Scientific) with a Varian Cary Bio 50 UV-Vis Spectrophotometer
(Agilent Technologies). At this point, all protein samples were distributed into 500
µl aliquots that were shock-frozen in liquid nitrogen and stored at -80 °C.
Samples of purified wild-type, R251C mutant, and R119C mutant enzymes were
subjected to SDS-PAGE under reducing conditions and visualized all together on
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polyacrylamide-Tris-Gly HCl, 10-well MP TGX gel (Fig. 3.2).
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